<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0901233075
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KENACORT-A 40MG\ML INJ
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRIAMCINOLONE ACETONIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT ANGANI S.R.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT ANGANI S.R.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BRISTOL-MYERS SQUIBB
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H02AB08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KENACORT-A contains the active substance triamcinolone acetonide and belongs to a group of medicines called systemic corticosteroids, which act against inflammation.</p><p>KENACORT-A is used in <strong>adults and children over six years of age</strong>, and is administered:</p><p>&Oslash;&nbsp;&nbsp; by <u>intramuscular route</u> (injection given directly into the muscles), when treatment by mouth is not possible, to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergies, particularly in the case of serious or debilitating conditions for the body that cannot be treated with conventional therapies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dermatosis, skin disorders characterized by the appearance of pale-pinkish patches that tend to flake off</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generalized rheumatoid arthritis, a disease that affects the joints causing pain, swelling and stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other connective tissue disorders (the tissue that connects the parts of our body).</p><p>&Oslash;&nbsp;&nbsp; by intraarticular (injection given directly into the joint) or intrabursal route (injection given directly into fluid sacs located where a tendon or ligament rubs against another tissue within the joint, known as bursae) for short term treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the pain, swelling, and stiffness that occur locally in joints caused by certain inflammatory diseases (e.g., traumatic arthritis, rheumatoid arthritis, osteoarthritis, synovitis, bursitis).</p><p>For generalized arthritic diseases, KENACORT-A is used as an adjunct to treatment with other medications, especially through injection into a joint.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use KENACORT-A or give it to your child</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you/your child are allergic to triamcinolone acetonide or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you/your child have an ongoing infection that spreads from the infection site to the entire body (systemic infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your child is less than two years old (see also section Children and adolescents)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the case of intramuscular administration, if you/your child have a blood clotting disorder that can lead to easy bruising and excessive bleeding (idiopathic thrombocytopenic purpura).</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using KENACORT-A if you/your child:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have problems with the thyroid (a gland in the neck) producing less hormone than it should (hypothyroidism), or liver disease (cirrhosis). In these cases, the response to the medication may be increased.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are suffering from an eye infection caused by the herpes simplex virus, since perforation of the cornea (transparent membrane located at the front of the eye) is possible in this case. Prolonged use may result in serious eye problems (posterior subcapsular cataract or glaucoma) and increase the likelihood of eye infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are suffering from depression or a mental illness. Using this medication may aggravate pre-existing unstable conditions. The use of antidepressants does not alleviate these disorders and may exacerbate mental disorders induced by this medicine, which may include euphoria, insomnia, mood and personality changes, severe depression or symptoms of frank mental illnesses</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have an inflammation of the intestine (nonspecific ulcerative colitis) with a risk of perforation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have accumulations of pus that form within a tissue (abscesses) and infections caused by pyogenes (germs that penetrate tissues and produce pus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from inflammation of one or more diverticula (sacs that form in the intestine at the level of the colon)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have recently undergone surgery to connect two sections of the intestine (intestinal anastomosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from a lesion of the mucous membrane of the stomach or of the intestine (peptic ulcer) in active or latent form (i.e., without symptoms); if the therapy is prolonged, you may be prescribed an antacid</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from kidney disease (kidney failure, acute glomerulonephritis, and chronic nephritis), as fluid accumulation (edema) may occur</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from high blood pressure (hypertension). Your doctor may prescribe you a low-salt diet and supplements containing potassium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; your heart is not pumping enough blood to meet your body&rsquo;s needs (congestive heart failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from inflammation of the veins (thrombophlebitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from the formation of blood clots inside of the veins (thromboembolic episodes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from reduced bone mass (osteoporosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have skin rash (exanthem)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from a disease characterized by weight gain, fluid retention, skin striae and abnormal hair growth due to excess corticosteroids (Cushing&rsquo;s syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have diabetes mellitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have seizures disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have a malignant tumor with metastases (cells that detach from the original tumor and spread to other organs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suffer from a disease that affects the muscles, causing them to gradually lose tone and strength (myasthenia gravis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are elderly. Your doctor will monitor you during your treatment with KENACORT-A as some side effects including osteoporosis (reduced bone mass) or hypertension (high blood pressure), which are common in corticosteroid therapy, may have more serious consequences for you if you are elderly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have a history of allergic reactions to medications, as this medication can cause severe allergic reactions in rare cases</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are in a particularly stressful situation (such as trauma, surgery or serious illness); in such cases, your doctor may prescribe appropriate additional therapy.</p><p>&nbsp;</p><p>During prolonged therapy, good protein intake is essential to counteract excessive weight loss and weakness.</p><p>Contact your doctor if you have blurred vision or other visual disturbances.</p><p>Female patients should be advised that menstrual irregularities may occur and vaginal bleeding may occur in postmenopausal women. If your doctor considers it appropriate, you will be advised to undergo appropriate investigations.</p><p><em><u>Intraarticular administration</u></em></p><p>In the event of intraarticular administration, you/your child must take special care:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; not to overstress the treated joints for which an improvement in symptoms has been achieved, as these may deteriorate further</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if there is increased pain associated with local swelling, increased difficulty in moving the joint, fever and malaise. These may be signs of an ongoing infection in the joint (see section 4. Possible side effects). In this case, consult your doctor immediately; they will decide whether to discontinue treatment with KENACORT-A and start another suitable therapy.</p><p><em><u>&nbsp;</u></em></p><p><em><u>KENACORT-A and other diseases</u></em></p><p>Corticosteroids can hide symptoms of infection, and infections can occur simultaneously during their use. When receiving corticosteroid based therapy, your body&#39;s defense capabilities may be diminished and it may be difficult to locate a possible site of infection. Also, if you are taking medications that lower your body&rsquo;s defenses, including corticosteroids, you are more prone to infections than people who do not use these medications.</p><p>Therefore inform your doctor if you or your child:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; have chickenpox or measles. These infectious diseases can worsen or even be fatal. Avoid infection for you and your child during corticosteroid treatment if you have not had these illnesses. If infection does occur, inform your doctor because appropriate treatment will need to be implemented;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; have an ongoing pinworm infestation (a disease caused by a very small worm that is able to penetrate through intact skin). Inflammation of the intestines and serious infections may develop that could even be fatal;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; are about to have a vaccine, since your body may be more susceptible to complications because its defenses are lowered;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; have active tuberculosis (an infectious disease caused by the bacterium <em>Mycobacterium tuberculosis</em>, which usually develops in the lungs). Your doctor may prescribe appropriate treatment against tuberculosis in combination with KENACORT-A;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; have latent tuberculosis or a positive response to tuberculin (extracts of tuberculous bacteria used to diagnose the disease). Your doctor will prescribe drug-based therapy to prevent possible infection (chemoprophylaxis).</p><p>&nbsp;</p><p><u>For athletes</u></p><p>The use of this medicine without therapeutic necessity constitutes doping and can cause anti-doping tests to be returned positive.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>KENACORT-A contains 9.9&nbsp;mg/mL benzyl alcohol, so this medication should not be given to premature babies or newborns. <strong>KENACORT-A is contraindicated in children under 2 years of age</strong> and may cause toxic and allergic reactions in children up to 3 years of age.</p><p>If consumed in excessive quantities, benzyl alcohol may cause a syndrome called &ldquo;gasping syndrome&rdquo;, characterized by effects such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; nervous system depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; uncontrolled body movements (seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the head</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; hypotension (low blood pressure), particularly in newborns</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; metabolic acidosis (increased amount of acids in the blood), particularly in newborns</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; slow heartbeat (bradycardia)</p><p>Moreover, due to the presence of benzyl alcohol, the child could experience:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; an increased risk of nuclear jaundice (yellowish discoloration of the skin, sclerae, and mucous membranes caused by excessive elevation of bilirubin levels in the blood), particularly in premature babies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rare cases of death, especially in premature babies.</p><p><strong>&nbsp;</strong></p><p><strong>KENACORT-A is not recommended in children under six years of age</strong>.</p><p>If your child is undergoing prolonged corticosteroid treatment, your doctor will need to monitor your child&rsquo;s development closely as corticosteroids can slow growth (see section 4. Additional side effects in children).</p><p>Children also should not be vaccinated or immunized during corticosteroid therapy because these substances can affect the body&rsquo;s production of steroids.</p><p>&nbsp;</p><p>Other medicines and KENACORT-A</p><p>Tell your doctor or pharmacist if you/your child are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Tell your doctor if you/your child are taking one of the following medicines in particular:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; amphotericin B (a medicine used to treat fungal infections) or other substances that cause a decrease in blood potassium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; anticholinesterases (drugs that inhibit the elimination of acetylcholine, indicated for certain gastro-intestinal and respiratory disorders, postoperative vomiting, vomiting during pregnancy, etc.)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; anticoagulants (medicines to make the blood thinner) given by mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; antidiabetics (medicines to treat diabetes, which is characterized by high blood glucose levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; antitubercular medicines (medicines used to treat tuberculosis, a disease caused by a bacterium, called <em>Mycobacterium tuberculosis</em>, which usually develops in the lungs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine (a medicine that depresses the activity of the body&rsquo;s defense system, used to prevent organ transplant rejection reactions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; digitalis glycosides (drugs used to increase the strength of contraction of the heart)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; estrogens (female sex hormones), including oral contraceptives (the pill)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; liver enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin), medicines that affect how the liver works</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; human growth hormone (e.g., somatrem), a hormone that promotes growth in height</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; muscle relaxants (drugs that reduce muscle tone)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; NSAIDs, nonsteroidal anti-inflammatory drugs (medicines used to treat inflammation, pain, and fever)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; thyroid medicines (medicines used to treat thyroid disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; vaccines (products that stimulate patients&rsquo; immune systems to build specific resistance to infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; acetylsalicylic acid (medication to make the blood thinner or to treat inflammation, pain, and fever), if you have low levels of prothrombin (a protein involved in blood clotting processes) in your blood, your doctor will consider carefully whether to prescribe KENACORT-A</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; drugs that inhibit an enzyme present in the body (cytochrome P450 3A4) such as ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Your doctor will evaluate the relationship between the possible benefit and the potential risk to you and/or the fetus, breast-feeding infant or child.</p><p>If you used high doses of KENACORT-A during pregnancy, your baby should be carefully monitored because they may have impaired function of the adrenal glands (glands located above the kidneys) with reduced production of one or more hormones (hypoadrenalism).</p><p><strong>Driving and using machines</strong></p><p>While taking KENACORT-A you may experience side effects such as vertigo. If these symptoms occur, do not drive vehicles or operate machinery.</p><p>KENACORT-A contains benzyl alcohol and sodium</p><p>KENACORT-A contains 9.9 mg/mL benzyl alcohol. Benzyl alcohol may cause allergic reactions. Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called &ldquo;gasping syndrome&rdquo;) in young children.</p><p>Do not give to your newborn baby (up to 4 weeks old), unless recommended by your doctor. Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist.</p><p>Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding, or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>KENACORT-A contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine or give it to your child exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will determine the most appropriate dose for you based on the disorder being treated, the route of administration, and your age and response.</p><p>The initial recommended dose may vary from 2.5 to 60 mg per day, depending on the specific disorder to be treated.</p><p><strong><em>Intramuscular administration</em></strong></p><p><em><u>Adults and children over 12 years</u></em></p><p>The recommended initial dose is 60 mg.</p><p>The maintenance dose is typically between 40 and 80 mg, depending on the response to treatment and the time it takes for symptoms to improve. Lower dosages of 20 mg or less may be sufficient in some cases.</p><p>If you/your child suffer from seasonal allergy (allergic reaction of the mucous membrane of the eyes, nose and airways to seasonal pollens) or pollen asthma (generally reversible obstruction of the lower airways caused by pollen exposure), a single injection of 40 -100 mg of KENACORT-A may be sufficient to achieve remission of symptoms lasting for the entire pollen season.</p><p><em><u>Children aged 6 to 12 years</u></em></p><p>The recommended initial dose is 40 mg.</p><p>Your doctor will determine the most appropriate dose for your child based on age, the disorder being treated, the route of administration and response to treatment.</p><p><strong><em>Intraarticular or intrabursal administration</em></strong></p><p>Your doctor will determine the most appropriate dose for you based on the disorder being treated, the route of administration, and your age and response. See the information at the end of this leaflet.</p><p><strong><u>Method of administration</u></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use the product under conditions of absolute sterility</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the bottle well before use to ensure uniformity of the preparation and absence of agglomerates. Do not expose the product to low temperatures, since this causes agglomeration; in this case, do not use the product</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the suspension from the bottle using the syringe</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the injection immediately after withdrawal to prevent deposits from forming in the syringe.</p><p>Take all precautions to avoid the risk of infection or the needle penetrating a blood vessel.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Intramuscular administration</u></em></p><p>For intramuscular administration, inject deeply into the gluteal muscles. Otherwise there could be a more or less marked thinning of the subcutaneous fat. The gluteal region is preferred over the deltoid (shoulder muscle) as a higher incidence of local atrophy (reduction of the muscle mass) occurs in the deltoid area.</p><p>For adults, it is recommended to use a needle with a minimum length of 4 cm or longer for obese patients and to change the site with each subsequent injection.</p><p><em><u>Intraarticular or intrabursal administration</u></em></p><p>The medicine will be administered by an experienced doctor. See the information at the end of this leaflet.</p><p><strong>Use in children</strong></p><p><strong>KENACORT-A should not be administered to children younger than 2 years of age</strong> (see section 2 &quot;Children and adolescents&quot;) <strong>and its administration is not recommended in children under 6 years of age.</strong></p><p><strong><em>If you use, or give to your child, more KENACORT-A than you should</em></strong></p><p>If you use/give your child too much KENACORT-A, contact your doctor or go to the hospital immediately.</p><p>If you take high doses of the medicine for an extended period of time you may experience symptoms such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cramps (sudden, violent muscle pain)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the stomach and/or intestine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moon face</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>If you forget to use KENACORT-A or forget to give it to your child</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking KENACORT-A</strong></p><p>If administration of the medicine is to be discontinued after long-term therapy, gradual rather than sudden discontinuation is recommended. If treatment is stopped abruptly, the adrenal glands might not be able to produce a sufficient amount of cortisol, an essential hormone for the body (acute adrenal insufficiency), which also occurs under stressful conditions.</p><p>After stopping KENACORT-A therapy you may experience a sudden recurrence of symptoms of the disease for which you were treated, so your doctor will closely monitor you even after you stop treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you/your child experience any of the following side effects, <strong>STOP </strong>treatment with this medicine and <strong>immediately</strong> contact your doctor, who will advise you on the most appropriate treatment to follow:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast-onset allergic reactions (severe anaphylactic reactions) or a severe allergic reaction that can cause death (anaphylactic shock)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased pain associated with local swelling, increased difficulty in moving the joint, fever and malaise. These may be signs of an ongoing infection in the joint.</p><p>The following side effects, listed below according to frequency of occurrence, may occur during treatment with KENACORT-A:</p><p>Common (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp; infection</p><p>&middot;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp; opacification of the crystalline lens, the lens of the eye that focuses images (cataract)</p><p>&middot;&nbsp;&nbsp; injection site reactions</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; accumulations of pus that form at the injection site (sterile abscess), masking of infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; reactions that occur with symptoms similar to those of allergic reactions, but do not affect the immune system, the body&rsquo;s defense system (anaphylactoid reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a state similar to that caused by Cushing&rsquo;s syndrome characterized by: full moon face, buffalo hump, trunk obesity, increased hair quantity, irritability (Cushingoid-like appearance); suppression of the function of the adrenals, glands located above the kidneys</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fluid or sodium retention, reduced blood acidity caused by potassium deficiency (hypokalemic alkalosis), high blood sugar levels (hyperglycemia, diabetes mellitus), which may not respond to therapies (inadequate control of diabetes mellitus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; mental illnesses, depression, euphoric mood, mood swings, personality changes, insomnia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; uncontrolled body movements (seizures), transient fainting (syncope), increased pressure in the head in the absence of disease (benign intracranial hypertension), inflammation of a nerve (neuritis), tingling (paresthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; blindness, a disease characterized by increased pressure of fluid in the eye (glaucoma), bulging eye (exophthalmos), perforation of transparent eye membrane (cornea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; vertigo</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; weakening of the heart, which does not pump enough blood to meet the body&rsquo;s needs (congestive heart failure), heart rhythm disorder (arrhythmia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension), obstruction of a blood vessel (embolism), inflammation of the veins, associated with blood clot formation (thrombophlebitis), chronic inflammation of blood vessels (necrotizing vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; lesion of the mucous membrane of the stomach or intestine (peptic ulcer), possibly associated with perforation and loss of blood, inflammation of the pancreas (pancreatitis), an organ involved in digestive processes, swollen abdomen, inflammation of the mucous membrane of the esophagus (the tube that connects the mouth to the stomach) associated with the appearance of lesions (ulcerative esophagitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; hives, skin rash, dark and light spots on the skin, thinned skin, skin fragility, small hemorrhages caused by blood leakage from small blood vessels (petechiae), bruises (ecchymosis), skin reddening (erythema), increased sweating (hyperhidrosis), appearance of patches on the skin of different sizes ranging in color from bright red to purple, to brownish red (purpura), stretch marks (skin striae), in women presence of hard and coarse hair in locations typical of men (hirsutism), skin eruptions similar to furuncles (acneiform dermatitis), red, raised lesions often located on the face (cutaneous lupus erythematosus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; loss of bone mass (osteoporosis), bone death (osteonecrosis), fracture of bones weakened by another disease (pathological fracture), delayed fracture repair, musculoskeletal discomfort, muscle weakness, muscle disease (myopathy), loss of muscle mass (muscle atrophy), growth retardation, an inflammatory disease characterized by resorption of bones in the joints of the foot (neuropathic arthropathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; high levels of sugar in the urine (glycosuria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; irregular or no menstruation (amenorrhea), vaginal bleeding after menopause (postmenopausal bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the tissue lining the inside of the joints (synovitis), pain, injection site irritation, injection site discomfort, fatigue, incomplete healing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decreased levels of potassium in the blood, electrocardiogram changes (graphic representation of the electrical activity of the heart while functioning), decreased tolerance to sugars, negative nitrogen balance (more nitrogen is lost than is absorbed), increased pressure of the fluid inside of the eye, laboratory test interference</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fractures of one or more vertebrae of the spine caused by compression (spinal compression fracture)</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; hiccups</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbance</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30<sup>o</sup>C. Do not freeze or refrigerate. Protect from light. Store vials upright.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice agglomerates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is: triamcinolone acetonide. Each vial contains 40 mg triamcinolone acetonide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: <strong>sodium</strong> carboxymethyl cellulose, <strong>sodium</strong> chloride, polysorbate 80, <strong>benzyl alcohol</strong> (see section &ldquo;KENACORT-A contains benzyl alcohol&rdquo;), and water for injections, hydrochloric acid/<strong>sodium</strong> hydroxide (pH adjusters).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                KENACORT-A is presented as a suspension for injection for intramuscular and intraarticular use.
KENACORT-A is available in packages containing 1 vial of 1 mL suspension for injection

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BRISTOL-MYERS SQUIBB S.r.l.</p><p>Piazzale dell&rsquo;Industria 40/46</p><p>Rome &ndash; Italy</p><p>BRISTOL-MYERS SQUIBB S.r.l.,</p><p>Via Virgilio Maroso, 50 - Rome (Italy)</p><p><strong><em>Manufacturer</em></strong></p><p>CATALENT ANAGNI S.R.L.</p><p>Loc. Fontana del Ceraso snc</p><p>Strada Provinciale 12 Casilina N. 41</p><p>03012 ANAGNI (FR)- Italy</p><p>or</p><p>&nbsp;</p><p>Swords Laboratories Unlimited Company T/A Bristol-Myers Squibb Pharmaceutical Operations, External Manufacturing Plaza 254</p><p>Blanchardstown Corporate Park 2</p><p>Dublin 15, D15 T867, Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Aug 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار كيناكورت-ا على المادة الفعالة أسيتونيد التريامسينولون وينتمي إلى مجموعة من الأدوية تسمى الكورتيكوستيرويدات الجهازية، التي تعالج الالتهابات.</p><p dir="RTL">يستخدم كيناكورت-ا <strong>للبالغين والأطفال ممن تزيد أعمارهم عن ست سنوات</strong>، ويتم إعطاؤه:</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عن طريق <u>الحقن العضلي</u> (حقنة تُعطى مباشرة في العضلات)، عندما لا يكون العلاج عن طريق الفم ممكنًا، لعلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية، لا سيما في الحالات الخطيرة أو المنهكة للجسم التي لا يمكن علاجها بالعلاجات التقليدية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأمراض الجلدية، اضطرابات الجلد التي تتميز بظهور بقع وردية اللون شاحبة تميل إلى التقشر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الروماتويدي العام، وهو مرض يصيب المفاصل ويتسبب في حدوث الألم والتورم والتصلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النسيج الضام الأخرى (الأنسجة التي تربط أجزاء الجسم).</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عن طريق الحقن داخل المفصل (حقنة تعطى في المفصل بشكل مباشر) أو داخل الجراب (حقنة تعطى مباشرة في الأكياس السائلة المتواجدة في المنطقة التي يحتك فيها الوتر أو الرباط بأنسجة أخرى داخل المفصل، والمعروفة باسم الجراب) للعلاج قصير الأمد للحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم والتورم والتصلب الموضعي في المفاصل بسبب الإصابة ببعض الأمراض الالتهابية (مثل التهاب المفاصل الرضحي، والتهاب المفاصل الروماتويدي، وهشاشة العظام، والتهاب الغشاء الزليلي، والتهاب الجراب).</p><p dir="RTL">بالنسبة للأمراض المفصلية العامة، يستخدم كيناكورت-ا كعلاج مساعد مع الأدوية الأخرى، لا سيما عن طريق الحقن في المفصل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم كيناكورت-ا أو تعطيه لطفلك في الحالات التالية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت/طفلك تعانيان من الحساسية تجاه أسيتونيد التريامسينولون أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت/طفلك تعانيان من عدوى مستمرة يمكنها الانتشار من موقع العدوى إلى الجسم بالكامل (عدوى جهازية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمر طفلك لا يتجاوز العامين (انظر أيضًا قسم الأطفال والمراهقين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة التعاطي عن طريق الحقن في العضل، إذا كنت/طفلك تعانيان من اضطراب تخثر الدم الذي قد يؤدي إلى التعرض للكدمات بسهولة والنزيف المفرط (فرفرية نقص الصفيحات مجهولة السبب).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام كيناكورت-ا إذا كنت أنت/طفلك تعانيان من الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وجود مشاكل في الغدة الدرقية (غدة في الرقبة) تنتج هرمونًا أقل من المعدل المطلوب (قصور الغدة الدرقية)، أو أمراض الكبد (تليف الكبد). وفي هذه الحالات، قد تزداد الاستجابة لمفعول الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عدوى العين الناجمة عن فيروس الهربس البسيط، حيث من الممكن أن يتعرض الشخص لحدوث ثقب في القرنية (غشاء شفاف يقع في مقدمة العين) في هذه الحالة. وقد يؤدي الاستخدام المطول إلى حدوث مشكلات خطيرة في العين (إعتام عدسة العين الخلفي تحت المحفظة أو الجلوكوما) وزيادة احتمالية الإصابة بعدوى العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب أو المرض العقلي. قد يؤدي استخدام هذا الدواء إلى تفاقم الحالات غير المستقرة الموجودة سابقًا. ولا يؤدي تناول مضادات الاكتئاب إلى الحد من هذه الاضطرابات بل إنه قد يؤدي إلى تفاقم الاضطرابات العقلية الناجمة عن هذا الدواء، والتي قد تشمل النشوة أو الأرق أو التغيرات في المزاج أو الشخصية أو الاكتئاب الشديد أو أعراض الأمراض العقلية الظاهرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء (التهاب القولون التقرحي غير المحدد) مع خطر حدوث ثقب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تراكمات القيح التي تتكون داخل الأنسجة (الخراجات) والالتهابات الناجمة عن البكتيريا المسببة للالتهاب (الجراثيم التي تخترق الأنسجة وينتج عنها القيح)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في أحد أو أكثر من الرتوج (الأكياس التي تتكون في الأمعاء على مستوى القولون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الخضوع لعملية جراحية لربط قسمين من الأمعاء (التفاغر المعوي) خلال وقت قريب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المعاناة من آفة في الغشاء المخاطي للمعدة أو الأمعاء (القرحة الهضمية) بشكل نشط أو كامن (أي بدون أعراض)؛ وفي حال طول مدة العلاج، فقد يصف لك الطبيب مضادًا للحموضة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكلى (فشل الكلى، التهاب كبيبات الكلى الحاد، والتهاب الكلى المزمن)، حيث قد يحدث تراكم للسوائل (الوذمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم. قد يصف لك طبيبك نظامًا غذائيًا يحتوي على القليل من الملح بالإضافة إلى المكملات التي تحتوي على البوتاسيوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عدم ضخ القلب ما يكفي من الدم لتلبية احتياجات الجسم (قصور القلب الاحتقاني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تكوين جلطات الدم داخل الأوردة (الانصمام الخثاري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كثافة العظام (هشاشة العظام)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض يتميز بزيادة الوزن واحتباس السوائل وخطوط الجلد والنمو غير الطبيعي للشعر بسبب زيادة الكورتيكوستيرويدات (متلازمة كوشينغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالسكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ورم خبيث مع النقائل (الخلايا التي تنفصل عن الورم الأصلي وتمتد إلى أعضاء أخرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض يؤثر على العضلات، مما يجعلها تفقد قوتها تدريجيًا (الوهن العضلي الشديد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التقدم في السن. سوق تخضع لملاحظة الطبيب أثناء العلاج باستخدام كيناكورت-ا حيث إن بعض الآثار الجانبية بما في ذلك هشاشة العظام (انخفاض كثافة العظام) أو ارتفاع ضغط الدم، التي تعد شائعة عند العلاج باستخدام الكورتيكوستيرويد، قد يترتب عليها عواقب أكثر خطورة إذا كنت من كبار السن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تاريخ من ردود الفعل التحسسية للأدوية، لكون هذا الدواء قد يتسبب في حدوث ردود فعل تحسسية شديدة في بعض الحالات النادرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وضع مرهق بشكل خاص (مثل التعرض للصدمات أو الخضوع لجراحة أو الإصابة بمرض خطير)؛ وفي مثل هذه الحالات، قد يصف طبيبك علاجًا إضافيًا مناسبًا.</p><p>&nbsp;</p><p dir="RTL">يعد تناول كمية جيدة من البروتين أمرًا ضروريًا للتغلب على فقدان الوزن المفرط والضعف عند طول مدة العلاج.</p><p dir="RTL">في حال التعرض لتشوش الرؤية أو الاضطرابات البصرية الأخرى يرجى الاتصال بطبيبك.</p><p dir="RTL">ينبغي توعية المريضات بأنه قد تحدث لهن اضطرابات في الدورة الشهرية وقد يعانين من حدوث نزيف مهبلي عقب انقطاع الطمث. إذا اعتبر طبيبك أن هذا الأمر غير مثير للقلق، فسوف ينصحك بإجراء بعض الفحوصات المناسبة.</p><p dir="RTL"><em><u>التعاطي داخل المفصل</u></em></p><p dir="RTL">في حالة التعاطي داخل المفصل، يجب عليك/على طفلك توخي الحذر بشكل خاص في ما يتعلق بما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عدم المبالغة في الضغط على المفاصل التي تمت معالجتها والتي شهدت تحسنًا في الأعراض، حيث إنها قد تكون عرضة للتدهور بشكل أكثر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان هناك ألم متزايد يرتبط بتورم موضعي، وصعوبة متزايدة في تحريك المفصل بالإضافة إلى الحمى والتوعك. وقد تدل هذه علامات على وجود عدوى مستمرة في المفصل (انظر القسم 4. الآثار الجانبية المحتملة). وفي هذه الحالة، تجب استشارة الطبيب على الفور؛ حيث سيقرر إذا ما إذا كان يجب إيقاف العلاج باستخدام كيناكورت-ا وبدء تلقي أحد العلاجات الأخرى المناسبة.</p><p><em><u>&nbsp;</u></em></p><p dir="RTL"><em><u>كيناكورت-ا والأمراض الأخرى</u></em></p><p dir="RTL">قد تعمل الكورتيكوستيرويدات على إخفاء أعراض العدوى، وقد تحدث العدوى بالتزامن مع استخدامها في العلاج. عند تلقي العلاج القائم على الكورتيكوستيرويد، قد تتضاءل قدرات الجسم الدفاعية وقد يصعب تحديد موقع محتمل للعدوى. ومن ناحية أخرى، إذا كنت تتناول أدوية تحد من قدرات الجسم الدفاعية، بما في ذلك الكورتيكوستيرويدات، فإنك تكون أكثر عرضة للإصابة بالعدوى من الأشخاص الذين لا يتناولون هذه الأدوية.</p><p dir="RTL">لذلك يتعين عليك إخبار طبيبك إذا كنت أنت أو طفلك تعانيان مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; جدري الماء أو الحصبة. فقد تتفاقم هذه الأمراض المعدية وتصبح ذات تأثير خطير. كما ينبغي لك أن تتجنب أنت وطفلك التعرض للعدوى أثناء العلاج باستخدام الكورتيكوستيرويد إذا لم تكن قد أصبت بهذه الأمراض. وفي حالة التعرض للعدوى، يجب عليك إخبار طبيبك لكي يصف لك علاجًا مناسبًا؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الإصابة المستمرة بالدودة الدبوسية (مرض يتسبب في حدوثه دودة صغيرة للغاية لديها القدرة على اختراق الجلد السليم). وقد يؤدي التهاب الأمعاء والإصابة بالالتهابات الخطيرة إلى تفاقم الوضع بشكل خطير للغاية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; انتظار الحصول على أحد اللقاحات، وذلك لأن جسمك قد يكون أكثر عرضة للمضاعفات بسبب انخفاض قدرته الدفاعية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مرض السل النشط (أحد الأمراض المعدية الذي تتسبب في حدوثه بكتيريا <em>المتفطرة السلية</em>، الذي عادةً ما يتطور في الرئتين). قد يصف طبيبك العلاج المناسب للسل بالتوازي مع تعاطي كيناكورت-ا؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مرض السل الكامن أو استجابة إيجابية للسل (عينات من البكتيريا السلية المستخدمة لتشخيص المرض). سيصف لك الطبيب العلاج القائم على الأدوية لمنع حدوث العدوى المحتملة (الوقاية الكيميائية).</p><p>&nbsp;</p><p dir="RTL"><u>للرياضيين</u></p><p dir="RTL">يندرج استخدام هذا الدواء بدون ضرورة طبية تحت بند &quot;تعاطي المنشطات&quot; وقد يؤدي إلى إيجابية نتائج فحوصات المنشطات.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يحتوي كيناكورت-ا على 9.9&nbsp;مجم/مل من الكحول البنزيلي، لذلك لا ينبغي إعطاء هذا الدواء للأطفال الخدج أو حديثي الولادة. <strong>يُمنع استخدام كيناكورت-ا مع لأطفال دون سن العامين </strong>حيث قد يتسبب في حدوث تفاعلات سامة وحساسية لدى الأطفال حتى سن 3 سنوات.</p><p dir="RTL">عند تعاطي الكحول البنزيلي بكميات مفرطة، فقد يتسبب في حدوث متلازمة تسمى &quot;متلازمة اللهاث&quot;، التي تتميز ببعض التأثيرات مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب الجهاز العصبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حركات الجسم غير المنضبطة (النوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الرأس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، لا سيما لدى الأطفال حديثي الولادة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الحماض الأيضي (زيادة كمية الأحماض في الدم)، لا سيما لدى الأطفال حديثي الولادة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب</p><p dir="RTL">علاوةً على ذلك، قد يعاني الطفل بسبب وجود كحول البنزيلي من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر الإصابة باليرقان النووي (اصفرار لون الجلد ، تصلب الجلد، الأغشية المخاطية الناجمة عن الارتفاع المفرط لمستويات البيليروبين في الدم)، لا سيما لدى الأطفال الخدج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حالات نادرة من الوفاة، لا سيما لدى الأطفال الخدج.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا ينصح باستخدام كيناكورت-ا مع الأطفال دون سن السادسة من العمر</strong>.</p><p dir="RTL">إذا كان طفلك يُعالج باستخدام الكورتيكوستيرويد لمدة طويلة، فسيحتاج طبيبك إلى مراقبة معدل نمو طفلك عن كثب وذلك لأن الكورتيكوستيرويدات يمكنها أن تعمل على إبطاء وتيرة النمو (انظر القسم 4. الآثار الجانبية لدى الأطفال).</p><p dir="RTL">يجب عدم تطعيم الأطفال أو تلقيهم للقاحات أثناء العلاج بالكورتيكوستيرويد وذلك لأن هذه المواد يمكنها أن تؤثر على إنتاج الجسم للستيرويدات.</p><p>&nbsp;</p><p><strong>الأدوية أخرى وكيناكورت-ا</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت أنت/طفلك تتناولان أي أدوية أخرى أو في حال تناول أي أدوية مؤخرًا أو عند الإقدام على تناول أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL">أخبر الطبيب إذا كنت تتناول أيًا من الأدوية التالية على وجه الخصوص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أمفوتريسين ب (دواء يستخدم لعلاج الالتهابات الفطرية) أو غيره من المواد التي تسبب حدوث انخفاض في معدل البوتاسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الكولينستريز (الأدوية التي تمنع القضاء على الأسيتيل كولين، التي يتم وصفها لعلاج بعض اضطرابات الجهاز الهضمي والجهاز التنفسي، والتقيؤ بعد الجراحة، والتقيؤ أثناء الحمل، وما إلى ذلك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر (أدوية لجعل الدم أكثر سيولة) تُعطى عن طريق الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مضادات السكري (أدوية لعلاج مرض السكري، الذي يتميز بارتفاع مستويات الجلوكوز في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مضادة للسل (أدوية تستخدم لعلاج مرض السل، وهو مرض تسببه بكتيريا تسمى المتفطرة السلية، الذي عادةً ما يتطور في الرئتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين (دواء مثبط لنشاط نظام الدفاع في الجسم، حيث يستخدم لمنع حدوث ردود الفعل الناجمة عن عمليات زرع الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; غليكوسيدات الديجيتاليس (الأدوية المستخدمة لزيادة قوة تقلص القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الاستروجين (الهرمونات الجنسية الأنثوية)، بما في ذلك وسائل منع الحمل عن طريق الفم (حبوب منع الحمل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; محفزات إنزيم الكبد (على سبيل المثال، الباربيتورات، الفينيتوين، كاربامازيبين، ريفامبين)، الأدوية التي تؤثر على وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; هرمون النمو البشري (مثل السوماتريم)، وهو هرمون يعزز النمو في الطول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الباسطة للعضلات (الأدوية التي تحد من التوتر العضلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية، الأدوية المضادة للالتهابات (الأدوية المستخدمة لعلاج الالتهاب والألم والحمى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الغدة الدرقية (الأدوية المستخدمة لعلاج اضطرابات الغدة الدرقية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات (المنتجات التي تحفز أجهزة المناعة لدى المرضى لتكوين مقاومة محددة للعدوى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمض أسيتيل الساليسيليك (دواء لزيادة معدل سيولة الدم أو لعلاج الالتهاب والألم والحمى)، وإذا كنت تعاني من انخفاض مستويات البروثرومبين (بروتين يشارك في عمليات تخثر الدم) في دمك، فسيفكر طبيبك بعناية في ما إذا كان سيصف لك كيناكورت-ا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تمنع الإنزيمات الموجودة في الجسم (cytochrome P450 3A4) مثل ريتونافير، أتازانافير، كلاريثروميسين، إندينافير، إيتراكونازول، نيفازودون، نلفينافير، ساكوينافير، كيتوكونازول، تيليثروميسين.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعًا، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاستشيري الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">سيقوم طبيبك بتقييم العلاقة بين الفائدة المحتملة والمخاطر المحتملة عليك و/أو على الجنين أو الرضيع أو الطفل الذي يرضع رضاعة طبيعية.</p><p dir="RTL">إذا كنت قد تناولت جرعات عالية من كيناكورت-ا أثناء الحمل، فيجب مراقبة طفلك بعناية لأنه قد يعاني من ضعف في وظيفة الغدد الكظرية (الغدد الموجودة فوق الكلى) مع انخفاض إنتاج هرمون واحد أو أكثر (قصور الغدة الكظرية).</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">قد تعاني من حدوث آثار جانبية مثل الشعور بالدوار عند تعاطي كيناكورت-ا. في حالة حدوث هذه الأعراض، ابتعد عن قيادة المركبات أو تشغيل الآلات.</p><p><strong>يحتوي كيناكورت-ا على الكحول البنزيلي والصوديوم</strong></p><p dir="RTL">يحتوي كيناكورت-ا على 9.9&nbsp;مجم/مل من الكحول البنزيلي. وقد يتسبب الكحول البنزيلي في حدوث ردود فعل تحسسية. هذا وقد تم ملاحظة وجود ارتباط بين الكحول البنزيلي وخطر حدوث آثار جانبية شديدة بما في ذلك مشاكل في التنفس (تسمى &quot;متلازمة اللهاث&quot;) عند الأطفال الصغار.</p><p dir="RTL">لا يعطى هذا الدواء للأطفال حديثي الولادة (حتى عمر 4 أسابيع)، ما لم يوصِ الطبيب بذلك. ولا يُستخدم لأكثر من أسبوع مع الأطفال الصغار (أقل من 3 سنوات)، ما لم ينصح طبيبك أو الصيدلي بغير ذلك.</p><p dir="RTL">اطلبي المشورة من الطبيب أو الصيدلي إذا كنت حاملاً أو مرضعًا، أو إذا كنت تعانين من مرض في الكبد أو الكلى. والسبب وراء ذلك هو أن تعاطي كميات كبيرة من الكحول البنزيلي قد يتسبب في حدوث تراكم له في الجسم مما ينتج عنه آثار جانبية (تسمى &quot;الحماض الأيضي&quot;).</p><p dir="RTL">يحتوي كيناكورت-ا على أقل من 1 مليمول صوديوم (23&nbsp;ملغ) لكل جرعة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم استخدام هذا الدواء أو إعطائه لطفلك وفقًا لإرشادات الطبيب أو الصيدلي. وينبغي استشارة الطبيب أو الصيدلي إذا لم تكن متأكدًا من الأمر.</p><p dir="RTL">سيحدد طبيبك الجرعة الأكثر ملاءمة لك بناءً على الاضطراب وطريقة الإعطاء وعمرك ومدى استجابتك.</p><p dir="RTL">قد تتباين الجرعة الأولية الموصى بها بين 2.5&nbsp;إلى 60&nbsp;مجم يوميًا، اعتمادا على الاضطراب المحدد المراد علاجه.</p><p dir="RTL"><strong><em>الحقن العضلي</em></strong></p><p dir="RTL"><em><u>البالغون والأطفال فوق سن 12 عامًا</u></em></p><p dir="RTL">الجرعة الأولية الموصى بها هي 60&nbsp;مجم.</p><p dir="RTL">تتراوح جرعة المداومة عادةً بين 40&nbsp;و80&nbsp;مجم، اعتمادًا على مدى الاستجابة للعلاج والوقت المستغرق في عملية التحسن. وقد تكون الجرعات المنخفضة التي تبلغ 20&nbsp;مجم أو أقل كافية في بعض الحالات.</p><p dir="RTL">إذا كنت أنت/طفلك تعانيان من الحساسية الموسمية (رد فعل تحسسي للغشاء المخاطي للعينين والأنف والممرات الهوائية بسبب حبوب اللقاح الموسمية) أو ربو حبوب اللقاح (انسداد منعكس بشكل عام للممرات الهوائية السفلية بسبب التعرض لحبوب اللقاح)، فقد تكون حقنة واحدة تتراوح جرعتها بين 40&nbsp;إلى 100&nbsp;مجم من كيناكورت-ا كافية للحد من الأعراض التي تستمر طوال موسم حبوب اللقاح.</p><p dir="RTL"><em><u>الأطفال الذين تتراوح أعمارهم بين 6 و 12 عامًا</u></em></p><p dir="RTL">الجرعة الأولية الموصى بها هي 40&nbsp;مجم.</p><p dir="RTL">سيحدد طبيبك الجرعة الأكثر ملاءمة لطفلك بناءً على العمر والاضطراب الذي يتم علاجه فضلاً عن طريقة التعاطي ومدى الاستجابة للعلاج.</p><p dir="RTL"><strong><em>التعاطي داخل المفصل أو داخل الجراب</em></strong></p><p dir="RTL">سيحدد طبيبك الجرعة الأكثر ملاءمة لك بناءً على الاضطراب وطريقة الإعطاء وعمرك ومدى استجابتك. راجع المعلومات الواردة في نهاية هذه النشرة.</p><p dir="RTL"><strong><u>طريقة الاستخدام</u></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم المنتج عندما يكون معقمًا فقط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رج الزجاجة جيدًا قبل الاستخدام لضمان تجانس المستحضر وعدم وجود تكتلات. لا تُعرض المنتج لدرجات حرارة منخفضة، لكون ذلك قد يتسبب في حدوث التكتل؛ وعند حدوث ذلك، لا تستخدم المنتج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسحب المستحضر من الزجاجة باستخدام الحقنة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء الحقنة بعد السحب مباشرة لمنع تكون الرواسب في الحقنة.</p><p dir="RTL">اتخذ كل الاحتياطات لتجنب خطر الإصابة بالعدوى أو اختراق الإبرة للأوعية الدموية.</p><p><em><u>&nbsp;</u></em></p><p dir="RTL"><em><u>الحقن العضلي</u></em></p><p dir="RTL">للحقن العضلي، يتم الحقن في عضلات الألوية على مسافة عميقة. وقد يحدث ترقق ملحوظ للدهون تحت الجلد عند عدم اتباع الإرشادات. ويفضل استخدام المنطقة الألوية على العضلة الدالية (عضلة الكتف) حيث يحدث ضمور موضعي (انخفاض كثافة العضلات) بشكل أعلى في المنطقة الدالية.</p><p dir="RTL">بالنسبة للبالغين، يوصى باستخدام إبرة ذات طول لا يقل عن 4 سم أو أكثر للمرضى الذين يعانون من السمنة مع تغيير موضع الحقن في كل مرة.</p><p dir="RTL"><em><u>التعاطي داخل المفصل أو داخل الجراب</u></em></p><p dir="RTL">سيتم إعطاء الدواء من قبل أحد الأطباء المتمرسين. راجع المعلومات الواردة في نهاية هذه النشرة.</p><p dir="RTL"><strong>الاستخدام مع الأطفال</strong></p><p dir="RTL"><strong>لا ينبغي إعطاء كيناكورت-ا للأطفال ممن تقل أعمارهم عن عامين</strong> (انظر القسم 2 &quot;الأطفال والمراهقون&quot;) <strong>ولا ينصح بإعطائه للأطفال دون سن السادسة من العمر.</strong></p><p dir="RTL"><strong><em>إذا كنت تستخدم أو تعطي لطفلك، كيناكورت-ا أكثر مما ينبغي</em></strong></p><p dir="RTL">إذا كنت تستخدم أو تعطي طفلك جرعة مفرطة من كيناكورت-ا، فاتصل بالطبيب أو توجه إلى المستشفى على الفور.</p><p dir="RTL">إذا كنت تتعاطى جرعات مفرطة من الدواء لفترة طويلة من الوقت فإنك قد تواجه بعض الأعراض مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقلصات (ألم مفاجئ وحاد في العضلات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من المعدة و/أو الأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجه كوشينغ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط الدم</p><p>نسيان استخدام كيناكورت-ا أو إعطائه لطفلك</p><p dir="RTL">لا تتعاطى جرعة مضاعفة أو إضافية لتعويض جرعة فائتة.</p><p dir="RTL"><strong>إذا توقفت عن تناول كيناكورت-ا</strong></p><p dir="RTL">إذا كان من المقرر التوقف عن تعاطي العلاج بعد فترة طويلة الأمد، فإنه يوصى بالتوقف التدريجي عن العلاج وليس المفاجئ. إذا توقف العلاج فجأة، فقد لا تتمكن الغدد الكظرية من إنتاج كمية كافية من الكورتيزول، وهو أحد الهرمونات الأساسية للجسم (ما يطلق عليه قصور الغدة الكظرية الحاد)، الذي يحدث أيضًا في ظل ظروف مرهقة.</p><p dir="RTL">قد تواجه تكرارًا مفاجئًا لأعراض المرض الذي تم علاجك منه عقب التوقف عن العلاج باستخدام كيناكورت-ا، لذلك سوف تخضع لمراقبة دقيقة من قبل الطبيب حتى بعد توقف العلاج.</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، فيمكنك سؤال الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم تعرض جميع الأشخاص لها.</p><p dir="RTL">إذا واجهت أنت/طفلك أيًا من الآثار الجانبية التالية، فيجب عليك <strong>التوقف</strong> عن العلاج باستخدام هذا الدواء والاتصال بطبيبك <strong>على الفور</strong>، الذي سينصحك بأنسب علاج يجب اتباعه:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية سريعة الظهور (ردود فعل الحساسية الشديدة) أو رد الفعل التحسسي الشديد الذي يمكن أن يتسبب في حدوث الوفاة (صدمة فرط الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشعور بالألم المرتبط بالتورم الموضعي، وزيادة صعوبة تحريك المفصل فضلاً عن الإصابة بالحمى والشعور بالضيق. قد تكون هذه الأعراض دليلاً على وجود عدوى مستمرة في المفصل.</p><p dir="RTL">قد تحدث الآثار الجانبية التالية، المدرجة أدناه وفقًا لوتيرة تكرار حدوثها، أثناء العلاج باستخدام كيناكورت-ا:</p><p>شائعة (قد تصيب ما يصل إلى 1 من بين كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp; العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp; إعتام العدسة البلورية، عدسة العين التي تركز على الصور (إعتام عدسة العين)</p><p dir="RTL">&middot;&nbsp;&nbsp; ردود فعل في موضع الحقن</p><p dir="RTL"><strong>غير شائعة (قد تصيب ما يصل إلى 1 من بين كل 100 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تراكمات القيح التي تتشكل في موقع الحقن (خراج عقيم)، تلاشي أعراض العدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ردود أفعال تحدث ذات أعراض مماثلة لأعراض الحساسية، إلا أنها لا تؤثر على الجهاز المناعي، نظام دفاع الجسم (رد فعل تأقي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حالة مماثلة لتلك التي تسببها متلازمة كوشينغ وتتميز بما يلي: وجه بدري (كوشينغ)، سنام الجاموس، السمنة، زيادة كمية الشعر، التهيج (مظهر يشبه كوشينغ)؛ تثبيط وظيفة الغدد الكظرية، الغدد الموجودة فوق الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; احتباس السوائل أو الصوديوم، انخفاض معدل حموضة الدم الناجم عن نقص البوتاسيوم (قلاء نقص بوتاسيوم الدم)، ارتفاع مستويات السكر في الدم (فرط سكر الدم، داء السكري)، التي قد لا تستجيب للعلاجات (عدم السيطرة الكافية على داء السكري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأمراض النفسية، الاكتئاب، اعتدال المزاج، تقلبات المزاج، تغيرات الشخصية، الأرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حركات الجسم غير المنضبطة (النوبات)، الإغماء العابر (الإغماء)، زيادة مستوى ضغط الدم في الرأس في حالة عدم الإصابة بالمرض (ارتفاع ضغط الدم الحميد داخل الجمجمة)، التهاب الأعصاب، الوخز (التنمل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; العمى، وهو مرض يتميز بزيادة معدل ضغط السوائل في العين (الجلوكوما)، انتفاخ العين (جحوظ العين)، ثقب غشاء العين الشفاف (القرنية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضعف القلب، عدم ضخ ما يكفي من الدم لتلبية احتياجات الجسم (قصور القلب الاحتقاني)، وعدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، انسداد الأوعية الدموية، التهاب الأوردة، المرتبط بتكوين الجلطات الدموية (التهاب الوريد الخثاري)، التهاب مزمن في الأوعية الدموية (التهاب الأوعية الدموية الناخر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; آفة الغشاء المخاطي في المعدة أو الأمعاء (القرحة الهضمية)، ربما تكون مرتبطة بالانثقاب وفقدان الدم، التهاب البنكرياس، وهو أحد الأعضاء المعنية بعمليات الهضم، تورم البطن، التهاب الغشاء المخاطي للمريء (الأنبوب الذي يربط الفم بالمعدة) المرتبط بظهور الآفات (التهاب المريء التقرحي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشرى، الطفح الجلدي، تشكّل البقع الداكنة والفاتحة على الجلد، ترقق الجلد، هشاشة الجلد، النزيف الطفيف الناجم عن تسرب الدم من الأوعية الدموية الصغيرة (بقع حمراء)، ظهور كدمات، احمرار الجلد، فرط التعرق، ظهور بقع على الجلد بأحجام مختلفة تتراوح في لونها بين الأحمر الفاتح إلى الأرجواني، إلى الأحمر البني (الفرفرية)، علامات التمدد (خطوط الجلد)، وفي ما يتعلق بالنساء ظهور شعر صلب وخشن في أماكن مماثلة للرجال (فرط الشعر)، طفح جلدي مشابه للدمامل (التهاب الجلد الشبيه بحب الشباب)، آفات حمراء تعلو سطح الجلد وغالبًا ما توجد على الوجه (الذئبة الحمامية الجلدية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان كثافة العظام (هشاشة العظام)، هشاشة العظام (النخر اللاوعائي)، كسر العظام الضعيفة بسبب مرض آخر (الكسر المرضي)، تأخر التئام الكسر، عدم الراحة العضلية الهيكلية، ضعف العضلات، أمراض العضلات (اعتلال العضلات)، فقدان كتلة العضلات (ضمور العضلات)، تأخر النمو، وهو مرض التهابي يتميز بامتصاص العظام في مفاصل القدم (اعتلال المفاصل العصبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام الدورة الشهرية أو انقطاعها (انقطاع الطمث)، النزيف المهبلي عقب انقطاع الطمث (نزيف ما بعد انقطاع الطمث)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنسجة المبطنة للجزء الداخلي من المفاصل (التهاب الغشاء الزليلي)، الألم، تهيج موقع الحقن، عدم الراحة في موقع الحقن، التعب، عدم التعافي بشكل تام،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم في الدم، وحدوث تغيرات في مخطط كهربية القلب (التمثيل البياني للنشاط الكهربائي للقلب أثناء بذل المجهود)، وانخفاض معدل تحمل السكريات، وتوازن النيتروجين السلبي (فقدان المزيد من النيتروجين مقارنة بما يتم امتصاصه)، زيادة معدل ضغط السائل داخل العين، تداخل الفحوصات المختبرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تعرض فقرة أو أكثر من فقرات العمود الفقري للكسر بسبب الضغط (كسر ضغط العمود الفقري)</p><p>غير معروفة (لا يمكن تقدير معدل تكرار الحدوث من البيانات المتوفرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الفواق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في الرؤية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ عند درجة حرارة أقل من 30&nbsp;درجة مئوية. لا يتم تبريده أو تجميده. يحفظ بعيدًا عن أشعة الشمس. قم بتخزين القوارير بشكل مستقيم.</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء عند ملاحظة وجود تكتلات بالمستحضر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتويه كيناكورت-ا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي: أسيتونيد التريامسينولون. تحتوي كل قنينة على 40&nbsp;مجم أسيتونيد التريامسينولون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: كربوكسي ميثيل سليلوز <strong>الصوديوم</strong>، كلوريد <strong>الصوديوم</strong>، بوليسوربات 80، <strong>كحول بنزيلي</strong> (راجع القسم &quot;يحتوي كيناكورت-ا على الكحول البنزيلي&quot;)، وماء للحقن، وحمض الهيدروكلوريك/هيدروكسيد <strong>الصوديوم</strong> (لتنظيم درجة الحموضة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يأتي كيناكورت-ا في شكل مستحضر للحقن للاستخدام العضلي والمفصلي.</p><p dir="RTL">يتوفر كيناكورت-ا في عبوات تحتوي على قنينة واحدة من محلول قابل للحقن سعة 1 مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">BRISTOL-MYERS SQUIBB S.r.l.&lrm;</p><p dir="RTL">Piazzale dell&rsquo;Industria 40/46</p><p dir="RTL">روما - إيطاليا</p><p dir="RTL">BRISTOL-MYERS SQUIBB S.r.l.,&lrm;</p><p dir="RTL">Via Virgilio Maroso, 50 - روما (إيطاليا)</p><p dir="RTL"><strong><em>الشركة المصنعة</em></strong></p><p dir="RTL">CATALENT ANAGNI S.R.L.&lrm;</p><p dir="RTL">Loc.&lrm; Fontana del Ceraso snc</p><p dir="RTL">Strada Provinciale 12 Casilina N. 41</p><p dir="RTL">&lrm;03012 ANAGNI (FR)- إيطاليا&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">أو</p><p>&nbsp;</p><p dir="RTL">Swords Laboratories Unlimited Company T/A Bristol-Myers Squibb Pharmaceutical Operations, External Manufacturing Plaza 254</p><p dir="RTL">Blanchardstown Corporate Park 2</p><p dir="RTL">دبلن 15، D15 T867، أيرلندا</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تعديل هذه النشرة مؤخرًا في أغسطس 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KENACORT-A 40 mg/mL suspension for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One 1-mL vial of KENACORT-A 40 mg/mL contains 40 mg triamcinolone acetonide. 
Excipients with known effect:
•	sodium
•	benzyl alcohol


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intramuscular administration of KENACORT-A (triamcinolone acetonide suspension for injection) is indicated for systemic corticosteroid therapy in such conditions as allergic syndromes (to control serious or debilitating conditions that cannot be treated conventionally), dermatoses, generalized rheumatoid arthritis and other connective tissue disorders. Intramuscular administration is particularly valuable in such conditions when oral corticosteroid therapy is not feasible.</p><p>KENACORT-A may also be administered by intraarticular or intrabursal route. These methods of administration enable effective, local, short-term therapy for joint pain, swelling and stiffness resulting from traumatic or rheumatoid arthritis, osteoarthritis, synovitis and bursitis.</p><p>For the treatment of generalized arthritic diseases, intraarticular injection of triamcinolone acetonide should be regarded as an aid to other conventional therapeutic measures. Certain disease processes such as traumatic arthritis or bursitis may represent typical indications for therapy carried out exclusively via the intraarticular route.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">General</p><p style="text-align:justify">The initial dose of KENACORT-A may vary from 2.5 to 60 mg per day depending on the specific disease being treated.</p><p style="text-align:justify">In less severe cases, lower dosages may be sufficient while higher initial doses may be needed in other patients. Generally, the quantity of medicinal product administered parenterally ranges from one-third to one-half of the dose given orally every 12 hours. Higher dosages may be warranted in cases where the patient&rsquo;s life may be at risk. The initial dosage should be maintained or adjusted until a satisfactory clinical response is achieved. If this is not achieved after a reasonable period of time, KENACORT-A should be discontinued gradually, and the patient should be treated with another therapy.</p><p style="text-align:justify">THE DOSAGE REGIMEN IS VARIABLE AND MUST BE INDIVIDUALIZED ACCORDING TO THE DISEASE BEING TREATED AND THE PATIENT&rsquo;S RESPONSE.</p><p style="text-align:justify">It is recommended to use the lowest effective dose for the disease in question.</p><p style="text-align:justify">Once a positive response to therapy has been achieved, the appropriate maintenance dose should be determined by gradually decreasing the initial dose until the lowest dose effective in maintaining the desired therapeutic response has been reached. If the product is to be discontinued after long-term therapy, gradual rather than sudden discontinuation is recommended.</p><p style="text-align:justify"><u>Posology</u></p><p style="text-align:justify"><strong>Systemic administration</strong></p><p style="text-align:justify"><em><u>Adults and children over 12 years</u></em>: the recommended initial dose is 60 mg. Inject deeply into the muscles of the gluteal area<strong>.</strong></p><p style="text-align:justify">If the injection is not given correctly, subcutaneous fat atrophy may occur.</p><p style="text-align:justify">The dosage is typically adjusted between 40 and 80 mg, depending on patient response and duration of remission. In some patients, however, symptoms can be well controlled with low dosages of 20 mg or less. Patients with seasonal allergy or pollen asthma who do not respond to desensitization therapy and other conventional therapies may obtain a remission of symptoms lasting the entire pollen season with a single injection of 40 100 mg.</p><p style="text-align:justify"><em><u>Children aged 6 to 12 years</u></em>:<strong> </strong>the recommended initial dosage is 40 mg, although the dosage depends more on the severity of symptoms than on age or body weight.</p><p style="text-align:justify"><em><u>Neonates or premature babies</u></em><em>: </em></p><p style="text-align:justify">This preparation contains benzyl alcohol. Do not use in neonates or premature babies (see section 4.4 and in particular section &ldquo;<strong>USE IN CHILDREN</strong>&rdquo;).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Local administration</strong></p><p style="text-align:justify"><em><u>Intraarticular or intrabursal administration:</u></em> A single injection of triamcinolone acetonide is often sufficient, but several injections may be necessary to adequately relieve symptoms.</p><p style="text-align:justify">Initial dose: 2.5 to 5 mg for small joints, 5 to 15 mg for larger joints, depending on the type of disease being treated. In adults, doses of up to 10 mg for smaller areas and up to 40 mg for larger areas are usually sufficient. Doses of up to a total of 80 mg have been given via single injections without incident.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Method of administration</u></p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>General</strong></p><p style="text-align:justify"><strong>The product must be administered under conditions of absolute sterility. </strong>Before use, shake the bottle well to ensure that the preparation is evenly suspended and that no agglomerates have formed. Exposure to low temperatures causes agglomeration and the product should not be used if this occurs<strong>.</strong> After withdrawal, inject immediately to prevent deposits in the syringe. Take all precautions to avoid the risk of infection or the needle penetrating a blood vessel.</p><p style="text-align:justify"><strong>Systemic administration</strong></p><p style="text-align:justify">The injection should be made deeply into the gluteal muscle. For adults, a minimum needle length of 4&nbsp;cm is recommended. A longer needle may be required in obese individuals. Use alternate sites for subsequent injections.</p><p style="text-align:justify"><strong>Local administration</strong></p><p style="text-align:justify">In cases of significant intraarticular effusion, it is advisable to perform preventive aspiration of some of the synovial fluid, without emptying it completely. This measure helps to facilitate the remission of symptoms, while avoiding excessive dilution of the steroid injected <em>in&nbsp;situ</em>. Intraarticular administration should then be performed according to the techniques prescribed for injections into the joint cavity.</p><p style="text-align:justify">A local anesthetic may often be appropriate for intraarticular or intrabursal administration of KENACORT-A.</p><p style="text-align:justify">Extreme care must be taken with this type of injection, especially when performed in the deltoid region, to avoid injecting the suspension into the surrounding tissue, as this may lead to tissue atrophy.</p><p style="text-align:justify">Do not use KENACORT-A for intravenous, intradermal, subtendinous, intranasal (turbinates), subconjunctival, retrobulbar or intravitreal (intraocular), epidural or intrathecal injection. See section&nbsp;4.4 (Special warnings and precautions for use)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients (see section 4.4 “Special warnings and precautions for use”).
Corticosteroids are contraindicated in patients with systemic infections and in children under two years of age. Intramuscular administration of corticosteroids is contraindicated in the presence of idiopathic thrombocytopenic purpura.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">KENACORT-A contains 9.9&nbsp;mg/mL benzyl alcohol as a preservative. Benzyl alcohol may cause allergic reactions.</p><p style="text-align:justify">Benzyl alcohol has been associated with serious adverse events and death, especially in neonates. &ldquo;Gasping syndrome&rdquo; has been associated with benzyl alcohol. Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with &ldquo;gasping syndrome&rdquo;, the minimum amount of benzyl alcohol that may cause toxicity is not known. Premature babies and low-birth-weight neonates, as well as patients receiving high dosages, may be more likely to develop toxicity.</p><p style="text-align:justify">High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of accumulation and toxicity (metabolic acidosis).</p><p style="text-align:justify"><strong>Therefore, the product should not be administered to children under two years of age because it contains benzyl alcohol (see also section &ldquo;USE IN CHILDREN&rdquo; below).</strong></p><p style="text-align:justify">This is a suspension; do not inject it intravenously.</p><p style="text-align:justify">No studies have been conducted to demonstrate the safety of therapy with KENACORT-A administered by intranasal (turbinates), subconjunctival, subtendinous, retrobulbar or intraocular (intravitreal) route.</p><p style="text-align:justify">Cases of endophthalmitis, ocular inflammation, increased intraocular pressure, chorioretinopathy, including maculopathy due to deposits of crystals of the active substance and viral retinitis/chorioretinitis (mainly by cytomegalovirus) and vision disorders including loss of vision have been reported following intravitreal administration. Several cases of blindness have been reported following injection of corticosteroid suspensions into the nasal turbinates and injection about the head. Administration of KENACORT-A (Triamcinolone Acetonide Suspension for Injection) by any of these routes is not recommended or indicated.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Epidural or intrathecal administration of KENACORT-A should not be used. Cases of serious adverse events have been associated with epidural and intrathecal administration.</p><p style="text-align:justify">Cases of severe anaphylactic reactions and anaphylactic shock, including death, have been reported in individuals receiving triamcinolone acetonide injection, regardless of the route of administration.</p><p style="text-align:justify">KENACORT-A is a long-acting preparation and is not recommended in acute conditions.</p><p style="text-align:justify">To avoid drug-induced adrenal insufficiency, a support dose is indicated in stressful situations (trauma, surgery or serious illness), both during treatment with KENACORT-A and in the following year.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Visual disturbances</p><p style="text-align:justify">Visual disturbances may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, they should be considered for referral to an ophthalmologist for evaluation of possible causes, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after use of systemic and topical corticosteroids, including triamcinolone acetonide.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Prolonged use of corticosteroids may result in posterior subcapsular cataract or glaucoma with possible optic nerve damage and increase the likelihood of secondary ocular infections.</p><p style="text-align:justify">Average and high doses of cortisone or hydrocortisone can cause increased blood pressure, salt and water retention and increased excretion of potassium. These effects are less likely with the synthetic derivatives, except when they are used in high doses. A low-salt diet and simultaneous potassium supplementation may be necessary. All corticosteroids increase calcium excretion, which may then be associated with or exacerbate pre-existing osteoporosis.</p><p style="text-align:justify">Corticosteroids may mask some signs of infection, and intercurrent infections may occur during their use. When receiving corticosteroid therapy, defense capabilities may be diminished and it may be difficult to locate a potential site of infection. In addition, individuals receiving immunosuppressant therapy including corticosteroids are more susceptible to infections than those who do not use these medicinal products. Varicella and measles may be more serious or even fatal in patients receiving corticosteroid therapy. Special care should be taken to avoid infection in children or adults being treated with corticosteroids who have not had these illnesses. If this occurs, therapy with varicella-specific immunoglobulin (VZIG) or intravenous pooled immunoglobulin (IVIG) may be indicated. If varicella or herpes zoster develops, therapy with antiviral agents may be considered.</p><p style="text-align:justify">Similarly, corticosteroids should be used with great caution in individuals with <em>Strongyloides</em> (pinworm) infestation because corticosteroid-induced immunosuppression may lead to <em>Strongyloides</em> superinfection with widespread dissemination and larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.</p><p style="text-align:justify">Patients on corticosteroid therapy, especially at high doses, should not be vaccinated or immunized as they are predisposed to clinical complications, especially neurological because of the loss of antibody response.</p><p style="text-align:justify">The use of triamcinolone acetonide in patients with active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used to treat the infection in conjunction with an appropriate antitubercular therapy. If corticosteroids are administered in patients with latent tuberculosis or tuberculin-positive response, chemoprophylaxis is necessary.</p><p style="text-align:justify">Since there have been rare cases of anaphylactic reactions in patients undergoing parenteral therapy with corticosteroids, appropriate precautions should be taken before administration, especially when the patient has a history of drug allergies.</p><p style="text-align:justify">It is recommended that intramuscular injection be administered deeply, as local atrophy may occur. The gluteal region is preferred over the deltoid, as a higher incidence of local atrophy occurs in the deltoid region.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">A state of secondary adrenal insufficiency may occur following corticosteroid treatment and may persist for months after treatment is discontinued. Therefore, in any stressful situation (such as trauma, surgery or serious illness) that occurs during this period, hormone therapy should be resumed. Sodium chloride and/or mineralocorticoids should be administered concomitantly because mineralocorticoid secretion may be impaired.</p><p style="text-align:justify">In patients with hypothyroidism or hepatic cirrhosis, response to corticosteroids may increase. Caution is advised in patients with ocular herpes simplex because corneal perforation is possible.</p><p style="text-align:justify">Various psychiatric disorders may occur with corticosteroid therapy: euphoria, insomnia, mood and personality changes, severe depression or frank psychosis. Pre-existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. The use of antidepressants does not alleviate these disorders and may exacerbate mental disorders induced by corticosteroid therapy.</p><p style="text-align:justify">Corticosteroids should be administered with caution in the following cases: non-specific ulcerative colitis with risk of perforation, pyogenic infections and abscesses in general, diverticulitis, recent intestinal anastomosis, active or latent peptic ulcer, renal failure, acute glomerulonephritis, chronic nephritis, hypertension, congestive cardiac failure, thrombophlebitis, thromboembolic episodes, osteoporosis, exanthem, Cushing&rsquo;s syndrome, diabetes mellitus, seizure disorders, metastatic carcinoma, myasthenia gravis.</p><p style="text-align:justify">Although KENACORT-A may improve inflammation symptoms, the cause must be investigated and treated.</p><p style="text-align:justify">Intraarticular administration of a corticosteroid may produce systemic and local effects. Accidental injection of the suspension into periarticular soft tissues may also cause systemic effects and is the most frequent cause of local treatment failure. Patients undergoing intraarticular treatment should not exert excessive strain on the joints in which improvement in symptoms has been achieved, otherwise increased deterioration of the joint may occur.</p><p style="text-align:justify">During intraarticular administration, overdistension of the joint capsule and effusion of the steroid along the needle should be avoided, since subcutaneous atrophy may occur.</p><p style="text-align:justify">Avoid injecting the preparation into unstable joints. Repeated intraarticular injections may in some cases result in instability of the joint. In some cases, particularly after repeated administrations, it is advisable to perform an X-ray examination.</p><p style="text-align:justify">Intraarticular injection rarely causes joint discomfort. An increase in pain accompanied by local swelling, further restriction of joint motion, fever and malaise is suggestive of septic arthritis. If confirmed, discontinue corticosteroid administration and immediately start appropriate antibacterial therapy and continue for 7 to 10&nbsp;days after all signs of infection have disappeared.</p><p style="text-align:justify">Avoid intraarticular injection into joints that have been the site of infectious processes.</p><p style="text-align:justify">Edema may occur in the presence of renal dysfunction with a reduced glomerular filtration rate. During prolonged therapy, good protein intake is essential to counteract the tendency toward the gradual decrease in weight sometimes associated with negative nitrogen balance, weight loss and skeletal muscle weakness.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Menstrual irregularities may occur and vaginal bleeding has been observed in postmenopausal women. Female patients should be made aware of the risk but appropriate investigations should still be recommended.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In peptic ulcer, recurrence may remain asymptomatic until the moment of perforation or hemorrhage.</p><p style="text-align:justify">Prolonged adrenocortical therapy may cause hyperacidity or peptic ulcer; administration of an antacid is therefore recommended.</p><p style="text-align:justify">It is essential that patients be monitored even after discontinuation of triamcinolone acetonide therapy because there may be a sudden recurrence of the main symptoms of the disease for which the patient was being treated.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">KENACORT-A contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &ldquo;sodium‑free&rdquo;.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em><u>Use in Children</u></em></p><p style="text-align:justify">Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of nuclear jaundice, particularly in small premature babies. There have been rare reports of deaths, primarily in premature babies, associated with exposure to excessive amounts of benzyl alcohol.</p><p style="text-align:justify">KENACORT-A is not recommended in children under six years old.</p><p style="text-align:justify">The growth and development of children on prolonged corticosteroid therapy should be closely monitored because corticosteroids may suppress growth. Caution should be used in case of exposure to varicella, measles or other infectious diseases.</p><p style="text-align:justify">Children should not be vaccinated or immunized during corticosteroid therapy. Corticosteroids may affect endogenous steroid production.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em><u>Use in the elderly</u></em></p><p style="text-align:justify">Side effects such as osteoporosis or hypertension, which are common in systemic corticosteroid therapy, may have more serious consequences in elderly individuals.</p><p style="text-align:justify">Close clinical monitoring is therefore recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Amphotericin B injection and potassium-depleting agents: </u></em>Individuals taking these agents should be monitored for possible hypokalemia.</p><p><em><u>Anticholinesterases:</u></em> Antagonism reactions may occur with these agents.</p><p><em><u>Oral anticoagulants:</u></em> Corticosteroids may increase or decrease anticoagulant action. Therefore, individuals taking oral anticoagulants and corticosteroids should be closely monitored.</p><p><em><u>Antidiabetics:</u></em> Corticosteroids may increase blood glucose; diabetic individuals should be closely monitored, especially when corticosteroids are initiated or discontinued or the dosage is modified.</p><p><em><u>Antitubercular medications:</u></em> Isoniazid serum concentrations may be decreased.</p><p><em><u>Cyclosporine:</u></em> Increased activity of both corticosteroids and cyclosporine has been noted when taken concurrently.</p><p><em><u>Digitalis glycosides:</u></em> There may be a possible increase in the toxicity of digitalis when administered concomitantly with corticosteroids.</p><p><em><u>Estrogens, including oral contraceptives:</u></em> Corticosteroid half-life and concentration may be increased, whereas clearance may be decreased.</p><p><em><u>Hepatic enzyme inducers</u></em><em> (e.g., barbiturates, phenytoin, carbamazepine, rifampin): </em>Increased metabolic clearance of KENACORT-A has been noted. Individuals taking these therapies should be monitored closely for possible diminished efficacy of the steroid and the dosage of corticosteroids should be adjusted accordingly.</p><p><em><u>Cytochrome P450 3A4 inhibitors:</u></em> Triamcinolone acetonide is a substrate of cytochrome P450 3A4. Therefore, caution should be exercised when administering KENACORT-A together with potent cytochrome P450 3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin), because an increase in systemic corticosteroid adverse events may occur (see section 4.8).</p><p>During postmarketing use, clinically important interactions were reported in patients taking triamcinolone acetonide and ritonavir, resulting in systemic corticosteroid effects such as Cushing&rsquo;s Syndrome and adrenal suppression (see sections 4.4, 4.6 and 4.9).</p><p><em><u>Human growth hormone </u></em><em>(e.g. somatrem):</em> The growth-promoting effect may be inhibited.</p><p><em><u>Nondepolarizing muscle relaxants:</u></em> Corticosteroids may decrease or increase the neuromuscular blocking action.</p><p><em><u>Nonsteroidal anti-inflammatory drugs</u></em><em> (NSAIDs)</em>: Corticosteroids may increase the incidence and/or severity of gastrointestinal bleeding and ulceration caused by NSAIDs. Also, corticosteroids may reduce serum salicylate levels and therefore decrease their efficacy. Conversely, discontinuing corticosteroids during high-dose salicylate therapy may result in salicylate toxicity.</p><p>Aspirin should be administered with caution in conjunction with corticosteroids in individuals with hypoprothrombinemia.</p><p><em><u>Thyroid medications:</u></em> Metabolic clearance of adrenocorticoids is decreased in hypothyroid individuals and increased in hyperthyroid individuals. Changes in the thyroid status of the patient may require adjustment of adrenocorticoid dosage.</p><p><em><u>Vaccines</u></em>: Individuals receiving corticosteroid therapy who are vaccinated may experience neurological complications and loss of antibody response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Many corticosteroids used at low doses have been shown to have teratogenic effects in laboratory animals. Because adequate reproductive studies in humans have not been conducted, the use of corticosteroids during pregnancy, breast-feeding or in childbearing age should be evaluated in light of the possible benefit versus the potential risk to the mother, embryo, fetus or breast-feeding infant. Newborns born to mothers who received substantial doses of corticosteroids during pregnancy should be closely monitored for any signs of hypoadrenalism.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Studies on the ability to drive and use machines have not been performed. However, given the possible occurrence of undesirable effects on the central nervous system (e.g., vertigo), patients should be informed of this possibility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Table 1&nbsp;shows the adverse reactions listed by system organ class, according to MedDRA terminology, and by frequency.</p><p style="text-align:justify">The frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1 000 to &lt; 1/100); rare (&ge; 1/10 000 to &lt; 1/1 000); very rare (&lt; 1/10 000); not known (cannot be estimated from the available data).</p><p style="text-align:justify">Table 1: Adverse reactions during treatment with KENACORT-A, according to MedDRA classification by systems and organs</p><p><img src="data:image/png;base64,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" alt="" width="561" height="793" vspace="0" hspace="0" border="0" style="width:561px;height:793px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="541" height="73" vspace="0" hspace="0" border="0" style="width:541px;height:73px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAiwAAAMECAYAAACc/34GAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAOLjSURBVHhe7P1Pa+Net++LDt+XURQhWH4N1SicsPg1Ir+ANOysxSWtgASb0yns3UhjL8jZIFGdZ8GyoVpplbTOSee0bpxGeIhENeo1RKIoitqN3brcu+E0LszbeDTmGhqe8p+Uk8jx9wMmmVPzv4amhuccnqNjjDEEAAAAANBi/h86AgAAAACgbUBhAQAAAEDrgcICAAAAgNYDhQUAAAAAraezqdFtp9PRUQAAAAAAW0WrJ09SWDbMAkCrgAyDXQByCvYZl/xjSwgAAAAArQcKCwAAAABaDxQWAAAAALSeF1NYwjCkTqdDnU6HwjCksiwpjmOdbGO2UcYmDAYD2w/+5Hmuk7WGsiwX2luWJeV5Tmma1u5Lm/sB/rGnu+wzGAx0FgBeHC2XrnkljuNamjAMdZJG5JwVx/FCWcueiV6vt5BGfsqyrKWXDAaDhfJcuN4R+uMaE7CaF1FY4jim2WxGxhgyxtDx8TF5nqeTbUyapnR/f6+jnwV+8c/nc8qyzPbF9306Ojra6IF7KeI4tuPM7TXG0MnJCR0dHRER0XQ6VblAWzHGUBRFRETkeV7tnhZFoZMD8CoYYygIAjv3fP36VSepkWXZRvPQdDqlIAhseDwe1+Q/SRL7rMzn85qC8Pj4aJ8h3/ft8yOfK5fSUpYlzedzms/nzusaXa6Mk20Hm/EiCsv9/X1NQRkOh388wZZlSaPRSEc/GycnJ0REFAQB9ft9G397e0tERLPZjNI0tfGvTZqmNJlMiIgWxvrx8ZGSJKnFgd2m2+1aWQSgDVxcXBBVc6Mkz3P6+PFjLe45GI/HVjk4Pz/Xl2ucnp7a/3///l27RkR0c3Pj/N/FqudwOp3W3iFgfV5EYaHqpSmX3LrdLo3H44XlvLIsKU1T6nQ61Ov1iNQy3mAwoLIsrQKkNWhZHm8XcXkcx+Xx8p4s20Wapvalf3Z2pi+T7/tERHR5eUmkysvzvFa2XM6UH1Lt1O3huF6vV+tjk7bPbQmCgLrdrr5Mw+GQhsOhjiZasVyrr3H9chmU7xt4GaScyPuT57m9L/x8yPukl6XlfeW8ZVnWnj9dhpQ/mY7jZZyUb1k3PyMynUue+Nlp42omWEQqAfLL3K9fv+jdu3c2LJEyou+zlod1OD4+JqreP1reJayE+L7vVCZ+/PhhlZ8vX77oy0/G9b6Sz4Pc8pLvLn5O+P88zxee/TeJ2ZAnZDFFURgiqn2yLLPXgyAwRGSCIKjFGWNMFEW2zqIojO/7pigKkySJISLj+77Nw3FJktg6uR7f923dRVEYz/Ns2Bhjw7JdDLeB82q4/VwWt8PzPOP7vgmCwPi+b8vhvsk8OsztTZLEGGNMlmX2ehRFC2VJ5HhHUaQvL8BpsyyzeT3PM0aNC1/jNul7wWPDeduKHPNdQ8oif+QzYMQ98zzP3pssy6ycynvGyHsuZa0oipo8GSVffM9ZXk3VRi5Lpg2CYOG55esclu3gfrC8GTEv7APy/uwafJ9YLqSMRlFUkwuec1nueM6S955lQcsjp5VxUl6kLHO86xlaJldJkpgsy2plud4TLmRdmmXvK35WPc+zz1MURbU2yOeJqrHQz9cu4xqzF1lh6Xa7C3t30u6D9y9nsxnleU5lWVrN+ODggKj6psbL3q4VAxKrCh8+fLBp9P5pFEXU7Xatlv7cWyO3t7c0nU7p9vaWfvz4QUREh4eHRNV+KVUaNf3j7pAxhsIwpPl8Lkr5TzzPo/F4rKO3Bt+rx8dHGgwGte0kHtPRaER5ntt78f79eyLRn8fHR5sHPA/ShqWJq6srGg6HZIyhd+/e0Ww2I8/zavcsTVP7zY6X8F3fMJeR5znN53O70nhwcOD8RuuyU+Bvtn/99RdR9Qyw/FxfXxNV8kZVWz99+mTzgvbDWzFs+5GmaW3lRXJ1dUVEZLeLPM+j6+tryvOciqKwstvtdrdiB+L7PmVZRrRiS//h4YH6/T71+307x3Fb/4R13lcnJyc0Ho/p8fFxYd6fTqe1uVdff4u8iMIiFRMjDJHk3ibHff36lW5ubux2xXA4pCRJ7JZSk1BJPM+jTrV83bRl0sSvX790VG2/1bW/yXXwhM3opUtWVFhxYWWAl0fLyrD3+PjYlvXz50+b34Wrf1Khe4pRMi9JXl5e2geUx4VfkEdHR3Yrot/v2wdfLm2Cl6Fpz5wnMwk/R2x0/fPnTyuPfwpvz7KC4XqWGFZKltXd7/ftc5CmKf38+bPxywpoJ8Ph0M4hNzc3a93Do6Mj6nQ6VBTFH3/5kTLoeh76/b5Vflw2kWVZ0mw2s1stPGeva3y7DsveV/zO2JQ/Hbe28iIKS1n9jJaRxlB8g1g7nM1mC5MYf0v0PI9Go9HCTdXIX/E0TeabIDXrb9++6ct2NWSVYdd4PKYoiuwDQNULhB9grqPJtmQTWAFsWqnhlSxNWZZ0dHREnuc1ftNmpXM+n1vlpN/vk6l+NTWZTBa+XYP2wM+GMWar38rkqo8xZiM5blKs+VvoaDSyq61gt+CVu8lkstY95F/5yNW2p/Lw8EBUyWbTfCZX/rTdzOfPn2sybcSK5irj23XZ9vvqLfMiCgtVWrN8id3d3ZHv+zVtm5UYadjKRkcklog1aZpSnuf2wZDLdU2GtJtyd3dHVD10sh9cfhAECxO062H78uVLTfi5/1p5cOXdhPF4bL+d6pWeNE3p6urK+U1HryDJLaGyMsCkqnxWsNLqPBdqWPYHr4P8dtntdq08SOO+OI7t88ZKg5ZFLSd6omaFvigKuwKapulaq6Fc93w+t8+VfGbllwX9fIHdQG4B8T3U8wyJL3yspFIlC1K+WEZ4Pl5Gnud2FX9VetfWUNOXLn5PTSaThWdlE9Z5X+kv73uPNmpZxROyLBhgNRkFFZVRrSSKoppRqzQiZUMsaTAl6+C2SsMkTi/DrjxN6LTkMMCS12R7XcZe5DAsI9VGaVBGjvZKIzONNNKSZTOyHjZ21Gn5/6IonOmTJKnFLzNgawO04h63FX0fyXHvtYxp5DVtCCnvK//PRrXyurzX2nhWpjFKprXc8rOhn0/9PCVJUnuO9gVy3L9dQN5Llk+/+vGBUXOOlhd9jeVPy5eUJZ1Hp5NIedR1NJXD81xTGi2vjKsu/bzqZ8I45mxZftM7gpY8X7sKj4ekVd6ay7Kk79+/v+lvUrwVpHmuMQWLPKcMvxVcW5avRZqmNcPEfQFyCvYZl/y/2JZQE2xoGscxff78+U0rK2EYUhAEdjvIGENZltklbwDAP+AzJvI8p4eHh71TVgAAi7RihYW/zSVJ8qYVljzP7a8zGM/z/theBWzGc8jwW0KuAr6WfMpnpQ2rPK8B5BTsMy75b4XCAsBLAhkGuwDkFOwzLvl/9S0hAAAAAIBVQGEBAAAAQOuBwgIAAACA1gOFBQAAAACtBwoLAAAAAFoPFBYAAAAAtB4oLAAAAABoPVBYAAAAANB6oLAAAAAAoPU86aRbAAAAAIDnRKsnT1JYNswCQKuADINdAHIK9hmX/GNLCAAAAACtBwoLAAAAAFoPFBYAAHiDlGVJnU6H8jzXl16MOI6p1+vp6J3hudrf6/UojmMdbQnDkAaDgY7ee2DDAvYOyDDYBf5UTvkHElmWUb/f15fBCtI0pdFoRJ7n0ePjo74MnhmX/GOFBQAA3iBFUeioZydNU0rTVEfvJMPhkKIo0tHPQhiGVJaljgYKKCwAAAC2wuXlpY4CKyjLkmazmY4GDqCwAADADtLr9ajT6VhbiMFgUAu7CMOQOp0OdTqdmo0E27vwh7/tsw0Hl80rKDItr6h0Oh0qioJGo5G1+5C2GNzejrCrkeXK8Kp+xHHs7Af3L01TCsPQxud5XmuztOthexJZt0bmlytIsk/a1kVe03n5/zzPyfM8IiLyPM+2eTAY1NrPZZVlWYvfO8yGPCELAK0CMgx2gXXk1PM8E0WRDfu+b8NFURgiMlmWGWOMCYLABEGwcK0oCuN5ni0jCALjeZ5JksQQUa0MU9Upy5R5icgkSWKMMSaKIkNExvd9e122j+H0vu/bcrMsW6iXiaKoVgYRmSiKTJZltn+yXdzXoihsfi7b9/2FPnqeZ9us+xBFkf0/SRL7P9fBfXGNNV/zPK8W5r5y+4IgMERk80dRVMvL8W8dcsj/YswKXIUAsEtAhsEusI6cbqKwyJeihF/K+lMUhYmiqKaQaJIkaVRYTPXylQqLfMlz2Ii26o9Wbox44csPKzuuPkrlgZEvfj2GrKiZamxk/3R/JazkGYdipsNynFzt9n2/prA01fmW4XsgwZYQAAC8cVYZdPq+T9UXWPvpdrs6WY1er0ej0UhHL2U4HNJ8Pm/8qXVRFLU2jMdjnYSIiJIkqaW7vb2lfr9PQRCQ53m17RdX309OTpzxRETv37/XUUvhLTJp5Hx+fk5fvnyx4fl8Th8/frThTeAx4G2lpnbvA1BYAADgjcPKx+/fv/UlIqKFn+3Gcdz4YmRbj7u7O0qSRF9eSRAE9PXrV8rzfEE5kO0ry7LRjuXnz5+1MNt1TKdTMsZQFEU0Go0oz3Pqdrt0d3dXS09iTFywXcky2K7l4eGBjDG1PMPhkEgoGVEU/dFPyx8fH8kYQ77vr9W2twoUFgAA2FF6vR79+PGDqHqBzudzmkwmzhd9EAR0fn5uw6wQnJ6eUlEUNWPO+/t75wu9LEuaz+dUFEXtep7nVJalfZm66mfOzs5oNpvRt2/f7Eu82+2S7/t0dHRk093c3DhXJS4uLmgymdhVmjzP6fDwkPI8t30Yj8fk+z5RVV9RFLU2zWYz+vTpkw3f39/b/6+uruji4sKGm/j69SsFQUDT6bQWzwa/19fXK1eKiIjevXtn/3eNWxzHdrXo9vZWX94v9B7RKp6QBYBWARkGu8A6csr2D2zHwbYS2iaE7Vikkam0i5DlsD2FtG2RaXUZXLcRBqNRFNn/5XVG243IeM7jus64ytZGtNJuxdU/xquMbHU+3X9phOxVhseyTG57lmWNdkGmuq/80Ya4rj5ElaGvzvPW4fGS4KRbsHdAhsEuADl9GXq9Hl1cXCxdBdmUOI4XyivLkr5//263i8ByXPKPLSEAAABgS+R5TpPJREfT58+foaz8IVBYAAAA7CW9Xo+Komi0+3kK/GslNrjlz/HxsU4KNuRJW0IAAAAAAM+JVk+epLBsmAWAVgEZBrsA5BTsMy75x5YQAAAAAFoPFBYAAAAAtJ6dUljYq2YTHeVJ86UJw3CrnjTZUyoAALwEq+bYp/Jc5W4KH6O/TZa9d9gLdpMrArAZrVJYtItzEkcuDwaDmq8GF8aYV/vZWBiGNJvNdPSTSdPU+dM48Pxot/DaFT3Hb1M5BWBTnkNOHx8fF84P2QbPVe4m5Hm+se+jVaz6QtntdskY80fH8oP/pFUKy8nJSc2pVUc4erq9vW21D4XpdEpBEOjoJzMcDimKIh29FQaDgY4CgsfHR4qiiDzPW5hs+FqWZQtHcgPwkmxDTvdpLuj3+0/yfbQM7YMJPC+tUVjKsqSiKOjDhw82zqzhMRRsBvsbAQDsN5gLwK7RGoWFFRO9itL07SAMw9rWkd4rZPsPuc3UtM/IXjf5I/daee81juNafQy3Y9XSIO+dhmFIceUJlZdtuT72gqr3emXdctmXy5Tt4jJ4GZjbF4YhpWlqnYvJemQZ8hvXYDCw+fi69OAq74FcdtZbezzunJ7r4H7JOmU9ehzaCMuOvJ/LxkLePzl+Un6kLOsydZjEfdIyqsOMlht5TzvV/VpXrsFuwHIqZa5pLpDzpJYVRspWR8i1roflVJcr8667yiPnUG7zsrmb58JcOEVk5HO57jzjmsM1XCc/N3J+oA3fS8CBdi60iidkWRvpTEo622KkwyxSDqw4X5ZlC06qTOXIylWmqZx5sUMpdlrF8VwO1yvbEASBdZTFzsakwy0J181t47ZrJ2DsvMyItuhwURQmSZJaf2Q5vu/X2iHbyfUzUeWkzIjxz7Ks5lyMr8tygyCwY8Z95zCXYUR9fC0IgpojNHbsxdc4n+z3tpH9b2KZvERRZLIsW3AwVxSFHcOiKOx1vtey77Lfprp/XF9TmTpcFEXtPkkZ1WH+n/MynL8oCpuP1L3cF2drbUPepyY2lVP5TOm5gO8/3+9lcwzLjKnmBd/3G+vR5TbNOcuQz4CUx6a5O0kS2wZuH8eTeC/oPi5D5pH95zZx/xk5HkU1Z3OYy1p2//YdOZY2TkeswlXItnEpCqYSGJ5gNSwcLPhaENYVTD2hy4fUKIVCCq1RioGGhVqzrHzdB1OlT5Kk9qBqNlFYNHIMl5XD90d+AuFZVCInjFUKi877HCzrP+MaeyaqXgRGyAvLgVRS5MSskeNs1MStZXlVWN+nZWEpXwyJ54yUnLK8gZfnOeXUNMwF8v4vm2Mk8hl21WMcciXRz0ITrvZK5NzdlFbH6/l+GU19oGruc90HPR76fq37XtpHXPelNVtCktvbWzLGkO/7NJlMasvo/EscGbctBoOBXSZdBde/ro1NkiQ0Go3skuKfsm1jL17i3YQsy8hUBtLGGJpOp/Tjxw+djP7666+12judTmk+n9ul0tfk4OBAR9V49+6djlrANRZULUdr2GDy169f+tJWcd0H3/cb2wrazTbktAmXrGg6nc6Tf834lDmnCT13D4dD8n3fziXbeF8sm8NnsxkVReF8tsH2aI3CUpblghDwL4PkJB5FESVJsrZisQ68J3p5eUlZlunLS1lXQIfDIRljKMsyms1ma++baoqioPfv31Ov16OfP3/qyxvD+7L0D3VWX16KfrmGYUiHh4dOQ751bSFY+fE8b+08z0XTz+h//PixlqJ6eHjolA/O++3bN32J3r9/r6O2Sq/Xo/v7ex1Nh4eHOgrsCH8qp00sm2PYlsoYs/GvGf9kztEsm7v5i28QBHR0dOR8Fjdh2RyeJAlFUUQnJye1PGC7tEZhoUpLlQZIeZ4v/HKIhPa8rrHWKmazGWVZVvtZYFmWS7Xyfr9PnufVBHQ2m9FsNltQvEi8sPv9fu0B7/V69tttXlntS8+hcjKK45h836d+v0/n5+c0mUxqDyHX2+12bXxZlrV2yRdiHMd0fX1NURQtnJGwyhAsCAIajUa2njRN6fj4mE5PT4lEW4iIvnz5QpeXl0TVi1F+c5tMJjSfz63hKI/53d2dTfMa8Hk++l7q8DJOT09pPp/XxpLzB0FQu39pmtp7+5ycn5/X2lSWJc3n84X7D3aDP5FTPRdomuYYnpe1srFqzmCeOue4aJq7//Vf/9X2aTqdLvyY4yk0zeEM92edsQdPRO8RreIJWdZC7vmTMjo0wnCLqv12me4//uM/annkNd6Dl2GNTs9/dZ2+w7ZG19tksyDzyjbwHicRWVsPaWMQVYZkfF0ir5HDjoLr0u2S6eXYcHr5l0S/ZNioPsnyZf3k2J+W1+T+d1DZsDTl2xa0gQzLtup+ynvH7ZXhQhnMktoDl2PKY6DHTt8fHZYfPX6usBH7+PxhdD1SBlx79+B5kfdmFfLeyXttHHIq7UtknL7/ZskcI2XDNWfItLpcLX+c7+9//7sNa3QepmnuTio7P74WRdFCGXpc+Pomc7jOL9Po99JkMqnlX/Ve2nfIIf/w1gz2Dsgw2AX2VU7jOKbT09M/2s76E8IwbDxOA7wcLvlv1ZYQAACA/YVtW15DWeEzU87OzvQl0BKwwgL2Dsgw2AUgp2Cfcck/VlgAAAAA0HqgsAAAAACg9UBhAQAAAEDrabXCIg8Yagu9Xq92hkVnS6coLiMMQ/y2HwCwQK9yztpmwjDc2plZr81rv5M6S5wlakeLb5FWKyx8smBb6PV6tYPcut0uGWOe9bCvMAytOwIAAGAGg0HjKbdtYjqd0u3trY7eSV7znbTq5O9+v0/GmFf5hdVL0SqFJU3TRu2xDTw+Pm7lxMRNmE6nFASBjgYA7DnsugRszrorPnmet2YFax3fTm+dViksfHw7AAAA8Bykabr2y//q6kpHgVekNQpLp9OhoihoNBrZpa84jmvLYGHl6CpN05pNBzviYgeK7AWU8/K+oyyL9/v4swwuX9uR6D1DDg8GA0rTtGbbIuuSGjv3cTAY1PYnua+uZUDuj77O/nj4Go8Hl6vbDwB4G8jnXod5vuF5Maz8AXUq+ztOp+cHjud0JOYeLj+OYzuHyXlJrpTzvMTIdPzheYzTcls7VX90mJHxctWEbXt0vjiOaTQaUVEUtp1si8gfbmuv17O+3WR+PSfz+0HmJWXvwtfXXa3hdsdxvHBfGH5n6PccE1a2Q/IeP7e95bOjz+pfxROyrA37YzDCdwT7WMiyzPp4CILAxrOPCFP5t+A0URTV/DOwbxQuS/rlYR8+LtjngxFtSpKk5ntD+tcwwncH+8KRZfA17dtC+s1h3z1G+JaRfmCkrwvus/SpwTSN2b7znDIMwLZYR07Zf46cA/l/6aeLCYJgwdeYEfMS55V1sz8h6XtHz4lyjuL0RVHYeUnPZzxnynlJzmHsT437J8P8fxRFNb9rnE77EHLlk3NhEAT2GvdHzun6mswrfb/JuVr7KZL5V1EUhb1vPJYMqfcPI+uT+Uj4KQsq32K7gmusFmNW4CpkW/DNYKRg8Q2Rjrt0mmXxiVBY5IMhP5osyxbKlhOCbpMUbkbWy8iHVLfTVOMg+8kKiVEOuPjD+X3ft+mMo33gH7juNQBtYx051XOOfIEax5dA/mLkmht4/pBKiPxkWeZ86TbNYVyvnJe4XkaH9Ry2LOwpZ4skXs7LxsXVXkYrVLoc1ztJIhUMPVau9C64DXyvJFQpRK726/q0ghI5FNg24xqr1mwJraLf71MQBOR5nl3KI+HSm5e81v1JVxAEVCls9qP59u3bwvLfMq6vr+3yIS9P/vz5Uyej4+PjRut+XrJbZukdRVGt3U37sU1jBgDYD6IoouvrayIienh4WPqLRjnneJ63MD8uy6tpMgbu9/vkeZ6di759+0a+7+tka5MkSa2Nf/JrpDAMG9vt4tevXzqKPn78SFQdefFUut0uRVFER0dHzm2k2WxGRVH8UR27ys4oLFT9YsYYQ1EU0Wg0si/3x8dHMsaQ7/trC5y+2U37hE3KgAv+WVlRFDSfzykMQzo4OHAK16p26vSSHz9+1MJNbaclYwYAePucnp7SfD6nNE3p8PBQX16A0+gvVNombx3ev3+vo4gqQ9bRaESdTocmk8kfKRn6C+GyubAJthdZ9kXSBffPNS7LvnCuw3g8JmMMJUlCk8mk9mUzSRKKoohOTk5qefaBViks/BLXGiVVQsHCOB6PrVYex7G9mVLwWVFgLi8vqSgK6vV6dHZ2RvP5vFaPS0E4PT2loihsvXmeW8Ng12oFr8Z0u11KkoSo+t0+qQfp+vq60fqcv4FIYZzNZjSbzSgMQzo/P6fZbGbrd7WbaRozAMB+0O12KQgCGo1GdHp6qi/T9+/fiap5ZDab0enpqZ2zpBHr9fX10hUW+aWM5yZX+rIs6fr6urYq8lQuLi5oMplYhSHP87WUsoODA/t/HMf05csXSpLE9ptJ07Rm0KrnWp6rz8/PbdzXr18piqJauk0py9KO/XA4dB5rwTsLT1HQdhq9R7SKJ2RZG7YtiSpjKt6X9DzPZJWhLMfxPibvy3G8tIGRe5x631Lv0zYhjZl83zdeZcOijaqkgZmrTBnPbdR9bEovbVia8rnGpmnM9h19bwBoI6vkVM9v8lmXdhc8D0h4/pJ5pM0E21HIa01zJs+tsj2Ma/6RZfBHt5/tL5aFjbJHlPYrTeVGUVTrG7efw7oPfC2oDHNlOkbXZxzvF/2+4LLkfWLY6JbTcr9k/iRJamn+9re/1a7rcZFt17LQVsgh/53qwtp0HC6fAdglIMNgF9iWnOZ5Tr9+/aqtIOR5TkdHR1QUxR9vX/AqxTrb52VZ0vfv3xdWM+I4tqsG+0QYhjSdTnU0aJD/Vm0JAQAA2C5XV1cLCsJrEYbhgt2J3mrZB/jMlE+fPulLYAlYYQF7B2QY7AJ/Iqe8gkJElGVZzZ5EXqPK/uSpqyxxHNNkMiGqbBBXrbKUZbnwg4N18oH9wyX/UFjA3gEZBrsA5BTsMy75x5YQAAAAAFoPFBYAAAAAtB4oLAAAsKOwk782oZ0d7jLaoeBLUlZOGV0H05HD+e4+AIUFAAB2kMFgsNHJrC/F7e3tm/mp7nA4XLCjeCm0cbKGT1Z/qsH0LgKFBQAAdpDb29uVLzXwD+SpvctI09R5ivlr0EZl9LWBwgIAAODNkqbp2j+bvry81FGgRUBhAQCAHScMQ+pUHut1mG1c2MlfGIbW/oH/cryE42UZXE6v17P2HR3lCV7b1ch0/GEfPWzvwm3rVO3XYUbGy1UTrlPni+OYRqMRFUVh2yn73BF963Q61lcct4/7KnHllWnZ9oTrWwe+X2maLtwHptfr1fqt7Wt4LOV4vzn7Fn1W/yqekAWAVgEZBrvAOnLKfmzYPxn7OjPCz5okCIKaLx32icO+blzl8LUoimo+cqQ/N6r8qbF/G/aRw3UVRWHr5zqlvxtOz/2RYf4/qnzMMZxO+wpy5ZO+f3zfX/Dnxsgx4L5qv0GrxoXT63qbyLKs5huJ8/DYZVlmsiyrlSV9E3E+DnNZvu/vtP84eV9snI5YhasQAHYJyDDYBdaRU/liNtVLSr/U5QuYHRzyC48VCc4bBIFJkmThRStfpK4XsaxHtonrYXRYv1SXhVmZkR9WyJaNg6u9jG6P7IdReTcdF1d6F657YYTCElSOHzWsJDF67ALlNHfXcMk/toQAAOCNEkURXV9fExHRw8ND7Yh+Df/aRPv6ISI6Pj5eagTaZPzb7/fJ8zy7NfLt2zfyfV8nW5skSaj6ok3GGLq9vdVJ1mYwGNRcFKziKeOyDv1+n4IgIM/znNtIs9mM5vN5LW5fgcICAABvlNPTU5rP55SmKR0eHurLCxweHtLBwQEVRbFg/9CklDDv37/XUUSV88XRaESdTocmk8kfKRlaaWiy91gG24tcXl5SlmX6ciNPHZd1mE6nZIyhKIpoNBrVzl7JsoyCIFj7l05vGSgsAADwRul2uxQEAY1GIzo9PdWX6fv370TVIWWz2YxOT0+tZ2epDFxfX9PV1ZUNyxc3rwi4Vm/KsqTr6+vaqshTubi4oMlkYl/meZ6vpYQdHBzY/+M4ptlstuAQsixLyvPcKh/SmJZZZ1yeQp7ntszxeOxcgZpOpzSfz53t2iv0HtEqnpAFgFYBGQa7wCo5lTYdTcanprKR0DYQbDch87B9C8Px1GDXIetndJt0OfKarJvtNJaFjTIulfYrTeVGUVQzMtZlcF62NeFrUWXgK9MxHEdiXHRabYTL1+V9Yfj+cPpAGUZTdW9kP2X5pO4j267I8C5CDvmHt2awd0CGwS6wLTnN85x+/fplVwg47ujoiIqi2Pik1DiO6cuXL2udbVKWJX3//r1WN1VljMfjWtw+EIbhmzkF+LlxyT+2hAAA4A1zdXW1oDC8FGEYLtidaBuQfYDPRvn06ZO+BDYAKyxg74AMg13gT+SUV1CoMtqU9hryGlX2KOuussRxTJPJhKgyNl21ylKW5YJR6jr5AHDJPxQWsHdAhsEuADkF+4xL/rElBAAAAIDWA4UFAADARrDfmpfCdaAaw76B/sQ2RvpeaqrnKWhfRGEY1s5T0f6AwHKgsAAAAFibMAxf9ORV7XxQ0+/3yRizth2OJo5jOjw8JGMMBUGwVY/N4/HY2uvwGTCS4XC4sO0BmoHCAgAAb5DnOhl1Op06Dzd7Lp7bQPf+/t4eLjedTp+tvvF4TEEQ6OgaZVm+6MrVrgGFBQAA3hh5nr/oKsgu81wKylP4/PmzjgICKCwAALCjSNsLtuNI09T+bLnT6VAcx9bOg9Pzt/g4jmv5mbIsqdPp2HydTse5YiPzl2VZC3MdbKfhyq/h/HEcN640DAYD6nQ6dqtI24GwnYhsu/TNw/D1oiisr6OyLK19juyXa5wZfa0j+q5tVjTSxmUwGNBsNqPZbLZQHref+75NO5udQh99u4onZAGgVUCGwS6wSk75+HbG8zx7DDsf3S7TkToaPkmS2pHzfLy7qermjyyD83NaGeb/dbmmOvJ+FUVR2OP2+Sh7hqrj6HWf2cUAx8kj8rksPua/CT5K36hj+xldpx5n2Vd5jdsi65Zt4Xuk74EcKzmupuqvdJPwlpFjzmCFBQAAdpBut1sz2Dw5OaldZ7rdrvVKLB0gXl5e1hz38ZHxaZpSURRE1aFzJJwo3t/f2/RBENjj9bvdLv348YNIOAlkR315ntPx8bHNt4z5fE55ntN4PF4wRn14eKCTk5NafL/fpyRJbJjtRHzft16h13GQyLB9jrQ1WTbOP3/+rBkFX1xc2NWXVTYrw+GQoijS0TUuLy9pMpnYMr9+/fpqpxa3ASgsAACww/D2jf4FyipYKWG63S55nrdwlD6zyYv/6uqKvnz5QrTBS7bb7VIURXR0dESdaltIMpvNal6iXxrXOJ+entJ8Prdtur+/p7/++kvk+jP6/T75vk83Nzf60l4ChQUAAHaUTqdjVx2WfZt34XkePTw86Gj7ixkX6/50eDgcUlEUG9ta8MpKkiQ0mUxq+ZMkoSiKGleSnpOmceaVJ8/zqFPZ0WzbqeP5+bkdi7OzM315r4DCAgAAO0iapk6/PGma0vv3721Yr1QwFxcXNJvNrEEn/5WrId++fbP/TyaTjV6YURTRaDRaOw8bvFLVBpcCxspAk0Huc7BsnNM0tWe4GGPsNtRTYYUwz/Pa/fA8jy4vL2s+ofYSbdSyiidkAaBVQIbBLrCOnLKBKBtvkjCE5Xg27uRPURQ2vzRSlcafbGjKxrVcjhEGt0RkgiCoGapKg9GiKBaMb7k+aUjKsNEtl8XGqbLtSZLU0vztb3+rXZdtYYNVXR4jDXZlGlkWI9PIcXaVQUQmy7KFtuiwa+z5Xum2RlG0MGbc1izLavFvBXLIP5wfgr0DMgx2gdeUU/ayrD09b0JZlnRzc+PcIgnD0Br57jJpmtKHDx8WtsriOHb2+6nEcUynp6cL9Swb413HJf/YEgIAALB1Pn/+XPtVEokzUz59+lSL31VGoxH9/v27FpemKX38+LEW96fc398vKCthGNLJycmbVFaagMICAADAwqsrRERHR0fOQ9ea4F/SdDodOj4+XnjJsu8cHb+rJElif9XEn4eHhyevSknkIXwu25jndCPQVrAlBPYOyDDYBSCnYJ9xyT9WWAAAAADQeqCwAAAAAKD1QGEBAACwMb1er/GMF7Zl2cT+5blpY5sk0hEicAOFBQAAwEYMBoOFo/0l7H9nG8an24INidvKeDzeOyPaTYHCAgAAewaf0vpUbm9vW68AaJYpWGA3gMICAAB7xuXlpY4CoPVAYQEAgB2F7UgGg4E9s0MShqGNZ/87nU6HiqKg0WhkbSbk+SmdTqfmEVmWwb5+JPI6k+d5rRwO86fJ9sWF7JvMp8uUbZZ5XH6Her1erT+ucjhNnufWvkTWyf5+ZJjRbZPX+HyVOI5rbQvDsDa+3Ic8z5192Ev0Wf2reEIWAFoFZBjsAqvkVPq9YX8ynudZPzRBEFj/P+wbiMPyf+3zJwgCG2ZfQbIMWZcsx/M8kySJTUfCb5Hv+zYd+9BZB9/3bX3styfLMvu/TMftZD89Mk9RFAvt4jC3kdvPJElisiyr+WKSY6vD/L8ul/ubZZn1lyTj5f98LUkS2wff9xd8C+0DLhlZjFmBqxAAdgnIMNgF1pFTz/NqTvH45Wqq/PrDL3USioZ0wic/+sWr0XU3KQoarWw0IRUM+YmiyARBsOAMUOZxoRUuU40Dh+XYmUoJYaIoqil1y8JSyWM8zzNBEDjbwEilR7dlH3H1H1tCAADwRnj//n0tnGUZVV9MyRjT6HDQ9/1aun+8L7bPYDCgo6MjHb2Uoihq7RqPx7XtH4n267MJw+GQPM+jNE2pLEs6PDzUSdbC1baTkxMqy5K63S5FUWSP82/aGhsOh+T7vnNLaZ+BwgIAAG8I+eudX79+1a412ULon9PKF+mfKAEM27lcXl5SlmX68lJk/WVZUhzH1O126cePH7V0RETv3r2z6Z7CxcUFXV5e0s3NzYLjxnXpdrt0d3eno63/pPF4TMYYSpKEJpNJ46+1bm9vyRhDQRDQ0dHRk/v0loDCAgAAO8z9/b39/+rqii4uLoiIKAgCGo1G9kWXpikdHx8TCaUmjmM6PT2loihqygx7Bw6CgM7Pz208KwybMpvNKMuy2rksZVkuXTnodrvk+35tRebm5oY+fvxIZ2dnNJvNavnDMLR5ZF/yPG9UCjTj8ZiKonB6R16Xs7MzKoqiNk6z2Yw+ffpEZVlaw9rhcEhBEIic/0mapjb/dDrduZ+QPxt6j2gVT8gCQKuADINdYB05ZSNbtu/QthNN19hoVNuc8Efansgy2E6DDW65DF2PLkvGcV42cuU8Tei6GGkMS8ouRObxfX/BHkb3V+YNhLGyUTY+bLezLGyWjCcb3XK8NuLluCRJaum435xOtu+tQg75h7dmsHdAhsEusI6c9no9uri4oPF4rC/tFGEYNtrXvDRtaksTu9DGP8Ul/9gSAgAA8CrweSVnZ2f60qvQdjsRPsPlrSsrTWCFBewdkGGwC6yS016vZ4+bj6Jo51dZXpMwDGk2m5HneQsGyOB1cMk/FBawd0CGwS4AOQX7jEv+sSUEAAAAgNYDhQUAAAAArQcKCwAAgBpl5Qxx2Tkpr0mn01n7bJXnQjsr1AwGg8aD+nh8t23km6YpdZQDzLcEFBYAAAA12nxQGXuYfk3iOKbZbKaja9ze3jp/zVOW5bON73A4XLD7eEtAYQEAAEBxHNsVFf71URtpw694xuNx4ym1q+h2u60e3zYDhQUAAABNJhMdBUCrgMICAAA7TKfy6CttTtiWgZ0Oyg/7qOFDyP7lX/7F2j0cHR0t2GX0ej3qdDqN8dKehA+CYxsNWZ8Ok3CKyJ9NbToGgwF1Oh27TcRh2Saug1eQOtU4cTppZyLbLdsTxzH1ej1bvrSf4bHmcpler1frqyz75ubGxnNaORY6fVOdYRhSHMcL7WS4zDRNG+1pdgp9Vv8qnpAFgFYBGQa7wDpyKtOwTxvpx0b7xGHfNQz78GFfO+xTR/reKYrChtknjud59n/26fP3v//d5uF2SX8/MizrYDzPW+pTSMJlcnvl/0EQ1MopisJEUVTrk/b5kySJKYrCxnM50t+RrIOvk/CDJOtlP0DsA0iPH+eVvoVk3Ub1idvA95PTcnxRFPZ/2TfZNl1+2yGH/C/GrMBVCAC7BGQY7AKr5FQ7/+NPlmU1xUAiX3pJkiwoKE1hzptl2YJjP/5weSRezKvCEq1oLEP2w1QvcA7rtrOyYhrq933fBEFQc2IoP6zw6Bd+EAQ1BVArhOwYka9pJUq2Q6bl9Fq59H3fxun+M7Kdrr7uEuSQX2wJAQDAjuJ5HlVfPO2n3+/rZJYoiuj6+pqIiB4eHpamXYWudzgc6iRrwVsfq351sy7dbpeCIKCvX78SEdGPHz+o2+3qZBZ5zff9hX4ty7su9/f3dHh4qKMb+fHjh46iv/76yxocJ0lCo9HIbgu56Pf7FAQBeZ63sKW0q0BhAQCAHUX/2iRN06Vnp5yentJ8Pqc0TTd6gbqQ9iZ5nj/phdjpdOjk5ISMMU/+1Y2Ls7Mzms1mlKYpHR8f68sL8FjoXyBJ+5A/xaWENHF4eEjz+VxHW/sU/vlylmU0m81qtjKS6XRKxhiKoohGo9FS2dgFoLAAAMAOwisa0hj2+vp66aoJrz6MRiM6PT2txTNNLz+m3++T53l0cnJi475+/UofPnyopVtFmqZOZ4NPUXw0/X6ffN+n0WjkXPn5/v07UaV0zWYzOj09pdPTUyqKorZicX9/v5UVlvPzc6tAEZE1uvU8z6kQ8b2Rbfny5QtdXl4SCcWl3+9TFEU2jSTPc5t/PB6T7/s6ye6h94hW8YQsALQKyDDYBdaRU7aF4I+0X+GPJsuyBfsIowxFdZk6bKr28Ufar8i4ZWHdds/zDFX1s1Gqy05Dl8n5dPokSRZsYriN3FdSdjq6D2y/IttohNEslyXT+L5fa5O0Y+E4aXTrSmsa7i0j289t0u3k+yzrlOlkXW2EHLILb81g74AMg13gueQ0z3P69euXc+WhbYRh6Dwtdh3SNKX379/XVpzyPKejoyMqimIrKye7zJ+M7Uvgkn9sCQEAwB5xdXXVemWFz4j5kxfqqu2xfYXPcPn06ZO+1HqwwgL2Dsgw2AW2Kae8skBElGXZm32Rp2lKo9GIqDJIlqsocgxc10G7cMk/FBawd0CGwS4AOQX7jEv+sSUEAAAAgNYDhQUAAAAArQcKCwAAgFYjnSq6YEPSlyYMwwWnkOD5gA0L2Dsgw2AXgJz+g7IsyfM8IhjK7hUu+ccKCwAAgNbS7XYpyzId/ezEcbzzR9m/NaCwAAAAAIrJZKKjwCsDhQUAAHaUXq9HcRzTYDCgTqdj7Tj44DX2OcM2Hhxmm5AwDO1fTsPXOp2O9SvEYfaF0+v1amG25eD4PM9tG/iz7moFtylN00ZPxFwmX4/j2PaNxLjINjSh62Pv0URER0dH1kaF6+uIcRwMBrU2cv9lGkbeo1X+mkAD6qj+lTwhCwCtAjIMdoFVcuryh+N5nvUTFEWR9TNjKt86nufVfNSwPxnpQ4fzs+8f6TtI+urxPM8kSVLzYVMUhb0uw77vO/0XabIssz5vgiCw7ef2FUVhkiSplcXt5LRyXLh/nuc5fec01cdjJMdVjg2nJ+GjR7aL8/N4+b5vy+K+SN9AYBFyyD9WWAAAYAe5vb0lz/MoiiJ7cu3V1RXN53OdtIa0CWGvwP1+n5IkIarKpcobtOd59O3bN5F7kfF4TEEQkO/7NYNYY4wN//XXXyLHcmazGZVlSdPpdMGT8+fPn+nh4cG2kap2So/FclzG4zGR8G7sYll9DMefn5/buOl0WvOAPBwObbu63a41FC7LkubzOR0dHVGn07Gn7a4aV7AIFBYAAHgjvH//Xkf9Ecte9OvS6XTWtgfp9/sUBAF5nme3aSSz2Yzu7u5qcX/CqvqeAm+tFUVRiy+Kgowx9sPKFFgfKCwAAPCG4G/22+Lg4EBHrQXbcxhjaisgq5hOpzbPaDSq2b4URUG9Xq/RtuUpLKtvE9j25+HhgYwxC/fh9+/f9v+yLGHH8gSgsAAAwA5zf39v/7+6uqKLiwuiStGQ3/IvLy/tC38Z/MLO85zm87n17Ox5Hv38+ZOoWkUoioJGo5FzVSLPc7uiIHGlleR5bpWR8Xhc23JhptMpzWazlWWtQ1N9cmtrXcXi69evFATBgofp79+/k+/7NceLNzc39PHjx1o6sAbaqGUVT8gCQKuADINdYB05ZSNbNjJlA1B5XRqgep5XM7AlYRjLxquyPGlEy9e5Hja6ZeNTzuuqm/8PgsCmlwa8TJZlC/1xtVeWK41+Pc9b6LPLCHdZfQzHy35zWF7nfLqd3A5tuCvbwWXr+wbc8o+TbsHeARkGu8A6ctrr9eji4mIr9hBpmtJoNFpZ57YIw3BhNWJfwVgs4pJ/bAkBAAB4MfhsFLyg/9Pu5ezsTF8CDrDCAvYOyDDYBVbJaa/XszYq8ie8T4FXV5hl9QLwErjkHwoL2Dsgw2AXgJyCfcYl/9gSAgAAAEDrgcICAAAAgNYDhQUAAHYUdvLXRGdLp7eu4qXqaaKzgXPFl0I7RtSww0iwPrBhAXsHZBjsAqvkdDAY0Hw+/2OD212nU3lWzrLM+lQCu49L/rHCAgAAOwg7+XsN2rQyoF9qr0UYhlSWpY62xHHculWgXQMKCwAAgLVJ07TRq/G+UpYlzWYzHV1jXQeQoBkoLAAAsOOEYUidTsduj1D1EpW2HXEcU6/Xo8FgYG1O2LNwGIYUxzGVZWmdFrJtDKeP45jiOKbRaERFUdgydD0c7vV6lOe5tW1hmw2us9PpUFmWC+F14TwuGx5us7zO7eKxGgwG9uA2vibT6zCJQ+/4k+c55XluV7o8z7N2K2xfxGUTER0dHdnVKW3jwm2W/o2AQh3Vv5InZAGgVUCGwS6wjpyyfxr2b8P+fUyVn33ZSH847NuG0xvh04Z9B7GPHsb3fRtmn0SMLtf3fVMUhfX5kyRJzd8P+81hXzwyvK5PHVkfly3r5//Zv4/088N1SJ9EVI21HCcZZkiMke/71ncSly+vkfAZxHVxu9ifEreFx0iXu8/IcWewwgIAADtMFEXWo3Kv17MelaWn5uFwSFEUked5NcPUoigoTVMaDodkjKl5KV4XWQ/z+fNn6na7ZIyh4XBI4/GYgiAg3/ftkfzdbnchvM4KS5qm5Pu+7Yc0OC7LkubzOR0dHVGn07Eekr99+2bbycfgd7tdyrKMSPTh/fv3zjC3S47RX3/9RU2ssi+aTqcLnqh5y+j29pZub29r18A/gMICAAB7SpIkNBqN7FbJNphOpzSbzahTbQttm4eHh5WKVVEUZIyxn23/iqrT6WzVJmU4HJLv+7WtJrAIFBYAANhTeGUlyzKazWZOe5BN4ZUVYwwVRfEsvyhatRLz+/dv+39ZllvpF1UrWJ3q57ZRFOnLf8Tt7S0ZYygIAjo6OlrZx30ECgsAAOwpvALS7/drL+Ber0c/fvwgqjwKz+dzmkwmFMcxHRwc2HQuRWAwGNiXLW+5bJOzszOaz+e2bjbqPTo6ot+/f5Pv+3YriIjo5uaGPn78aMNPJc9zu3IjSdOU3r17Z8OuMZErQq7raZra+Ol0unQ7aa/RRi2reEIWAFoFZBjsAqvklA1u2biTDT2JyEwmE/s/G3fy/9JgVuaR8dJIlY1AtQEpVUamsp4sy0wQBLW2FUVRq5+Na9cJswGxRhrHclptTMzXoyhytlP2ketaFi6KolYu/8+GsxzOsmyhfiPGOkmS2rgHQbAQJw2e9xVyyD9OugV7B2QY7AKQ03/8FJqNcsF+4ZJ/bAkBAABoFXzeCZQVIMEKC9g7IMNgF4Ccgn3GJf9YYQEAAABA64HCAgAAAIDWA4UFAAAAAK0HCgsAAICVxJXzRA0fptbZ0Hkh2A7sPHIfgNEt2Dsgw2AX2AU5HQwGdHl5Sf1+n3q9Hp2cnOCXPS9Inuf2kLy2y8qmuOQfCgvYOyDDYBfYBTntdDpUFMVK3z5tJgxD+vTp0872IU1TGo1GrZeVTXHJP7aEAAAAbMxb2P4py5Jms5mOBi0FCgsAAOwoYRha+xFtQ8KHr3WU1+Rer0dxHNeuS2SZ0oNzGIbWkWEcx9bfjed5tvyyLGvtYT8/VG0fybLLsrRt4XguR4fXIc/zhbHgcmS7OZznea0P3FdpkyPr5/7LeqRXZTme2uGjbBf7DOL0XAfbouh7JfuyisFgQB1x37j/HOY6ZB+4PRzme8Z1c5jby/frVVBH9a/kCVkAaBWQYbALrJJT9o/DeJ5n/dqwbyHG5cOG/dV4nmf/Z782RpSfJImJoshQ5eeH4etFUdg4Ej592BdPkiQ1X0GMbAvX6Qo3+ROSsF8ghv0RmapPst1ybDgf94HHyDT0X46BLDeKopr/H1Ljy33g+vhaFEU1H05JkthwFEU2n7y3Gh5nRvbdVO0MgmDBP5TMy/dMjze3vSiKWl9lfc+Fqw6ssAAAwA7S7XZre/wnJyf2/y9fvtDl5aUNG2NoOBzS7e0teZ5HURTReDwmEh6biYhmsxmNRiPqdDp29eHh4YHG4zEFQWDTuYjjmHzfp36/T0REw+GQfN+n6+trmk6n5Pt+rQzZluFwSFStdOjwz58/bZ4mvn79WvM2fXt7+yTjXx4jqsaXx4D77/u+vX54eGjzffnyhSaTiV2lICK6v7+3qxPcn36/T0EQ0JcvX2zeZfA9fHx8fFJ/JP1+n5IkIarGh6p2eZ5H3759U6kXmc/nlOc5jcfjBduSlwIKCwAA7DC8DSNtMYqiqKXZhCzLyBhjP+u+KH/8+KGj6K+//qLHx0cdvXW2bU/DWyebjGOSJLVxu729dSpbx8fHa5XLCiUrQdvuI7POtlu326Uoiujo6Ki2jfTSQGEBAIAdpdPp0MnJCRljaqsXnufRr1+/amnXRedb117h8PCQ5vO5jl7rhfindLtdp8K0KWzb8fDwQMYYu8KyDlo5CcOQDg4OqCiKBWVj3XIfHx/JGEO+76+d5ykcHBzoqAV4ZSVJEppMJjX7pJcCCgsAAOwgaZqS53kLKxhpmtLFxQWNRqNa/DqKRxAENBqN7As2TVM6Pj7WyZycnp4SqXr01tRzcXZ2RrPZrGYEy+04PDysjdFkMqH5fE6DwYDevXtn4+M4pq9fv1IQBAurSqtezhcXFzSZTGz9eZ7T4eGh3QqSY3J9fU1XV1dElaIgV1suLy+pKAprjMz18hbOOnS7XXv/+FdQs9ms1gbZzvl87tyCS9OUiqKg0WhE//Zv/2YNiYfD4crtwWdDG7Ws4glZAGgVkGGwC6wjp2xESUTG87yaQac0dOWyOA2ncxnhyjhpuMpxvu/XjFA5zghDVf6wMaerTN2WVWEug8vUsAGprtuocZJGt0a0I8uymmEqiTGVbdH9l0a4Oo6RZWojYt1PaXQrx03nM44+G3UP2FiXx5zTy3Kl0bQsLwiCBaNbvqb79xxwfyQ4OA7sHZBhsAtAThcpy5Jubm6sfQfYjF06ZM4l/9gSAgAA0HrCMKSTkxMoK3sMVljA3gEZBrsA5BRsE15dYdouWy75h8IC9g7IMNgFIKdgn3HJP7aEAAAAANB6oLAAAAAAoPVAYQEAAFCDT8+V55oA8NpAYQEAAFDjOU9VBeCpQGEBAABAcRzbFZV1fN08N2EYLhxpD/YbKCwAAABoMpnoqFeDj5QHQAKFBQAAdphO5c1X2pywt+EwDGvXO8LTbhzH1Ol06F/+5V+o0+kQEdHR0ZH1GcP0ej3qdDqN8Z1Ox/q8YeeBbAMj69NhqlZRZNvKsqQ8z+2WlOd51gcO90mm1eWkaUphGNp2cDrZHs6n84AdQJ/Vv4onZAGgVUCGwS6wjpzKNOzfRvrDkf5ntA8dU/m/McL/DPvfkf5oiqKwYfY743me/Z/9z/z973+3ebhd0jeNDMs6GPZ7Y4yxfeA6OMyw356iKEyWZTWfR+yLR5ch+9CUB7QHeb8ZrLAAAMAOwqsavHIgt3SSJCGqPOsy4/GY5vO5zZemKZ2dndnrLrIso263S91ul4iIfv/+TXmeU1EU5HkedTode3rq//gf/4OyLCMSNjDv3793hsuypG63WzsY7OTkxP6vubq6oiiKbJi9Kd/c3BAR0Ww2o7IsaTqdLnivbuIpecDrAoUFAAB2FM/zyBhT+/T7fZ3MEkURXV9fExHRw8PD0rSr0PVK5WgTeLtmmc2KS6HwfZ9+/PhB/X6fgiCwChQrZMt4Sh7w+kBhAQCAHUX/midN06Vnp5yentpVlsPDQ315I6QNSZ7nT3rpdzodOjk5IWMMBUGgL1t6vR7d39/raNuH6XRKxhiKoohGo9HSMWCekge8LlBYAABgB+EVDWkMe319vXTVpNvtUhAENBqN6PT0tBbPSKNYF/1+nzzPq23hfP36lT58+FBLt4o0TcnzvIXVkzRN6d27dzYcxzGdn5/XtrPKsqT5fE7j8ZjyPLdGs+PxmHzfJyKyZfz+/ZuIiD5//kxUrUr9H//H/+HMA1qONmpZxROyANAqIMNgF1hHTqVxLFVGs9LQ1VVGlmULxrfGGOP7viEia7wry9RhU7WPP0mSLKTT7dBh3XbP8wxV9ZvKCJdEfTo/w/3heDamNcI4l8vlepflAe1A3mMG3prB3gEZBrvAc8lpnuf069evJ9ucAPASuOQfCgvYOyDDYBd4LjkdDAZ0e3urowFoFS75hw0LAAC8ceRBapeXl/oyADsBVljA3gEZBrsA5BTsMy75xwoLAAAAAFoPFBYAAAAAtB4oLAAAAABoPVBYAAAAANB6oLAAAAAAoPVAYQEAAABA64HCAgAAAIDWA4UFAAAAAK3nSQfHAQAAAAA8J1o9eZLCsmEWAFoFZBjsApBTsM+45B9bQgAAAABoPVBYAAAAANB69l5hKcuSOp0O5XmuL+0UbejHa7chjmMaDAY6urWwB92yLPUlALbOYDCgMAx1NAA7Q2sUFnZ9rj/P/QLqdrtkjKF+v68v7RSe5+moF+c1xzKOY5pMJjr6SUj5S9O0dq3X69lrfzL5l2VJR0dHOhqAtZGyKGU1DMNafBzHRER0e3tL0+lUlQLA7tAahcUYQ1EUke/7ZIwhYwxlWUbz+fzZlZY/IQzDV/uGLOsuikJf3ivG4zFFUaSjnwTLHxHRaDSq3d/Hx0eKooiyLFtr8k/TdEHpoUq5y7JMRwOwNo+Pj5QkCXmeR8YYGg6HREQ0nU6tbBVFQePxWOUEYDdpjcLiot/vk+/79Pj4qC+1grIsaTab6egX4TXr3heCICDP8+jk5ERfWpvLy0sdBQAA4Am0WmFJ05Tm8zldXFwsxPNyZ6/Xs/FxHNslULlcz8ulvIQq82g7gjAMaTAY2LR5ntty+ZPnOeV5brdhPM+z9XF5Mi3De8jyOn+4fllvE011M1yGXpmS9fEyMVXj1uv1aDAYUKcaKznGHMfoPnLb9ViSWp7W7WHY9oU/sj+9Xo/iOK7dA0lT/La4u7ujoigWxliix4r73+l0qCgKGo1GNZlrQvd/Vd/l2HL58t6EYbgQlvn4ORkMBrV0y2QP7C4sT4yWW52W4+M4rslHWZa1Z1bOXWxHpsvk/IPBgNI0hYyBp2E25AlZ1iaKIkNE9uP7vk5ikiQxQRDYsOd5JggCUxSFTc/l8HUurygKY6o+cB55TdbPaTk9h33ft/VkWVa7xuVxmMvLsswEQWDLlnieZ5IkseEkSUyWZbU0Lprq5jjdFlkP542iyCRJYvPJej3Ps+EgCIznebW8jO/7zrHkfHyv+Lqrb0EQmCiKjKn6z2X4vm/L5Oue59n/oyiqyQg1yIxG34MmuO3cJh6/KIpsP/R48H3mMZD5NPIeJklSa/umffc8z94jfe+Nox1RFNXkncsKgmCtMQTPzzpyKp9f14dlgOVJPmcsL0bJlpwruHyzZM7Rzyo/G57nWVnS84drHgBA4pL/xZgVuArZFnISlhOwRD4Y/PE8b+kLkRyTtX6A5Et22YQt2+jKK5UpIxQqI17uEjkhGPGSXIWu29V/DuvJySglRI6HC5lfKhca3Sb5/7rol62cSE01hnJilf3VL/Em1pVheS+kIiIVFtkehsSLQcuehMfLJTdmRd/1vdYvApmWx5THJhFKsZb3dccQPD/ryKnr2TaOZ9EoefJ93ymXWZY5yzOOMlc9q3Ju09cAWIVL/lu7JXR9fU1FUdSWMJkoiqhStsgYQ4+Pj9TtdimKIjo6OrLLmE0cHBzoqLXodDpLf4niMr49OTlxxjPD4ZA8z6M0TaksSzo8PNRJ/pifP3/qKDo+Pl7LULfX69FoNLLhZX2RrJtOEobh2r92KsuSiqKgd+/e6UvPwnQ6ddqzuOyrfN+nHz9+6OhGZrMZ3d3d6ehGXGPLv8z69esXERH99ddfdH9/T0RENzc31oC9LEv6+fPnq/ySC7QHl9ySkJ9t8P79e/v/9fU1TSYTuy0EwFNorcLS7/cpiiKaTCYL+536ZcB78+PxmIwxlCQJTSYT568zmHVsChjezzXVL5ma6Ha7zhdPt9vVUTUuLi7o8vKSbm5u6PT0VF/+Yw4ODqgoioUX3TLlgPeh7+7uKEkSG9/tdhfG3wX3+ffv3/rSAmyjsa4SJVmn/G3B9ixSae31elYxkGyieBZFQb1eb6mdjITH9tu3b/qSfUmcnp5aBYWq58nzPPr+/bvKAfaRXq/n/CLz/v37jZ/BZfAc0+/3yRhDRVHQfD5fW9YBkLRWYaFKAfF9n46OjqzScn5+TrPZzCojPCGXZWk19+FwSEEQiJKIHh4e7P+Xl5d0fn5eu95EnudUFAX9Y4XqP0nTtPbtPo5jOjs7W1gVms1m9OnTJxt2MR6PqSgKur+/X6ncMLruZfDPHeUkcX19TVdXVyLVf1KWJc3ncyqKotaePM/pn/7pn2g2m9WUyKbJJwiC2jiXZels65cvXyhJEttOZpnC2e12rWwwX758edafwXe73ZryRpU8zufzmjzO53P7U1KesF39lkyn05pcryIIAppMJlb+0zQl3/ftykm32yXP8+jz58/08eNHomq1bzQaPXmFEbwdzs/Pa/JD1XPMiq18ptlIlucc/pLw+fNnokrGuRypvF9dXdkfTPAXRNczBMDa6D2iVTwhy1qQskvhPXbeJ+UP2xBwmPdbC2X4JffhOczXeC+V92T588///M/O/J4w3OX/2eaAw9xeXSbv78r6XfYKQRAs7Clz+ia4bm14p9vAbZNxXJdrLI1qL9cjbSB0+bpOV7+b9sZ1G1z/s22FDBt1b7Q9RhO0ZEyNw/hb2+FEwobFOMZDwrYvev/eNV78v1fZb3G4qe9cNjUYG0fKNknbIOj8st+u8sDLQivkVMoIiWda3leWFy1PZoWcy3iXLReXI/N5lZHtqny0ol8AmAb53wtvzZ1Ox/kNvk2EYeg8iCxNU3r//j1sDrbILsow2D92TU57vR5dXFzgoDqwFVzy3+otoX1B25YwvV6PHh4eoKwAAADYe978Cos8vKhtqyxhGNJsNiPP8xqt9sH22TUZBvvJLslpr9ezxrpRFGGVBfwxLvl/8woLABrIMNgFIKdgn3HJP7aEAAAAANB6oLAAAAAAoPW8eYWlrJx0sWGry0Hfn6Kdij0Fbqc+JK+JwWBQq3MbbVhFWjmQBAAAAF6aN62wlGW5cJorn7i47gFt6/D4+PjHRma6ncsYDAY0n89rcdtowzLSNK0d0Q8AAAC8JG9aYel2u1s9Zpp5jpNUN2nn7e0t+b6vo5+V4XCIEyoBAAC8Gm9aYXkO0jTFT5ABAACAF6ZVCkun06E0Ta3jPV7J0GGG4zvKOzPbg3Q6Hbq5uanlSdOUOuJsFg7zR/pyYaeHZVlSGIYUxzGNRiMqiqKWVv4vy3e1TbZZtmMdmsaBVBu4/71ej/I8r/VJ1i/LYdueMAztX1Ljo52lcR7dlziOqdfr2brSNLXl8Dhu04YIAADAHqDP6l/FE7KshfR1kWVZzbeKDLMPF9/3F/z3yHTaX0pRFDX/LbJeLicIAut7JYoi65vD8zzrF0P7Z+F2J0my4B/GCD8zpmqnzEvCr4fun4Z9vRjRX+1Ph9vr+74pisKWKX2MSP8eVPmMkWMtfd4kSbLQVw5nWVbzN+P7vvF9v+ZXR/aF8/F17Z/nJeH7AUCbgZyCfcYl/4sxK3AVsi3ky3VZWL5g5SeKIhNFUe2lrBUYqUBo5AtaKyaMK162U5fPyoULqYQsU1j4mkTmNaoNvu/XxsA4xsEo5YHbKa+zAiLTc9+1MzP+mDXG6LXRYwlAG4Gcgn3GJf+t2hLalKIoqFK6yBhD4/GY7u/v6fDwUCddSa/Xq/0Khn9xw9sd29zC4K0U/UufJr5//77Rr4im0ynNZjO7LUTCJbzkw4cPjdeIiObzOb1//15HW4IgqI3/P2TMTZIkNBqNattNAAAAwLrstMIiX7RlWVpbkR8/fohUy2E7i7u7u4VfwTw+PpIxhnzf30hhaIJtS66urmy567LJr4i63a5VIIqioMFgQO/evSOqlB8NX3Px69cvHWXRStwyRWQ4HJIxhrIso9ls9uxnxgAAAHhb7KTC0u12yfd9Ojo6snE3Nzf08eNHOj8/p9lsZg1N2ejW87yFF2xZljSfz6koitq5LHme03/9r//VlnF7e2uvHRwc2P83fene3NyQ7/u18qgybF0GO2xkI1lu92QycbZhMBjYvmZZRiTGTK4i3dzcUBAEjWfSBEFAo9HIlnV9fU1FUVCv16OzszOaz+cLxs5N8EpPv9+nKIr0ZQAAAGA5eo9oFU/IshbSDkIabjaFjTLUlfYcURTZeGl0q8sxlZ0Gh7k8tg+R17hOaT+j2/1f/st/qYW1Ea62veH6/va3vy3k08i8nufVbFhk3iRJrPGwrJeRfWI7F1c7m9JL2xTXeMqxl2n1OL8m3FYA2gzkFOwzLvmHt2awd0CGwS4AOQX7jEv+d3JLCAAAAAD7BRQWAAAAALSeJ20JAQAAAAA8J1o9eZLCsmEWAFoFZBjsApBTsM+45B9bQgAAAABoPVBYAAAAANB6oLBswGAwWHqa6zp0lEfoddlG3ZowDJ2en7dJmqb20DgAAHguXmI+20fYlcyyg0FfitYoLJ3KZ8+qgen1emul2zZhGK7t+6eJp764t1G3Jo5jms1mOnqrpGlaO1l3V5Ay1ul0KM9z57VtK5AAPBV2MbLPsjmdThdOEQd/Tr/fJ2NM44noL0lrFBZjDAVBQEREnz9/1peJKk2vKArrdO8lB3A6nW7k+8fF4+OjjlqLTete51vGeDy24/1cDIfDBf9Mu8Dj4yNFUUSe55Exhvr9/sK1LMtoOp3W8gHw0rB/Muk/zBhDd3d3a39BWme+AM3kee50kQK2T2sUFiKiw8NDiqKIZrOZc/Xk6urq2V+yu06apk9WjAAAu8XJyQn5vr+gPD8+PlJRFCtXWvCi/XOurq50FHgmWqWwEBGdnp4SOVZZyrKkv/76qxbHy59sE8LL9RxO09Quj8ZxXFOC5PJpmqY2bac6Z4b37Tjsgr/d6HbQiroZXsaV34Tk0u6yyUTXXVbeqkejERVFYdsj+7GqTI3MJ7+FsT2NHDPZPxn/8+dPG/8Wkfu7LH/yJaHvk9xeCsPQxksZ4Dx5ni+UqcMk7kccx7Y8ql5GMszI+8NtZzqV3HDb1v2WDl4eXnE+Pz/Xl4gq56Xyy5+833EcUxiGNJlMaD6fW3kjJZfLZFnOd2FlPyJlTsq6jO8oeeR6pLzpectVFveB0XZ+PJfmeV6LX8ayPrrm9F6vZx3Ryn6tajt/JFyfHgum6d2gx4rvN98TnjO4HU3b2tz3Xq9HeZ4vvEcZ1zi8GNq50CqekGVtoigyRVFYB3qSIAhMURQmCALrtM9U7WHHhKZyiCidIxrhpI+d+pFwMBhF0UI6hp0CMr7vL9TN5XDedepOksQ6M5T4vm/L47o5LOsuiqLmQFA6JZT94XzcJj2uQRAY3/dtWBJF0YJzxCzLrDNJEs4TZduSJKnV73neqzs71Ohxd6HHURJFkcmybMGZZVEUdqyKorDX+d7L8Wbnmowcp6YydZifB77GzjC9yvGlDPP/WqY5P8sUl8UyI/8HL4u8Ty54bnE5SzXieefnltNJ2dBzQBAEC45epSy45jvp8FSWy+3XcwI7QjVCVmUb9HMj+1EURe0Z4nK4PjkPcVt832+c5zRNfTRL5nT5fHEZjGzjOuMg65P/N70b9PPMc7G8J9xOvs5t5XGW87ict5Ikqc09TNM4bBtZp43TEatwFbItokphMeqhMpVA8l/+n9PJCdUTCou+ZqpBbhJevgFMkzAYxwuHr3Ocq26OD5TXY6O8McuPfOhk3TodVYITLXnR6v7oyWoZ1KA8GXVPfKEgGcdD2gbkGDSxbByjSmExYkxZbuVkGwmlTyPH06hJiMvg66vC+n4sC8sJi5FyRkueJ/CyrJJTnq+kHEl4nsgqhcX1rOt4cswrQfUC1PnlfKfLkTKqZUi+EI1D5uR8wnieZ4LqS2tTn6Wc67l8HVb1UbeTkQoL16s/TxkHTr/s3cD3xoW+J3r+N0qh0vMGo8dSt/O50G01xpjWbQkxURTRZDIhqpbRPn36pJOsJEkSGo1GtaWvbW1R/PjxQ0fRX3/9Ze1HXHUzs9mMiqJwLqUVRUFGGM+Nx2OdhIiIfN+vpTMrjJAHgwEdHR3p6JXwEua6zOdzev/+vY7eOQ4ODnRUjXfv3umoBVwyQtXSq4YNe3/9+qUvbRWXfZPv+41tBe2Fn7MmmeF72u/3aTqd2q2fVc9zlmW1eWU6nTrlQ853GjkXFUWxcM3zvMa52PV8nJycUFmW1O12KYoiOjo6WtgakQyHQ/J93/ZXbss0saqPy+Z0CRvry0+/3994HDSud4NrrJpwycnHjx+JqjGfTqc0m83stlAT647Dc9BahYVf1HEc048fP5a+jJsYDodkjKEsy2g2m1Ecx3RwcND4kG3C4eGh86fGfKNddTNJklAURXRyciJy/oPfv3/b/3mv2YXuQ9NeIu+HXl5eUpZl+nIjct/SGKMvL8X1YOwieoJh1pXHw8ND5z3hvN++fdOXnl3Z6/V6dH9/r6Pp8PBQR4GW0+/3yfM8ury81JeIiOju7q72IwV+0Xmet/SFpJ/fMAxXzndNvHv3jjzPo4eHB32p8UtBt9ulu7s7HW2fm/F4TMYYSpKEJpNJzc5Ecnt7S6b69enR0ZHzWZSs6uOyOV2i5w22Jdx0HDSud0O323UqWi54bnEpb91ut/ZLs6IoGn89tu44PAetVVioMhqbTCZ0dnamL1mkhpqmKRVFQaPRiFJxYFm/36coioiqwS6KojbI/LLnG8qCzdbfrm8kbBwsNcwvX77YycNVt4QVMs7f7XbJ9/3aKsjNzY3VgCWnp6cLvwC4v7+nbrdbE/64Omsly7LaT3PLsnQKreT6+pqiKFpY4WmaHJggCGg0GtkxvL6+pqIoVk5sbWM4HBKp++sKL+P09JTm8/mCcSIJ2eZxStOUfN+v3afn4Pz8vNamsixpPp8v3GewG9zd3S3MBSTmH/71UBiG9pmXygArqmVZUpqmC89vmqZ0fHy8cr6janWVieOYfN+nbrdLFxcXNJvNbP38l58xzdnZ2cIcPZvN6NOnT1SWpX2RDofDxl+Npmlq80+nU/I8TydZYFUfm+Z0jk/TlD58+ECkfip+fX1N/X5/43Fglr0bzs7OamXSkjmKFVxppP3161fbl8FgYO/7si+3TePwIug9olU8IctayL053kcrhHGpax+vKIranmFQ2Ybw/ppfGTURUc0eQZcl9wBlHr2/52qfLEfuq7rqlmmTypaGw2wD4QnjK26Xq27ej9T5ZZuMMEbjdvBfGa/3bY1jL1bmlW2R5XDbdHubbEFeCx6bdZBjIPtoHPdAhwtlMEuOvXqO53ugZUrfBx2WH96zXhY2jnvL6HrkvX6JPWtQR96bVch7RWpOM8Kega/zXMXyKZ9Rl8wYh2zK+U6Xr595nkv1NVmelDH93Mj5TdbDz41us55feTz4mWuS52V9bOof943HalkZ646D69lzvRuM43lmmyUO6/m9qRyeq/mafr+S413IfeD7pev6E7g+Cbw1g70DMgx2gV2S0zAMqSzLnTlpNgzDhbNrwJ+zzXF1yX+rt4QAAACAbcE/ItjWSxX8g7I6w+X4+Fhf2ipYYQF7B2QY7AK7IqdhGFq/ZL7v78wqC2g3LvmHwgL2Dsgw2AUgp2Cfcck/toQAAAAA0HqgsAAAAACg9UBh2QK9Xu/ZD89hB1erDj8CAIBN6ShHf5uwzfnvT9pBynHoMqQjwVVpd4W32CcNFJYt8Pj4+OwHb/X7fTIrjt8HAIBN+ZNDHQeDwcLJrn+CMWblQWrLWOeAuDAM6fz8nIwx5Pu+PSB0l3mLfXIBheUJNB1ZvE3yPN/atxYAAJCkaWpXMrSbj024vb1dS0l4KdZRnu7u7uyp5re3t1v7VdNrztnP1ScpJ20ACsuGpGn6Rw/4urxVDRkA8Po0+R/aB9ZRap7Ca87Zz9Wn1smJPvp2FU/IsjbLjjSWRw3LI405T5Zl9shgeTywV7n+lkciS2S5q46hlmWQwy24PMaY26CPvtbl8pHTEn3MtnG4+OZwULkX53J4DPh4ZnnEdVEUtfpl3bI+Oe5vETmOALSVdeSU5zd5XDqjj7fnY9hlHM9LpNyF6KP1XcfhM9wGRh/nLucZPf/JNHIuZ5qOmJftIdFnVxmMbhfn85SrErOkfNNwvL6eszms3atwOIoi43mejed3iaxXjmkT2+qTa5xlWs/zVvaJ3TNwOr4HcmyaXCK40G005h+eGTfCVcg2YEFj4ebOm+rmSmHlwTOOF61LgZGDKh8u9jlhRP1Jkqxsi3yY+WZwOTxJSGQdMi/7bnAh2yknHnndCIEtKr8PUpi4zZyf+6P7J8vlh/Et89b7B94Gq+RUzm/y5cDPve/7du7Rz7Wcszgsy5H/B5XPMJlWz8d6rmL4RchzjSd8vcm5yzjaIOuV83qWZbV5k8T8vkxhYeR1HkNZ3rLy9btIjqMcB1fY930TRVFNyZDt9H3fhnkcl/VD8id9ahpnTiflpKlPLF+kFFTP82xY3+9VkEP+F2NW4CpkG0RRVHsoJPrGyZupB1inbxpgTqc/QbVi0dSWSCkspuGmyvboSUN/XDdQt5tvNqPrdKVheLxcCot8eORn3QdlF3GNEQBtYx05XTVPMDwHMHr+0GFWLPSXG+N48cg2yPmVIbW60zRX67lc19uErFOX4UJf12OokeXruV2iy9FhWY5+j3C79WdZuyR/0qdl40wOuWjqk/xibxwrfPzR760myCHHrbFh+fHjh44iqn6mpun3+0RE9OvXL31pY7IsI/MPxY2MMTSdThvbsi4XFxd2PzPPc+tynKqjq2V95om//EmShEajEXU6HetOfDgcku/7G/+0zfO8hTbxGAMAdgc2vJQMBgM6OjrS0Wvx+/dvHWXnM9c1l32f7/t2Tg2CgL5+/UpUzY0k5nOJa97X8FEP8/lcX9oKrvKfy1aEKYqiNg9v+9enuk/rjPOfot8tf/IrsNYoLIeHh87B45f5t2/f9CXnw7kpWukJw7CxLetyenpK8/mcyrKkb9++1RQS/UDHcfykuobDIRljKMsyms1m1jr99vaWjDEUBAEdHR2tVbZ+CNM0XVvZAQC0C/7VThiG1Ol06PLykrIs08nW4t27d0RE9P37d33JXpP0ej26v7/X0XR4eEhERJ8+faLZbEadToeOjo4a28Vzpksp4rNWrq6uyFQ/490my8r3PG/hnbFNZH/Lstzar46a+rRsnLeFfAflef5HvzpqjcLCL3nZGV45CIKAJpOJ7XiapuT7vlMz34QgCGg0GtXKPT4+XtqWg4MDG9ckTN1ul3zfp8+fP9fSn56eUlEUtiwiovv7e+cKC5+NkKapU+ng6/1+n6IoIqrScpum06mduHhiYaH8/PkzUfXw8bcl+VPt6+vrPx5bAMDLIBWEq6sruri4ICKi2WxGWZbVnuWyLCnPczs3NM1hDM9lo9HIxt3c3FAQBM556/z8vDZ3lmVJ8/ncrhScnJysvZIbBAGdn5/bML/Ab25unE4W/+RFKFlW/sXFRW0sSLwb9Jzd6/XsylKe5zSfz2kymTjHnMdZroTd3NzQx48fa+meyrI+NY0zCeWXw5v0qd/vk+d5dHJyYuO+fv1a23HYGL1HtIonZFkbvecl97rYeIuEwZfe99P55SdSlvRyz5XjpN2KLovbIus01XjoNGaNvWT+NO0dRpW9CxsGyzxGtZv3QhNh5U9q/1OOH5etbVr407RH+1bgMQSgzawjp574pQmpOUw+81714wCeK/gazwX8SZLEpuWwWTJPyrQ837jmK0aWwx/f9xvnINc8p9NyG/72t785y2B0uzzxyxdyGO7q8nks5LiS6J+cs42a6/3qRxCRMlCVdiymYTw5vZzPmW31yTXORsmJWdIn1/uZkfWua79iGuQf3prB3gEZBrvAOnLa6/Xo4uJi67YOz0UcxwttTdOUPnz44FyxAf9JGIY0nU519JvFJf+t2RICAADwdonj2Gnf8vDwAGVlCWmaUqfToU+fPulLewdWWMDeARkGu8AqOe31etZgPoqihZWLNiLbzBRFAYUFLOCSfygsYO+ADINdAHIK9hmX/GNLCAAAAACtBwoLAAAAAFpPqxWWjjitlQ++ee4DzcIwrJ2TAgAAu0Kv11vrPJIwDGtnLz03zzWvxnFszz8Bb5/WKiydTqcW7na7ZFYcNPSnhGFIs9lMRwMAQOtxGbS6iOP4Ree555xXx+Pxwunh4O3SWoVFG9u8BNPplIIg0NEAANB6Hh8f7cmkyxiPxy86z2FeBduitQoLAAAAAADTOoWlU3ka1r4J2Muk9PvTqTwVaweCXIYuh/c7B4MBdTodu9fLTsJce6FxHNuy5J5vr9ez+Xj7isvN8/xZ9msBAEDT6/XsXKiRc5TrOsNzl5zPZF6eR3k+5LJ4Xpb5mGXzKsNpeG7l8jks531XP0OHLY5sj2v+Z3vIjngHgB1Bn9W/iidkWRsS/h/Yf0KWZTU/COz/hv0dsC8FGc/+CtjvQRRFNZ8L0sdEEATW9wPXw2H2+8BwWex3QfpcSJLEpmUfC6CdPKcMA7At1pFTOd/xHCd93vD/PLfJazxHZVlWm8t4njPVHKjnMukrR16T896yeVUj22JEndr/TVEUdk4visK+I2TedeZ/7msURQu+fEB7cMn/YswKXIVsg6Ry3CchoVxIQeVr2pFSUjnukgRBsFRAZZlGPWjSiRR/uI2e59WUGX4gQPvBfQK7wCo51YqGUS9sPXeRUBq0kiBhh3aMnGuTJLFzsnR4Jz+cp2le1ei2SCVJz/usxHBY5t10/nelB+3BJf+t2RLa1J9EkiQ0Go1qS4Q/f/7Uyej4+LjRcp5/Ir2s3iRJqFLsyBiz4J6bGQ6H5Pu+XWp87p9fAwD2m2/fvi3dbiEiyrKsNn8tc57H2y/z+bwWH0URXV9fE1XztPylZhAEtfKNMWvNq8/BpvM/2D1ao7BQddbKugyHQzLGUJZlNJvNKI5jOjg4oKIoFspZZTmv00v0Q7BsH/j29paMMRQEAR0dHS0tFwAA/pRVP+n99etXLeyav9im4+rqiowx5Pt+7frp6SnN53NK05QODw9r1/QcJ8vX156bp87/YHdojcJydnZG8/ncGkmxMdTR0ZFztYK/WfT7fYqiiKhSYkg9NNfX13R1dWXDkn6/T57n0cnJiY2bzWY0m80oDEO6uLigyWRi68/zfOGBZdI0tW2fTqd4SAAAz8rp6SkVRVEzgC2KgkajEaVpSkEQ0Gg0qv1Q4fj4WJVCdHNzQ77vL6we8xzc7XZtWaenp/a6nrOpUlJWzauaw8PDmuI1mUxoPp8vGNOuYtP5H+wgeo9oFU/IsjbSMIr3R7Mss/uY/CmKwviV4Ssp41dTtZE/vPfKBlqr0uu9VrlPK+1XOI73etkGR8eD9kHPKMMAbIt15FTOjb7v12xYTGWPIuc245jTtHErz2+yHG1gy8g5W7dXxut5VSPTsg2Lnvd1+J//+Z/t/7JtMk3T/C/b7XmeHRNtFwleD3LIP7w1g70DMgx2gTbJaZ7n9OvXL7uK8VYJw3CpnQ94OVzyD4UF7B2QYbALtElOB4PBwpbRWyKOY5pMJq0Zb+CWfygsYO+ADINd4LXlNM9zOjo6Iqp+bfScftwA0LjkHwoL2Dsgw2AXgJyCfcYl/635lRAAAAAAQBNQWAAAAGwV7fvtKbDvn03ZRt0aPqvGdcSGi8FgUPu5d6/Xq4VfG/bF11nhY6ptQGEBAACwNcqytLYvTyVNU5pMJjp6Jduo28Um52oNBoOF04IfHx9pPB7X4l6LPM/p+vqajDGUJAnNZrOtKnfPCRQWAAAAW6Pb7VKWZTp6I4bDoT0QdBM2rTtN07U8Nm9yvP/t7e3CacFt4tu3b9ZtAp8Yv6kbhTAMX0XJgcICAABgL7m8vNRRb54fP37oqI0oy5Jms5mOfhGgsAAAwI7CthFhGFKn07E2Hzocx3EtzDYM0kak1+tZ2w9p18B5ZXpOy3YZg8GgFnbBbdL10pK6GbZL6XQ6dkVExnU6HZ2lhqyby+90OtaVAbeH+7FOmRrO63IpINvNYe6vHDNZvxwH3VdpSzMYDCgMw9p9InXfmE6nY90kyDY13Ru23ZHXeXvM8zznvXpOoLAAAMAOMhgMqCgKmkwmdHx8TMYYKoqCOp1OLZymKY3H49oWy3A4pCRJbDiOY+v8UPoAiuOY7u/vyVSemLm8x8fHml3Hqm2QOI6pLEtbDgl/cE11S75+/UpRFJExhobDIeV5bvOYymGjS1Gg6mUsx2M2m1GaprYdSZLQ4+Mj5XlOj4+PtTYuU8Akg8GA/vrrLzLG0OXlZc2GRStnYRhaL9pyDGUZ7NS3LEtrl1MUBRljKIoi62MvDEOaz+d2xYPLZCWFw9wPUznnZS/bw+Fw6b2R7ePrvOVWFMXLnwqsjupfyROyANAqIMNgF1hHTj3Pq/ktWxaOoqjmRy1JEhvW1xjP80yWZTraGEddvu/bMPv9KYrCmKovshy+nmVZY90c7/v+go8f6Q9JfkxD3frDfo1oif8g2R/2t+QaC74mkXmNqicIggW/TK4yGJcfJvZ/ZKq65PVVYV2e7pe8N65+6/F9LlzjgRUWAADYc/gXLLzszwaVmxibNuEyzuRTc3/9+tVYN1X1z+dzenh4sHEMrxLITxO8osGfZSsDvP2if+nTxPfv3zf6FdF0OqX5fF7brvn9+7dOZnGN38nJiTN+U1xlyHvTNqCwAAAAsNshvu/X7BT+9MXFv0D59u2bvkTv378naqibqvqNMXYbR6JftsvsKXQfXGnZXoO3mpZtcWk2VexYcfI8j3q9Hr17947I0Seqxu/u7k5Hb/zLHhfr3Js2AYUFAAD2gIODg9qL9fLykoqisIa7rBBIJ4cXFxc0Go1smMTLvtfr2V+c5HlO8/mcJpOJ0+4jCAKaTCb2hZymKfm+T/1+v7FuSZIkNBqNbP6zszOaz+e1ulwve6rqlnnTNKXj42MiYaMRxzHd3NyQ7/sLbdCKkoY9WLMNTVmWS8ciDENrNMuKSLfbJd/3Fwxt0zSls7MzKoqiVtZsNqNPnz7Z8J+w7N64YOWKNrDx2Rp6j2gVT8gCQKuADINdYJWcep5nbTLY3mNZuCmPqexFfN+316Rdh7YXYdiWgYiM7/vWbkPGk7B1kOVIGw5X3VEU2TDb0XCY7S+SJFloV1Pdsnxtz0HVWLC9hqyXiMzf/va3WvwyOxbOJ21YZN4kSawNi6s8eX/kGK3br1VhWYas23Vv9Hi42plVNkgkZGxbkEP+4fwQ7B2QYbALQE7BLhGG4VLboE1xyT+2hAAAAADwJPhMn21tUS0DKyxg74AMg10Acgr2GZf8Y4UFAAAAAK0HCgsAAAAAWg8UFgAAAAC0HigsAAAAtgqfFtt0Nkqb4HNoQPuBwgIAAGBrlJWzvl2AHUiC3QAKCwAAgK3R7XatR9+2c3t7u5EfIPC6QGEBAAAAQOuBwgIAADsK21+EYUidTod6vR5RdeqoDMdxXAvzYV8c5rLY7kT6tOG8Mj2nZduPwWBQC2vYpoU/Ml2n01loLyPrTtN0IUyiLeyfR9bDcezYkD8u54ckxq1TeVGO45h6vV4tv/QtpPvF8PiGYUhxHFtbHh6nPM8b2wCWoM/qX8UTsgDQKiDDYBdYJafa/44RfmtkmP+XvoNM5YtH+hLidJ7nWX877OeHkeV5nlfzHyP957DvG+nzRraD+8Y+aWQdGtlO4yg7yzLr50aOmawnCALbNvZBxPllP2S89FUkx4n/z7Ks1m6/8qfEZcoyiqKwPpJ0WuBG3ksbpyNW4SoEgF0CMgx2gXXkVCsNy8KrFBZ5jfEqx4MudF3LFBYJX2NIOVt0QcL5HisBXFeTM0T+6PazUz+psLDzP40eFzlmLmeCXIarT9w+sB6uscKWEAAA7Dnj8ZhIbKfwFsa2f0EzGAye9Asi3/fp27dvRET08+dPiqKIvnz5QkREh4eHNp3neVR9Ebeffr9vr4dh6DSync1mRNUWzyYEQbBQHxFRkiQ0Go1q20/D4ZB837djvGldADYsAAAAiOjx8ZGMMeT7vn2pe55Hv3790kk3hm1DLi8vn/QLovPzc/ry5QuVZUkHBwd0enpKRVFQnud0cHBg02kFK01TyvPc2r4cHx8vpCEiiqKIkiTZWJnS58xI5cQYQ1mW0Ww2szY7t7e3ZIyhIAjo6OhoIT9YDhQWAADYAw4ODmov68vLSyqKwhrusjHp7e2tTXNxcUGj0ciGSbyUe70e/fjxg6hamZjP5zSZTJyGt7PZjLIsq612lGW59irDhw8fqCgK+vz5Mw2HQ+p2u+R5Hh0dHdGHDx+IKiWBqlUc5vr6mvr9Pn358oWSJLFpGGlAyysgMv8yzs7OaD6f1/rLCggbD/f7fYqiiKiqi9NOp1PnSg9Ygd4jWsUTsgDQKiDDYBdYJadeZbBKlT3HqnBTHiOMa/matL/QthoM26JQZTTLNiwynipbEVkGt0G2Rdfpwvd9a69iHPYlRtin8IftV6LKAFfXq8dDtlO32WWEq+1mGDmWMq2MlzY4tEb/9w05nkynurA2HYfLZwB2Ccgw2AUgp/tFGIY0nU519N7ikn9sCQEAAACvBNvXQFlZDVZYwN4BGQa7AOQU7DMu+ccKCwAAAABaDxQWAAAAALQeKCwAAAAAaD1QWAAAALwIfObLW4IdJO4Ku9ZeCRQWAAAAz85gMHCeMrvLpGlKk8lER7eWXWuvBgoLAACAZyFN09oJum/tdNfhcGhPst0mcRyvfQrwJjxXe18KKCwAAACehcvLSx0F1mCXV0GeEygsAACwo7BNCDsXZNuEpnCn07E2JHxgGfsGyvPcpukob8KDwYDCMKyVw35zdD4uv9PpUFEUNBqNFmwmZDk63NS+Zaw7Dlwmh9M0rYW5LO6frJvz6vQu5Hg0rZRw3fxJ05TKsqRONSZHR0c0GAxsHPeFfR3p/NKRIo/HYDCw1zXyvvFKGIe5Dk6zqr8vhj6rfxVPyAJAq4AMg11glZy6fP+4wvw/+wuSsG8e9sFTFIVNS5UvHulTh8vyfd/6yPF9v1aHbLf2kcO+eziOffRw3qb2LeMp4yB9ECVJUvOpJNvG9eu2LStP9l+Ph8TzPOvrKAgCWwbfC77GfZFjwf6aGL5HRVHUxoPL8DzPtp/bJMP8vy7XrHkPngPdDmOMWYxZgasQAHYJyDDYBdaRU8/zrBO9dcLyRZskSe2FqV9M8oWtHQ/yi40VHB3PyPqMoz3sMJFpat8qdLnLwlrB0AqLvMZI5UIj8yTKGaJWHJqQbdAKiw4bx7iZauw4Tvef22UcfZR1G3Wvi6JYqOelcMk/toQAAGBPiKKIrq+viYjo4eGB+v0+EVFtO4E5OTlxxhMRvXv3TkfRYDCgo6MjHb0RTe17KcbjMZHY0uH+b/LrJs/zqFoMsJ9l/ej1ejQajXT0Uh4fH3UU+b5PP3780NFERPT+/Xsd1cjl5SXNZjMiIrq5uaHT01Od5NWAwgIAAHvC6ekpzedzStOUDg8PbXy326W7u7taWo5fRrfbtbYVl5eXlGWZTrIRTe17SR4fH8kYQ77v2181eZ5Hv3790kmdaOUmTVOnHQvbl9zd3VGSJPryUnq9Ht3f3+vopWO27i+0+v0+eZ5HcRzTjx8/VsrASwKFBQAA9oRut0tBENBoNKp9cz47O6OiKGqHus1mM/r06ZMNS4Xm8+fPFASBTZdlWW0VoSxLyvPcviTXPSyuqX3b5ODgoKZUXF5eUlEU1lBV/gybubi4WFgFcRkDD4dDokoZYa6vrxdWWMqypPl8TkVR1BQCrdg0jdv5+blV7EiUxytERFRTaK6uruji4sKGV3F1dUWTyYSOj4/1pddF7xGt4glZAGgVkGGwC6ySU68yYGXbhVVhJsuyBeNWjuf0pOxTfN+vGXPK/NIol+tkmwi+5mqPLG9V+7gcaQ/D6HJXhZvyGGGAytdkfbKfJOxBOKxtUPjTZL8i6+H2cL/5mixfl6XtZSReZWTL16TxsKxTliHtWIxD/lg+9L15LnT9xhjTqS6sTcfh8hmAXQIyDHaB55LTPM/p169fdjVgHQaDAXW7XZpOp/rS1lnWvjAMX6QNu06v16OLi4vaisumNI11U/y2cck/toQAAGCPuLq6cioDbcHVPj4D5SVelOAf4312dlaL4/NgXnObCAoLAAC8ceQhYZuePjsYDGg+n9NsNnPabWyDVe0bj8cL37aBm16vR0VR0GQyabSBaYLvAVXGt5Jut0vGmAVl8iXBlhDYOyDDYBeAnIJ9xiX/WGEBAAAAQOuBwgIAAACA1gOFBQAAwB8RhmHt7JG2MhgMNrbrIOFoELwuUFgAAAA8mTiO7VHubYaNh5/CcDhcsKcALw8UFgAAABtRlqX9xdB4PLan3j4HYRg2+jTahNvbW/J9X0c7SdPUniIL2gMUFgAAABvx+fNnHfUslGX5Kqs3rp9Wg9cHCgsAAOwofJiX/pRlSXEcU6/Xs072eMWAw51Ox9qdsI1Gp9Ox/nRkWOebzWY0m81sXYzMp/3iMGzv0uv1auk4zG2Vvog8z7MrOpxGtn9ZudxubWMjz36R/ex0OlQUBY1GI+r1ekTVthf/z8j2yvNpOK28N1it2RL6rP5VPCELAK0CMgx2gXXklP3BGOFbpiiKmo8Y6X8mCALrV8ZUdbBvGPYVw7BPHM7P5ZrK140sh/3scJyuh5G+bKSvIs/zbFj2g9vE16IosuXytSzLGsv1fd/6D+L0HPZ93/aH8zMk/Ahxe6SvHVkuj1MQBE7fPNJXEVgfeT9snI5YhasQAHYJyDDYBdaRU35hu8L6RckvVvlCl8qBUQoQv+Cl4zxO51JYpFM8diLoQqfVThf5kyTJgsKikf3V5XJ/JVLRkGhljetn5FjqtHyd4/S4J0kCheUJ6DE2xhhsCQEAwI4SBAF9/fqVqNriIMeR6szv3791FH348KF27eTkhB4eHoiI6Nu3b5QkSc2GpNvt2v+3TfUF2n6WHQHPvoWW8f37d7ultIzBYEBHR0c6upFfv37pKPr48SNRtUUHng8oLAAAsKN8+vTJ2pIcHR1RlmU6ieXdu3dE1Ytcw9fOzs5qCgorDU32KNtEvuzzPHfafcjzUP7xJXw5RVHoKEsYhtSpfBctGzfN+/fviRrG5DkVOgCFBQAAdpaTk5PaqkTT6gpVL1Pf92k0Gtm4m5sbCoLAvmg5fxiGdHp6SkREvu/T0dGRXUUg8WLO89z54t6Efr9PnufRycmJjfv69St9+PDBKlJUrapcX19TFEU0Ho9tPFWKjIaVLTa2LcuS5vO5dQo4m80oy7LamJVlWTP2dR0yx+09Pz+3cV+/fqUoimrpwDOg94hW8YQsALQKyDDYBdaRU9/3F2w/2E6Dw9p+QuZxGcZqWxC2c5FwHNuyNNWt7Vh0Wonsg7Qf8TzPUGWrIo1aqeobl+Uql+1YOK20YZFt4XJ4rPhaFEWNY8l5OJ1RRsVsDyTDfN1lRwPqkEP+4a0Z7B2QYbALrCOncRw7Vxs+fPiA7YkWE4YhTadTHQ0ELvnHlhAAAOwgcRzT/f29jqaHhwcoKy2FbXA+ffqkL4E1wAoL2Dsgw2AXWEdOe73egmFpURRQWMDO45J/KCxg74AMg10Acgr2GZf8Y0sIAAAAAK0HCgsAAAAAWg8UFgAAAK8OOy9sYjAY1JwMvgQup4dtoLOnDhWhsAAAAHhV+CC3Zdze3r7oT4HTNKXJZKKjX502KlAvBRQWAAAArwKvqIzHYwqCQF9+FbhNw+GwNafXxnFsTxR+fHzUl/cGKCwAAABeHNex969NG9tERK1c6XkNoLAAAMCO0uv1KI5j6724ozwYs4O/Tqdj7T84zDYQvV6vFmZbEU7HTgk53Ol0ai92tvPgQ9G0fQWX3+l07HZGGIY0mUxoPp9Tp9Op+SOS5ch47iuT53mtTU2ekgeDQS0dw+2W15vaJOvivpVlSZ1qXDudjl2Zke3X7eL8PCZye0fnS9PU1kFEdHR0tGDjw23ncuRYc/s5zZuwedFn9a/iCVkAaBWQYbALrJJT6T+HfdOwvxpT+cNhnzzsU4fD8n/OlyRJzb+OhK8bY0yWZbZO6SuH/RKxv5yiKEySJNa3j26D9lnEdXM5QRDY/7mv3DduA8M+jTRZltX8/7janWWZva7bxH3huCiK7P+638bRLu5TURQ130NFUdgyOL/nebYtQRDYdvO4yXbqtsv/pb8kU7VJ3utdQY6jjdMRq3AVAsAuARkGu8A6cioVFKNeVvxSkx9+OVKDwsJlyJdwkiS1l75RL9Qoihau6/IZWY9WDnRYKgfGoYw9xYGgHB9Xu11tkGnkWLgUCa0sGKEk8f9yXHT5zKp6dDlyXFlpYqXIpcjtAi75x5YQAAC8UbIso+qLKRljnvQrm58/f+ooOj4+XnAJIPE8rxbm7Y5leTahafunCd7Smc/n+tJWcRnE+r5PP3780NFERHRwcKCjqNfr0Wg00tFr0+/3yfd9urm50Zd2HigsAADwRvn161ct/JRzTA4ODqgoigUlQSslmvfv31tF4eHhgYwxK/OsS7fbbVQCJGwDcnV1RcYY8n1fJ9kqvV7P6ZDy8PBQR1nY/oRtTe7u7ihJEp1sI87Pz2kymVCapnR2dqYv7yxQWAAA4A0SBAGNRiOraKRpSsfHx0SVssErJ2maUlEUNBqNnIaZw+GQSCk719fXdHV1ZcNSoeEy+v0+ff36lYIgWFjZSdPUvsTLsnTWu4yzszOazWY1w1iXMnZzc0O+79Pt7W0tvqm+P2kTVYrCfD6vGebO53Maj8c2zcPDg/3/8vKSzs/PbTrtuFL2jzb4FdNwOCTP8+jy8pL6/b6+vLvoPaJVPCELAK0CMgx2gVVyKo042d5Dho0yzNV2KTKebSCa0htlE+Oyw5DtYdiegj+cJssye83zPGucSpWBa1QZu3JY99WoPnCZGrb/0PXL8qQNiWyTbAOPjyyrqW6dTkJVf/iatHeR8dw+tqfha7pstnWRYSaKogV7ml1Cj50xxsBbM9g7IMNgF9gVOY3jmL58+eK03wB1Op0OJUliV62ekziO6fT0tLZis0u45B9bQgAAAMAb4/7+fmeVlSagsAAAAHgScRzTZDKhoij22sfNOvABcE22QttAHiCo7XbeAtgSAnsHZBjsApBTsM+45B8rLAAAAABoPVBYAAAAANB6oLAAAAAAoPVAYQEAAABA64HCAgAAAIDWA4UFAAAAAK0HCgsAAAAAWg8UFgAAAAC0nicdHAcAAAAA8Jxo9eRJCsuGWQBoFZBhsAtATsE+45J/bAkBAAAAoPVAYQEAAABA64HCUnm4fG5Po3meb9X+JwxDGgwGOhoAAJz0ej2K41hHtxLMb8BFaxQWdomtP88ttGma0mQy0dFbJc9zOjo60tF/xHQ6fZPuw9tAr9eryWCe585rYRjW8gHwWgwGgwWZlcrJYDCgoihqedoM5jfgojUKizGGoigi3/fJGEPGGMqyjObz+bMqLcPhkKIo0tFbpd/vU5ZlOhq0lMfHR4qiiDzPI2MM9fv9hWtZltF0Oq3lA+A16HQ69Pj4aOdNYwxdXV3RZDKhsiyJiOj29pY8z9NZAdgpWqOwuOj3++T7Pj0+PupLAACw9wwGA/I8b2GOvL29pSiK6Pfv37V4AHaZVissaZrSfD6ni4uLhXhe+pS2J4PBgMIwrF3nbxhlWdaWTDdZzpfbALI+3mdl+xReimVk/Ldv32y8RKYpy7LWTm47t1fWz31lOp0OpWm6kI7UeHE6EmPCeeSHV7W4fc9t47Or8PiUZWnlRN4XLXdSPuS4y/HlPHmeL5SpwyRkIY5jWx5VtlkyzGh5YDmjFXIE2kVZljSfz+nq6kpfIiKi8XhcWx1k5P1f9pxLGeE5g5Rcadnirak8zxfmYlLzHdNZY37TW15gTzEb8oQsaxNFkSEi+/F9XycxSZKYIAhs2PM8EwSBCYLA5uPrvu/b/4MgMFEU2TKIyBRFYUxVr+d5tkxJkiS2HUVRGCIySZLU2srXgyCw/2dZVhsr3/cbx47Tcnu4nqIojOd5C2PBfeW+cRpum6nuE//veZ7Jsszm5b7q8TKOdpsqz1tC98/FMpmIoshkWWbvE3+KoqjdS3kfjZKPKIpq99TzvIX7osvU4aIoanLP8s3yIMP8v76/nF/KGjXIEXhZ5H1ywfMYP9urWCYHRj3nslz5LCRJUnsu5LzG8yLHs3xzOxlZ9zrzW5ZltTqlbIO3i5ZPU+13boSrkG0hJ3E5gUv4AZEfTicVFFMJvutlq18ky15OGs/z7AQuX0BGtT8QCpJpmCCYZQqLaXhp6L7qNLKdEjnhcD16wpNlF0Xx5iaHpvsgWSYTrLCYFfcuiiKn/Bn1QjCinEwoQnx9VVjLwrKw7/sL95PEC2BdOQLPzyo5bVJYOJ4/LsXVLHnOE/ElTaPlgWUxSZIFxYTR8Xou1DJnHDIscckweHu4ZKm1W0LX19dUFIXzZ3hRFFGlbJExZmH/dhlhGD7J+IyXNte1tL+7u6ODgwMd/ar0ej0ajUY6eoHLy0uazWZERHRzc0Onp6c6yZtn1b179+6djlrgx48fOoqoWsrX8NL9r1+/9KWt4npWfN9vbCtoL+/fvyciWthuHg6HZIwhz/MoSRIaj8e160zTc/7z50+V8j/R81+32yXP8+jnz580HA7J9327bSO3P7cBbyfN53N9CewJrVVY+v0+RVFEk8lkQfD15LqOPQrvux4fHy88dMvgh+Th4cFOAuuy7MF/SXj/9+7ujpIk0ZcX6Pf75HkexXFMP378oG63q5PsBU1ysu6YHB4eOpUTzqtfNCReQs9Fr9ej+/t7HU2Hh4c6CrQcfk7lr4E2oek5Pzg4cCq2RESe59HDw4OOtgr+7e0tGWMoCAI6Ojp6Urs0bNN1dXVFxhjyfV8nAXtCaxUWqozGfN+no6Mjq7Scn5/TbDarGY6uw5cvXyhJEhoOh7V4aUzm4uvXrxQEwcJPWFflu7i4qClbX79+JWpwHsnf1tmi//Pnz0TV5LBu/5pgw7yiKGov2TzPl/6CgH8WeXx8rC/tBSwnWhnW4WWcnp7SfD6vyQrnD4Kg9qJJ05R833caSW6T8/PzWptYPpq+hYN2c3d3R/QHc4XrOR8Ohwur23EcU1mWdHFxQbPZzM5r/Hc4HFKapjbPdDq1X+5YCef2sZGway50cXNzQ77vL5zLsmoOBm8QvUe0iidkWQu55yr3ZXmPlD+818phab/CcWy7IsM6D/+v4zW836rzyjJ4T1WGjTAe4zbQkrGTabks3Xfe59V91Wlk23g/msOu9pNjH9w8471+bTbplxwjajBQlmMow4UymCW1Vy/vHcuM654vC8tPUNlULQsbh40Do+vRcgReFnlvVqHnAVLzmZ7zJK56tBzKPE1zpp5rtL2MjOc6ZR1N85tuC/cFMvm2YRmRwFszaCQMw4WVpbcAZBjsAi8lp2/1OQe7jUv+W70lBF6POI7p7OxMRwMA3hB4zsEuAYUF1JAHMz23PQUA4HXAcw52EWwJgb0DMgx2Acgp2Gdc8o8VFgAAAAC0HigsAAAAAGg9rVZYOuK0ROkQ7jkJw3CjszYAAAAA8Py0VmHRhwp1u10yxjyrgVgYhvaoagAAAAC0h9YqLNrY5iWYTqcUBIGOBgAAAMAr01qFBQAAAACAaZ3CwucDaC/N7IRQ+l7pdDoUhqH1c8FwGbqcOI6p1+tZZ4DsiyIMQ+p0OtTr9WxamYfLGgwGNr7X69l8vH3F5eZ5DjsYAAAAYIu0SmHpdDqUZdnCdlBZlnR0dFSLu7y8JGMMHR8f02QysfG9Xo+SJCFjDGVZRpPJhOI4pjRNaTKZUFEUNu9wOLSKhTGG7u7uajYsrOwYY8gYQ/P5nOI4psFgQEVR0N3dnb2Wpin99ddfZIyhq6urJzkiAwAAAEAD2rnQKp6QZS3YcZaEhFM+diJXFIW9pp1fscM2SRAENi6KooXrskxTpWcncdpBIAkndZ7n1Zx7sUM50H5wn8AuADkF+4xL/luzwvLw8EDdbldHN5IkCY1GI7stRET08+dPnYyOj4+pKAodTSRcoy+rl1dr+KNdnDPD4ZB837dbRM/982sAAABgn2iNwkLV1s+6DIdDMtW2z2w2oziO6eDggIqiWCjH87xaWKPTS7QStMw25fb2lowxFAQBHR0dLS0XAAAAAOvTGoXl7OzM2ohQZVRLRHR0dORcrWAD2X6/T1EUEVVKDCml4vr6mq6urmxY0u/3yfM8Ojk5sXGz2YxmsxmFYUgXFxc0mUxs/Xme0+HhoSjhP0nT1LZ9Op2uVJIAAAAAsAF6j2gVT8iyNmwHQkQmCAJrw8L2K/wpisL4vm/DLrsU/rCdSxRFa6WXNiymsmnha9J+hePYjoVtcHQ8aB/0jDIMwLaAnIJ9xiX/8NYM9g7IMNgFIKdgn3HJf2u2hAAAAAAAmoDCAgAAAIDW86QtIQAAAACA50SrJ09SWDbMAkCrgAyDXQByCvYZl/xjSwgAAAAArQcKCwAAAABaDxSWNSnLkjrCW/S2YK/T4M95rnsEAGgHvV7PHtC5TeI4toeRvjZhGNJgMNDRoE0KC/vg0Z823LiyLJ/t5Fp2MQD+jG3eo16vV5NBedKyvLbMTQMAz42URddp4MxgMFgr3S7w+PhI4/FYR/8x4/GYHh8fdfSLE8cxzWYzHQ0qWqOwGGMoiiLyfZ9M5WgwyzKaz+evrrR0u91GB4qbkqapdTuwK7z2+K/DNu/R4+MjRVFEnueRMYb6/f7CtSzLaDqd1vIB8JKwLBJRo/uRsixpPp/beVXK8rYIw/DZVjV3Ye7ZJuPxmIIg0NGgojUKi4t+v0++77dC890Wl5eXOqrVPMfyKwBgOxwcHFAURTSfz52rJ58/f37WF2BZls+2IpCm6Zua+8Gf02qFJU1Tms/ndHFxsRDPS5xy33EwGFAYhhSGob3Omj/n4Wv8IpZp9R4m20R0Oh26ubmx8bwUy2Xwkqt8ucty+VtCp9OhoihoNBrZuuTeqWuJl8vmVRlZbtOWBLe71+tRnueUpmltWViXxe3m62VZUhzHFIYhTSYTms/ntTY1tYHL5rq43zrsQpbJbSBl48PX5Dg33aOXIs9z216+f3JMZPs6akm+SfY4T57nC2XqMAm5j+PYlkeVbMkwI58fbjvTqe4ht00/E6B9fPz4kTzPa1xlcTlslfefZXLVs8bPcZ7nFIYh5Xlut2E9z7NxHTHPyg+J54XDslwZH8cxjUYjKoqCOmLOkv9zOp2X4bTryHKo7EZ6vV6tD1SVp8uS/dH1y/mcP//6r/9q/y/LsjY/NK1S6bHUcyNf34svl9q50CqekGVtpINC6WxQkiRJzTmh53nWYSHnY4eHvu8bz/NqzhP5mqnqk3V4nmcdIxZFYahytGiEE0QOe55Xc3Do+74NSweKXE6WZcZU48dtYGeP0hmjLIfh9EEQ2P+5XNkfxvd9UxTFQhrt2LEoilqbZRtlvByjpjZIh5BZltlrOsx1SPgaw/dUO700YsxkvqZ71ISsq4koihacZDJRFC30kevlNsvxl+3jsVwme01l6nBRFDW553vG90KG+X/Oy8gxk/eQ77H8H7ws8j41kSSJybLMPhdS9llOtazJcnnOXfWsJUliZcj3fVueS96l7OlyZB7+Xz5nMq9+Blk+5fyp504udxNZ5jHgPnE5rrrlOGZZVgvLcXG9A7huOWbyumue4GuMa2509ektIPtt43TEKlyFbAv5YMkJXMLCJD+czvf92gtZCoZ+aEzVl0y8QDk9P+T65S6FSr4EjFI0ZDqNFjD9UCaV12cZZnS/qfIurdHjwHAfuM9RFDkfEomO1/XLNui+rQo3IR92fd/kZLfqHjUhy2tC3xcJvwjMislHt08i74NRsqfv06qwvt/LwlJOGRIvCX2PPM9b656B7bOOnCaVwmLEy4zh/+W8ys+T/mRC6WHks6av6TQs/zpsHHlluRopn65nUMqnlk1+LjhuE1nW85ye342jvEB8WZAf43jOZFiPkZ63dFsky+bGt4arb63dErq+vqaiKJzLXFEUkakMc40xjfuc796901EW1/IbG6T9+vWL7u/vnUupq3CVuwnD4bBxP5qIKMuyWt9dhp/T6ZRmsxl11DJot9ulIAjo69evRET048cP6na7Ng9v/eilTc06bXgKvDy67p74U+/ROhwcHOioGstki/nx44eOImqQESl7z4nrWfF9v7GtYHe4urqi2WxGZVlSmqZ0dnamkxBV2zfy+TVrGOMOh0Pyfd/OD03z01PhrZX5fK4vNaKN7LvdLnmeRz9//qzFPydBECyMJRHR+fk5ffnyxaabz+f08eNHkXMzNp0b3yqtVVj6/T5FUUSTyWTh4dCTq9zPd8EvZVfct2/f9CV6//49kaOedeByf//+rS+tDSsVeZ7btjD6hebqe7fbtQ9PURS1vdmzszOazWaUpikdHx/X8nEez/OW7veu04ZN6XQ6dHJyQsaYjYwEn3KP1kVPiIxU9JZxeHjoVE7Wkb3notfr0f39vY5+NsUPvBzD4ZA8z6PPnz/Tw8NDoxKi5TpN04U51sXt7a19Po+OjpyyvSn8Ir66uiJjDPm+r5M04nkePTw86OiVXza2iR4DnguHwyGRsAWKoqjxfqziqXPjW6S1CgtVP/HyfZ+Ojo7sA3V+fm5fuOQQmLu7O/v/Kgv5IAhoMpnUjJh836d+v79QDxt0ep5HZWVgyS/LPM9pPp/TZDKhOI4pCAI6Pz+39ZSVESvnpxW/vmGl4tu3bzUhD4KARqNRrb1a6aDKiI3TZFlWu8a/vBqNRvahoupB4zGWY8gvMv7Wtm4bNiFNU/I8b+HbvzSuc7HqHv0JPDZaGdPhZZyentJ8Pq/1g/Mvk73n5Pz8vNamsvrZ63OcbQFenouLC5rNZo3PJMu1/BJzfX29Uu7SNLVz1nQ6tfOYXGlsmtNYCWdZZ+PgTmUo7/s+3d7e1vKkaVpTPFxlc1953uK/cl57Ts7Ozmg+ny/8CICq5/z6+tp+CZTPF48Zf6n9/PkzUcO89dS58c2i94hW8YQsa6H3AfV+PX/YNoDDco/Tr4ye+FrTvq1E7kPqfUNZD6fTe7Wcz7Vn6WojlxNFUWM/TMMeqlHlNtlHBEFgPGF0pm06EmW4bMS+Kefh8ed+6nHWbeAwVfu8q8IaeZ3bLvtADYaBy+5RE5x3HWR9XAej26PDhTKYpSV74Cx7Wt5dYyfD8qPvoStsljwPuh45/q57Bp4XeW9cyPsj566me0rKRkrGaZlwya2UJTk3cTvks0jqOdR5qWqjbguXlSRJ7ZruC8tj0xyq0y6TZf0cyrTcT10eo8eN0WOhr8s6OW2hjOj5nsr8TXMjw/Gr5sBdQPaLeVPemgeDAXW73a3ZVLxV0jSl9+/fr/xW9VZpswwDwEBOd5c4jhdWLcuypO/fvz/7ClCe5/Tr169nr+e5ccl/q7eEwPOwzhIwAACAzcnznCaTiY6mz58/P7sSMRgM6Orq6tnreS3ejMIyGAxoPp/TbDbbyM5gX0jFYWFYgQIAgOeh3+9TEAR2vuVPk13RNrm9vV2wB3pLvKktIQDWATIMdgHIKdhnXPL/ZlZYAAAAAPB2gcICAAAAgNbTKoWloxxbtZU0TWsHq8XCgeFz0nmGEyYBAOA1ecl5n235doGXHJddoTUKy0u88LdBmqY0Go1qcePxeOFgn22zKw8ZAACsy0vO+3meL8zdbeUlx2WXaI3C8twv/FXEcbzW6sVwOKQkSXT0s6ONjwAAYNd5yXm/3++/ytz9FF5yXHaJ1igsr43rd/MAAAAAaAetVFj4d+vS30UYhjQYDKjX69VsOTis9/s4TpcTxzF1Oh2K45jCMKSycr5FRHR0dFRLK5HnmGhvoNw2Geb2yDNhZBmdTqfmN6LX69l83B4S/XD50hgMBgvXuT9cFrdL1ukqCwCwe8g5Q84pPNfwfNCp5iMdZmS8LIft85rysZdl/shV6sFgUGtfWflgc81znL6jPMzL+I6aB+Xcr/OsQvZH+wKS/dHjIPub5/lCmHnucdHvEnlP9DWdt+mduRPos/pX8YQsa6P9IlDl/0T6ZZA+EjzPs2H26cC+hthvCvvEYB8a7J/B5c+C/edo2BcF43meDXM5XG6WZbZu9unD8bJv0u8N+9mQdZiq/9wmrofDvu8v+PuR/j+kz5sgCGxaUn5A9hF5HwBoK6vklOctxvM8+6zzPKDnKRnm/4uiqM09PG9JPzlN+XgOk3XwHMh5mWXzHOfj8Kp5jn0bGdEO7SPIBfeJ2yDn9nXGgevk/smwbs9zjovnefZ/+Z7RdctrnM/1zmwjcoxsnI5YhauQbUEOx1I82FIgjMPxHH9cQss3ukkxaYpnfN9vbJdRbeN2aSHwlXNEo5QHTzk7lA8ko/uhP1EUOfuix27foWeUYQC2xaZyGgSB/aLCLyNmWVh+IZSfovryJ+c6PSdzfYxXKU2mmvNc113zoJxfWUlYNs9pOM8q9DjwfG02HIdl4eceF428J7I/OrzJO7MNyH4wrdwS2oRK6bIf6UOBt3+YbrdLURTR0dERdRq2WVzM53PrIn0VfCyz53m1JTeXEZXv+/Tjxw8dTUREDw8P1O12dXSNoihqfdfOtpjpdErz+dy53AgA2G14G2M2m+lLa+P7/sJcumr+kVvazMnJiTP+T1g2z/H2R1EUtTxP5SnjoHH1/znGhartHfnLp36/T57n2ffOt2/fyPd9kWP5O7PttFph+fnz58q9SSkEeZ5TmqZWiKm6OZLxeEzGGEqShCaTydp7eL9+/dJRjUynUzLGUBRFNBqNKM9z6vV6dH9/r5PS4eGhjrKsEvDfv3/b/8sVtiksnJ7nrRxTAMBu0Ol06OTkhIwxFASBvrw2+gtVHMcr559ut0t3d3c6euMX/Cpc8xzbiDw8PNh5bRs8ZRw0LzEubNdyd3e38Munq6srGo1G1Ol0aDKZLPgWcr0zd4XWKSzSoHUymdDl5WXtOsOa5MnJiY37+vUrffjwga6vrymKooUVh3/7t3+zRqjD4dA+4FKQXC/9IAhoNBrZG319fU1FUThf/HmeW0Pb8Xhstdvz83Oaz+dWOMqypPl8vtBG5uzsjObzuW0P5zs6OqLfv3+T7/t0dHRk09/c3NDHjx9tWBKGoTX6cj1IAIDdI01T8jxv4SW76Qvo9PSUiqKo/UDg/v5+5Qv27OyMiqKozZmz2Yw+ffpUS/dUut1u4zz39etXCoJgwZHrpn2XPHUcNM89LvzuKIqi1jY2Ar6+vq6toDDL3pk7g94jWsUTsmyE3FuTRkUcp20xXHtxvE/JH8/zDBGZv//979bASZfF8U37eTKfNGTSbcuybCEto9vFcPtI7c/K9FyPtE3R+fSerxw/2aYmW519QY49AG1lHTmVzzvPB3JeoGpOWxY2DvsGttuQZct82mZC5jOO+dI45ivdfrbFkOGmfLpeTiPjNbrfugxXua5xWBVuKsdscVxkOXyN32cyry5XX29637UBctxDeGsGewdkGOwCkNOnk6YpvX//nvr9vr70pinLkr5//75glxLHceNqfltxyX/rtoQAAACAp9Lr9ejh4WHvlBWqtv/1OWGb2uC0GaywgL0DMgx2Acgp2JSyLBcMkF12TruAS/6hsIC9AzIMdgHIKdhnXPKPLSEAAAAAtB4oLAAAAABoPVBYAAAAgCWU1WnC0okheHmgsAAAAABL0Ias4HWAwgIAAMDCp4GD/2RbvorAnwGFBQAAAFF14Nou/gQW7AdQWAAAYEfp9XoUx7F1htdR3tjDMLTx2vcZx7NDwTiOaTQaUVEU1Kk8zbMjWbbh4HgdZmQ856PqpNVer9eYj50Z8kfaiizro87H/nt0Hb1erxbmfoVhWHNwKOuQ9YCWoM/qX8UTsgDQKiDDYBdYJacu/2Ce51mfMlEU1fyleZ5nfd0EQWDzSF8zURQ5/eFwHPvNkWH+vygK+7+p6vAafBDpfCT87XAd2i+bq4++71t/OJyPIeUrh9vC/xvhX6goCpNlWa39cly4jfvuh+0lkffSxumIVbgKAWCXgAyDXWAdOfUq53sMv4BNlV++YFkBybLMOkTVSEXCqPJWhaUTQPlhB4K6XKk8SSexpuqXdA7Y1EcJ94+hJQqLvubC930oLK+I6x5jSwgAAN4I79+/J2rwH8O+dX79+kXT6ZTm8/nWtz5836fqi7D9dLtdnayGq60nJyfOeBJ9lAwGAzo6OtLRjSRJQqPRyG4LSXibaT6f1+LB6wOFBQAA3hCe51kl4du3b/qyfeGzQuF53oJ9y1PRBrvSPqSJbrdLd3d3OnqposM/M2YbncvLS8qyTCdrZDgckjGGsiyj2Wxm29npdOjq6oqMMeT7vs4GXhkoLAAAsMPc39/b/6+uruji4oKIiIIgoMlkYhWGNE3J933q9/sUhqE1bJXKwsHBgf2fDVjX5fT0lIqiqK1Y3N/fL1U8iIjOzs6oKIpafbPZjD59+mTDTX2czWaUZVnNM3NZlpTnOXmeZz0Xp2lKRVHQaDSiNE2tgtbv9ymKIiIiurm5Id/36fb21pbFeUFL0HtEq3hCFgBaBWQY7ALryCkboLK9iLYFCYLAXpM2K2zDwtfYNoNtNdjGg/9fJ2yUoS4J+xUONxnhuvIxy/oo++d5Xq1MWY80ADbKYJnTy77L8v72t7/V4mHH8jKQQ/7hrRnsHZBhsAusI6e9Xo8uLi5oPB7rS2+GfegjWMQl/9gSAgAAAEDrgcICAAA7SK/Xo6IoaDKZbGxvsivsQx/B+mBLCOwdkGGwC0BOwT7jkn+ssAAAAACg9UBhAQAAAEDrgcICAAAAgNYDhQUAAAAArQcKCwAAAABaDxQWAAAAALQeKCwAAAAAaD1POocFAAAAAOA50erJkxSWDbMA0Cogw2AXgJyCfcYl/9gSAgAAAEDrgcICAAAAgNYDheUJ5HlOnU6HyrLUl5z0ej1K05SIiMqypE6nQ3me62RbJQxDCsNQR7eOXWknAG8Bnn/WnbvWpdPp2DnuJej1ejvrDPGlx+ot0UqFpdfrUafTsZ+yLFsjnGVZ0tHRkY5uhL2NMt1ul4wx1O/3a+m2SRiGNJvNdHTr2IV2DgaDBVmEggXaQBzHNdkcDAY6yQI8/3S7XX3pjzDG0HA41NHPxuPjI43HYx29E7z0WL0lWqWwsPbf6/XIGGM/JycnNJlMdPJXodvtUpZlOrqRx8dH8jxPRz8r0+mUgiDQ0a2jze1kWaRqgpGyOJvNtv4NFYBNGY/H1igxyzK6vb3VSZ6NdZSjlyQMw9Y+k20bq12mVQrLyckJ+b6/8OA9Pj5SEAStFUjw9gjDkDzPc8piFEX0+/fvWjwA+0JbVruZsixbu1LbtrHadVqjsOR5TkVR0OXlpb5EVH0bl8uYcjlUarC8tymvS+QSPwsTf5sOw7BWntya6vV6tXJWwXn19oG2f+HwYDCgNE1rti1ct2wrVX3v9Xq2L7wfyu13tTVNU2dfBoOBzcft4nCapgvtZ7jdrvbJvLo+WtHONpDnOc3nc7q4uNCXiKpvtrylp8dB3j8eWy2LOkzi/rAs8hjqMCPj9bUwDGkwGNTa9tw2U6A9sDy4njM9/1DDnCjT8ofnhslkQvP53MoVy6KUMb1dxci0XO+yFQieR7luhvuY57ldwfY8z6Zpmu80HTHvczrdb0aWyfUzOs8mYyXnX9nWVWO1zjz95jAb8oQsaxFFkSEiUxSFvrRAFEUmiiIbJiITRZHxfd8QkQ0bY4znefZ/3/dNlmXGGGOyLDNEZP8SkQmCwJaZJInxfd8YY0xRFIaITJIktbxNbfU8z6ZNksTm5XJkXs/zjFHt0WXwtSiKbHkyrTHGBEFg28/1cDhJklrfPM+z6bksJssymzYIAts+je/7tn1870xVNpfJ1+X/y9r5Usj+uuAxluPrgtvP95LHgceQx0HKog5HUVSTQR5vLkuG5b2Q7ZMyxvmIyMpvEAT2f7A7rJJTRsrCsufPNf80zYn8P+P7fm1ekPLEZUp5lLLK87JMy+m5Ta5njec7I+Ys/l/2j9vKfWqa7zRcjuxLlmW1sO/7Nux5nm2nnBv/ZKz4vcV4nmfLXTZW2Zrz9C4jx9TG6YhVuArZBjzRaiVATsAspPKh5I8UKn4hmEp4oiiqPazyI6+5HhrGcygQuq18TQvPsry6vcbxwBsllPrlZar7ItsjFQOeMOSH88uHyzjatw76gSUxmRjVf122bOdLIdvqYl2FxdV2T0yOemyXhblOZllYT3JGTax6knSlB+1nlZwyWlaXPX/y+V42JwZBsDAvMVq+9Pwp65PXE6E06fa6njXXPMfIPuo5a9l8p5HlmKpvOi857oOco/9krHTfuS9ZgzLHYd3nt4hr3FuzJXRwcEBERN+/f6/Fa8Mytq5OkoQqhYuMMQu2Bk0URVHLt8rSnJcB5S99lvHt27elS5Ca6+trmkwmteW+nz9/6mR0fHzc2AZeXlxm+R9FUa3fj4+POgkREfX7fQqCgDzPW1j2dDEYDNb+1dQ67WwD79+/JyKiX79+6Us1XDZVJycnzvht8uPHDx1Ff/31V+M9BWAZrjnxT2RYz1Pdbpc8z3POa8vguVlus6zLuvOdiyAIanlN9f5her0ejUYjG96kXRJXPt5qXjX3bDpPvxVao7CwIiIFYRla+Nfdw5PGkuWSn0vznuTDwwMZYzb6pc8mD0e/3ydjDBVFQfP5nMIwpIODAyqKYkGgV7VBp5fol9yy8ZpOp2SMoSiKaDQaOe0feP/08vJyo19N0Yp2toF+v0+e5zXaU6VpSmmaUrfbpbu7O3352RWyw8NDms/nOnojRRkAxjUndrvdhTljXTzPo4eHBx1tv5RuwuPjIxljyPf9lfOfRLd92Xyn0fMT52U7kru7O0qSxF5/6ljxPPHt2zd9yX5pWsY68/RbozUKC1UrKLSGg8WLiwuaTCb2BuV5ToeHhzpZjW63S77v11YDbm5u6OPHj7V0zNevXykIAppOp7X4VZrs6ekpFUVhhTyvjIlHo5EzL79kut2ufQhYeZMP2fX1NV1dXdmwhF+wJycnNm42m9FsNqMwDOn8/Jxms5mtXz+QkjzPbb3j8Zh839dJiKrysyyrnSdTluXSh2ZVO9vE9fU1FUWxoASkaUoPDw80HA7p7OyMiqKoKb2z2Yw+ffpUy7NtTk9PiZR8fPnypVHBAsDFsjnx7OyMZrPZgnEoVQozVc+7a067uLio5eW/m549EsexLX/ZCvq7d+/s/3EcbzTfac7Ozmg+n9ee6bIsqSxLms/nVBRF7QtJnuf0T//0T08eqyAIaDKZ2DamaUq+7688p2vdefrNofeIVvGELBvj2oPUe/Byr5GvecK2hfftZdiVRu/j8n4h7xHyh/P9+7//ey3etYco8/q+b/d0dZlFUSzsmUpkPO+zSpsevS8r02v7Clc+OT6cNquMznS8Rrabx0aOLTnsjaQdiyy/qY7ngjaQYd0n3VbXPTWOsV0W1h+2V2kKG7EXzh+WW/1cyPuunyHQbvheNyHvLd9fGXY9fy7bBz0nMlru9NzoeV6jHLrmG1daHZboOdw1f3Ac92FZ/RpXOcbRb0a2hevjZ0rn2WSs9DNr1hirf//3f1+YU94a5JB/eGsGewdkGOwCzyGneZ7T0dHR1ssFYNu45L9VW0IAAACel73ZPgBvDqywgL0DMgx2gW3KqbQL3FaZADwnLvnHCgsAALxxTMNPdAHYJaCwAAAAAKD1QGEBAAAAQOvZSYUljuOlDrOWwQfCrfvb/F7lTPElYeeGLwWf5gsAAAC0lZ0zuo3jmCaTCfm+v/QwIQCaeG0ZBmAdIKdgn3HJ/86tsIzHY4qiSEe/Ok9d8aFKCVt2QuxLk+f5i68qAQAAAMvYOYWljfzpy30ymeioV6XJBQAAAADwWrRKYWHnUvyRxHHsjC/LkjqdDuV5Tr1ejzqdjvWxoMPksNcIw5AGg4G1beGymI7yhMlp2ElYGIY0mUxoPp/bvGyDwv1hZ3myb2ma2rYTER0dHdlVGm4Tw+lkXmZV+yXchjAMKY5ja8cjbWZ6vR7N53PrQZrhsdT1AwAAAC+CPqt/FU/IshZZltV8PpDwa8E+JeQ1Dkv/CkVR1HwuyLC+xuVymMtjPy9G+KdgPxNBEFj/D7J9Mo/0KSF9Y3ieV/Mdof1raB8Yur98nctPkmRl+zVcJ5dRFIX9X46953k1nyLsB0Pn3VX4/gPQZiCnYJ9xyX9rVlj6/T49Pj7asDw+WnuilTYsRVEQVZ6eu92u9dypw79//6Z+v19zCz4ejykIgpoBr/T6LNvD8HaJMYbG47G+TMPhkKIoIs/zah43Hx8fbfj4+FjkqMNtYuI4rnnvHA6H5Ps+XV9fr2y/pigKStOUhsMhGWOo2+3a9jaRV96mPc+jTqdDo9GIiIi+f/+ukwIAAADPRmsUFoa3NubzOVG1HVIURc2F+GsxnU7t1o/cLtmEXq9nX/rr8OPHDx1Ff/31l1OZWkWSJDQajey20CYYcVKmMWZjV/EAAADAn9AahYXtNK6ursgYs+Cg6/fv37Xwa8EvbM/zNjorhe1Z7u7uaqs8qzg8PLTKm2STuhleWcmyjGaz2UbGwvLcmjzPd96ORdoE4YNPGz+QU3z2+eOiNQrLzc2N82yV79+/k+/7dHR0ZOO+fPlC8/n8j35K/BTCMLQGrXd3dzaet2HKsnS+yMuypPl8TkVRULfbtfHaONalQJyenhJVdTN6i2xdWMnp9/tLt4E4XZqm9O7dO/I8j05OTuz1r1+/0ocPH0SO3UOvGOGDT9s+kFN89vnjRBu1rOIJWdaCjU/5ow1eOUxE1rBU55EGr67wf/tv/60WDoLA/u/7/oIRqy6L6+U4NoRlY142VuXr0pBV5uO+sHEsX+M6ZBtcYyONd2Va3X6NboNRhsc6LggCm1fWz/dkV6FnkmEAtgnkFOwzLvnfuZNuAfhTIMNgF4Ccgn3GJf+t2RICAADwNljlg20wGGxs+L8ttll3Z4NzqcIw3Fq9zL75ncMKC9g7Vslwr9ezP5en6ify/LNyeS0IAppOpzYdANtklZwy8gVSFAV9/vwZcgl2Hpf8Y4UFAMXj46M9S8cYs3CeThRFlGUZXgrg1RkMBhRFkTVUPDk5qf0goC2EYVj7pSF4Gnxqelsoy3Lrq0bLgMICAAA7ynw+p48fP9rw4+Nj7Rd9baAsS5rNZjoaPIGn/Dr0Ofn8+bOOelagsADwB/BBh2VZOn1XaT9Q8qfsYRjaeLkPval/LN6T1/62dJjRfq3kN99OtSfPbXvJ/XGwOZ7n0dHRUe0e8sqf9P/Fcufyb0bivBdpd6Jll7/ZS59vHMfywvn5Wp7n5HkeUdVWKceyLm7rut/Y5TPCbZHHXEjZ53SMrHvV87sM2QYS9iRy3ORqiLad0eMr76GcG7hfnU6HiqKg0Whkn8tQ+Z3jdPyRY7yqfRIel8FgYO8jKZuZwWBAs9mMZrNZrf1S7prKfzL6Z0OreEKWVuF5Xu1nuat+pqv96oDdZx0ZjqKo9rN0SRRFJsuyhZ+ba99VfJ39Lkk/T9o/lud5tr6mMnW4KIraT9tZTvln8zLM/3NehvMXRVE7OoCfCfk/eFnkfWpCy6CGjztgsiwzSZLUZIrz8TEQDDX4MDOV3MhjDziNcfhgk/JqxPEK3K4oimp5dbkudNt5HLhMXZ8+QiKKooWx08/WKjgfjymH5fEQ/D8/Z9w3ft4Y6V9Oji23ke8DiXHl4yf0PKLHncd3Wfs0HM9lyD7KPL7v1+6Xt0W/c+SQ58WYFbgK2RX0gwT2k3VkeNnDzAqLcUzGPMEURWGiKGqcfOUkZNTEoCepVWE9aSwL6xeYqdoiJ3r5fMgJELws68gpIxVXee+1fMprWkHhtMahUBv14s+Us1qWW0bKkW6DUUr0smetCf0MmCWOX3VfZN26bfL5XYVug+5HkiSNL3dWNvRnVf1yXI3D8a4eR6kIrWqfRI6RRJch+8RjqT9PnT/IIf97tSX0+Pholyeb0MtrYD85ODjQUTXW8W3l8gNFys0Bw4a9v3790pe2issHle/7jW0Fu8F0OiVjDAVBQLPZzC7F9/t98n2fbm5udJaluORB+jBjeeV6fv36VTvFexPYiaxra2QTXI5fO50OTSYTHd0KfN+natHAfv6Enz9/6ig6Pj6u/eJxXa6vr2kymdS2pNZF92mbfuf2SmFZRZ7nTr89YD9petB//Pix1uR8eHjonHw577dv3/Qlev/+vY7aKr1ej+7v73W0c7IH7Ue/TKbTKfm+X3t5nZ+f02QyoTRN6ezsrJa+iXV8mF1cXND19bVTxjfl8fGRTOVDbtWXymXws8V2FMaYpW5IXhP95UHamzzFd97BwQEVRbFwP54ynv1+n4wxVBQFzefzte166Jn9zrVKYdFGSJsaKLIxmH6Im4ypZN40Ta2/oo7DeIxhQzX+yJvDaV0Gi5yPjSO1UIF2wd8KtMzo8DJOT09pPp/X5IfzB0FAk8nEykGapuT7fu0n1M/B+fl5rU1l5eeKv+WC3WI+ny8YyupfDg2HQ/I8jy4vL9eWr3V8mLF8f/78eem3aLkaKdsq41getS+5VUilfzKZ0NnZGeV5TkVRLKxYbPPF+aecnp5SURS18b2/v6dut0tBEND5+bmNL8vSjhsrH65xdM1Z19fXdHV1JVKtB7+7ut3uUme9rCDyu/rZ/c7pPaJVPCHLWui9O7k359qD5H00uVfm2v+Xe/C8Z8thmU9el/XI9HKP12xosMjt5Tqa9ijB8yPv4SqkfFGDfYCUIxkulMGslAfj8AVlHEaULC9NYfnhZ2ZZ2AgZ5A+j63HJNHg55L1pIgiCBXsIadfBRFFUs0nQMqDl1Dhk0VWutpcyDjkyYi7NKtsXvs7tknKq87jmSm6bK58ReUn4bmN7Do6Xzx+3TYb/4z/+w9ah0WMjy+J3jgwbx1jp+mQ/Zb+kzQjXE1X2cZxGtlGWyWMiZaSpfRI9Nq4yjJCjVfU/Ba63FqcjVuEqZBvwDXBBGxgoyvT8cEj4ZhmH0RQPvkQOuv8HBov6Gng99D0GoI2sktP/SWT+f4+Pxhhj/td//+/mfxKZ//Xf/7sz/P8aDJZeb2P4//4//0+TVb9O0ei5+zlpei9tiuv9AZpxyf9izApchWyDwPEzObNEMFkBcF3nsF6ZMX+osHgOy2mpNWulRNYlNVpXP8HLoe8xAG1klZz+r//9fzf/75MT83//X/+X+Z9E5v/7b//2pv7+P4+OFuZvRs/dzwHX4VKYnoLv+8/a3reGS/4XY1bgKmQbuJQLhsQqhoxbtcISOX4u9ycKiy9+1sdIrVkLt6yLyarVId0f8HLoewxAG1lHTv8/YWj+Z8NKRRRF5n8jary+C2EXejumzUqA3EbBnL8ZLvlfjFmBq5Bt4NJmeSWC99N4jy9JEqs4aKXDOJQZLoeVBa5H5+XrphI0LkuvkmiFh9HtlwqLVJwitZ8MXpbnkmEAtgnkFOwzLvlfjFmBq5BtIRUK/fJ3GRi5NG0dlnG+71slwpXXVP0jcYAPf7TSwh9Gp/WUwWKTERV4eeR9A6CtQE7BPuOS/051YW06DpfPAOwSkGGwC0BOwT7jkv9WncMCAABgffh8p02RTuz+FO3U77nYpJ40TbfWP0ae2/VS6HPA9h2ssIC9AzIMdgHIKdhnXPKPFRYAANhz0jRd+5u8Pkn8rVKW5dorOi/Fvox9E1BYAABgz5FH7i9jn/ytff78WUe9KmmaLvgf2jegsAAAwI6ibVHYzkP6Ouv1erU4qvzN8Lf1TqdDRVHQaDSyZcn0XE6Tv7Ver1fzbbPM3xqnjeO41p51kPWs8iGnx4WET7nOCv9wVI3jbDaj2Wxm+5Dn+UJ/uG5dv0zb5MtOwmVIv0Gyj3Ec02g0oqIoau2X47gXqy/6Z0OreEIWAFoFZBjsAqvklI9Y4GMS5NEPDB+noM+BIof/l6bzpTzPs2dZcZ0Ml8/nSsmzrIw6Q0se7cDpXaeHu9D1cDnkOEBUj4up6pHneHGb+AgKmY7rkKeYy2MuuBx9OjtVY6qPxCiETzHOKwmCoHashu4jX9MHoerzvGTetwA55B8rLAAAsIMMh0OKosiGp9Mp+b5PQRDYuNvbW/I8jy4uLmzceDyupdF0u92asaP0vqvh8pmrq6uFNhER3dzc2LRRFFnv4HoVpAldT1EURESUZRn1+33rNZgc48Lemz3Po06nQ6PRiIiIvn//vuDN+PHx0em5vNvtUpZlNlyWJc1mM/r06ZONS5LEbpdx2qIoqNvt1jxWu+A2GGNs/dzHJr58+UKTyaS2MnR/f6+TvSmgsAAAAFiAtyRms5m+1IjLxsL3ffrx44eOfnHMPw5KtZ/hcOhs7zr8/v1bR9GHDx8ary1jOp3SfD6vKR7rkiRJrU+3t7c6yZsCCgsA4P/f3vm8NrJlef7E/9ArkxihUP8LSfOQc5ELh/4AL+SsRZtZGCKg6U1iFYwX3ZBVTQRvU49BglwZGhwB5U3tLC+SN1aQCy96N6tWBMZjcvMWQ9Nd0wXTcGdROrdOHN2QZFt2KqzvBwLr/v4RRxHH9x7dA0AFz/Nof3+fjDELV2M0nU7H+V9+q9XSUS+OtD3J89ye1XJ3d1fJtwq8YnJzc6OTlq6muGCFw/f9lVediGiu74vsZF4DUFgAAGDL4e2WJEkoyzLyfX9u9SHLMnrz5o0NS0Nb5ujoiMbjsTUKLcuSxuOxc5vlpeh2u+T7fmVr6/z8nN6+fUtHR0c0GAwqygy/9HmbKc/zucPi2u02BUFgt5dotu0VhmFle2oVoiiy9V9dXelky+7urv2cJAkdHx/TYDCwZfM83wjF8FnRRi3LeEQRADYKyDBoAsvkVHoC9n2/YtTKxqDSpxkbZLr8snGcNvjkul1pRVE466/zt6bzaiNcTncZpsqyg8GgUr/Lh5w2UDVqTNJPnZxH2T6PIwiCuTY4j2vOdV4d1uMLw7BSjzQirouTZTlOGlG/BuQ4GZx0C7YOyDBoAtsop3me0/39PfX7fZ30IJIkoS9fvrx6m47XjEv+sSUEAADgu9Pr9ejTp09PVlaY9+/f6yjQcLDCArYOyDBoApDTh5HnuT3YLggCrK40HJf8Q2EBWwdkGDQByCnYZlzyjy0hAAAAAGw8UFgAAAAAsPFAYQEAgFdCp9OpOPbzlKO/74101uc6x+U54Pa8B54iu2lzB6CwAADAq6DT6cz5nzGzI+g3gSzL6Pb2lowxFMcxDQYDnWXt8JywLcRDlKRNmjvwZ6CwAADAK2A6nVYcBG4a19fX9iTWk5OTOYPKVej1ejqqlrIsrfNBmikgi07cfUjd4PsAhQUAAMCzI4+/fwx5nltvyKvwECeED1l5Ad8PKCwAANBgOp0OeZ435/iOvS1LXzOe51Gv16Msyyr+cbgObVuSZVnFBkQqHZ1Oh5IkoSiKyPM867RPh7kf4/GYBoNBpU+9Xs/WLVc4uK9cl+d59owV3UcXURRV8nPdcpyyv4PBwHpMzvN8bu5I9ZWvX//61/Yz59Vh3S7sYp6APqt/GY8oAsBGARkGTWAVOfV93/rFYd83HJZ+aDivEb5uZLyuQ+Zj2G9NURQV3ze6PRmWPnuCILD+hrg+9r9jZvmDIKj4zJH5Zd9WQfc/TVPrb4fb4P6xPx+G2+c5Yt9HMp37xnVxXk6X86v9E2l/QmAe173GCgsAADQQ/g+eDUP7/X7FhkUb4NJs66Pb7ZIxhrrdrrMOti359OkTxXFsyw6HQ6KZV+LLy0vyfZ/iOLZlXeG7uztbXlKWJY1GI/r48aONS9PUbvlMJhMiIjo4OLDpT6Xf79vTb9vt9kJ7Hz13t7e3FS/MYRjS7e1tJY+LPM+pKAryfZ88z7PenW9ubnRWsAJQWAAAoIF8/frVbmuswtnZmd2S4S2S+/t7nc0ynU51FAVBsNKLehku+5K3b9/Wpq0T3ubSSskiPnz4QKPRyIavrq7o3bt3lTyLMMZULvz66HFAYQEAgIbiUirq4JWVoihoPB5TFEX05s2b2hd3p9OhL1++6Gj7S5+nsLOzQ1Sz0sBp64btYq6vr8kYs3CFRdPtdikIAmuHsr+//yClQ9r+5HkOO5ZHAoUFAAAayMHBARVFYY1tefvh8PDQ+ULk1Zh2u01pmhLNXsS+71cMdtkg9+joiMbjsa2rLEsaj8cLfxq8Ku12m4IgsFskNNtqCsOwsvUiefPmjf28zOjWxfn5OYVhaLe2mCzLrBJWlqVz7pIkoaOjI7tCIuvg/vJqFfeNjX5936f9/X2b//z83K4mgQeijVqW8YgiAGwUkGHQBFaRUzYspZnBKhvQSsNVNgBlo1m+JDJeGsKykagu4/u+jYvjeGF4MBhU6iBhdCqNd7ldOSaZ14h+SsNfaezK6LGGYThXL/dxMpnYNDaQlfkmk8ncPPDFfYvj2MbxZ22Ey5c09JVhUIUc8j8fswRXJQA0CcgwaALL5PQXIvNf06kxxpg//va35hci88ff/nZrwn/6/e9NURSVXxI9F3Vt1MU/BKkggr/gkv/5mCW4KgGgSUCGQRNYJqd//M1vzL/t75s//eEP5hci8x8//bRVf//7hw/2p9rPCa+46J8ix3E8F/cQeCUGuHHNzXzMElyVANAkIMOgCawip/8eReaXJSsRrzn8UsgtH77WsboC6nHJvzdLWBnP8+iBRQDYKCDDoAlATsE245J//EoIAAAAABsPFBYAAGgofAhaU0iS5EGH3T2Gdfvr0XPs8jMEXgYoLAAA0FDkUfqbTpZlNBgMdPRaWbcylOd55awYmp27YmauDcDLAoUFAADAs9Pv9yu+iZYRRVHlhNhVeMjJv6vQ7XbtIXvg+wOFBQAAwEbBzhEBkEBhAQCAhqJtQnq9HkVRZO0uPM+rrFJEUWTj2QEiCbsMvqQNSBRF1Ov15urUYRL+eviv53mVY/9ddDqdSrt5nls/P9JtgGxvla2fXq/nzKvbYzjOU3Oj4bHxmPkeyDmU9SZJUql7Wf1gAfp3zst4RBEANgrIMGgCy+SUj4vnw9PkcfR8emoQBPZzGIb2Mx+GxsfHy89cb5qmlfNHZJ06HIZh5Uh77hMfec/Hz/Ox/QwfhS/bLYrClpNp8kRY3/drT4jlPrjGVtdeHMdzrgH0fBgxb1xOHtnP45Jj5LqYIAhMEAQ2DOqR82bjdMQyXJUA0CQgw6AJrCKnWgGQCopRSopUACRxHM+9ROWLNQzDSvqisFY0jOqT62WurzRN5+qRPof4qjvllutg/Jl/pUXtaahGYTGOMep7kKapDcvPrjCoR845gy0hAAB45SwyXr29vdVR9P79+7UZsNZ5X2Zm/zjbq9/v6yxERBTHcSXfY/u3qD3evlkX/X6fiqKwP4G+vr6ueG4GDwMKCwAAvHJYafj27ZtOolarRePxWEfP2X48hVarpaMsUpnK87z2DBWtWC2zjanD1Z48a+XP/9yvjziOaW9vjzzPo6urKxoOhzoLWBEoLAAAsAWEYUhHR0c2XJYlJUlCBwcHREoB+Pz5M52entrwQ7m5uSESv/bhNiTdbpd836+sOJyfn9Pbt29pZ2fHxiVJQkdHRzQajawys2jFqI5F7Z2dnVEcx3RyclIpU6c8rUqe53R7e/vkVSEwQ+8RLeMRRQDYKCDDoAksk1NpEOv7fsXOg21XZNgoWxBpSyGNSUnYb8g62BZlUZjtO2Q7XJfuLyPb1bYnq5SX6Lq4Dlm3zmOEnYqsn4jM7373u0q8toMZDAaVMtoIV88rXy67GVCFHPI/H7MEVyUANAnIMGgCy+T0FyLzX9OpMQ4vxt8r/L+Ojw0Rmf/98aMzfe3hf/onI/llQ+dEp8dxbP7429+aP/3+9wa4ccn/fMwSXJUA0CQgw6AJLJPTP/7mN+bf9vfNn/7wB/MLkfmPn37aiL//jcgZv+6///ef/9n8n7/5G/Ofw+HGzsnJX/2VM/5//u3fml+IzH/9679W7in4Cy75n49ZgqsSAJoEZBg0gVXk9N+jyPzi+K/+e4Qnk4n5+5my8vezn/0uyr+O8P/7l38x//nTT0ayyXNCROZ//PVfV/IDNy7592YJK+N5Hj2wCAAbBWQYNAHIKdhmXPKPXwkBAAAAYOOBwgIAAACAjQcKCwAAAAA2HigsAAAAANh4oLAAAAAAYON51K+EAAAAAACeE62ePEpheWARADYKyDBoApBTsM245B9bQgAAAADYeKCwAAAAAGDjgcKygCiKqNfr6egn81z1AgCAi16vR1EU6egnk2UZdTodHb2xlGVJnudRnuc66VnJ8/zV2H/2ej1KkkRHvwgbo7BEUUSe59nrOb5cD2U4HNLl5aWOfjLPVS9YD51OpyKL8uEm0zZBRsH2ouW0TmajKKLxeFwpuw6yLKPDw0MdvdG0220yxlC329VJz0ae57S3t6ejG0mv13sWWVqVjVFYhsMhFUVBRERFUdBwONRZnp0oiqgsSx39ZJ6rXvA8TKdTiuOYfN+fe7hx2mQy+S4yCgAznU4pTVMrp3yFYUh7e3uUZRnR7NkaBIEu/mT6/T6laaqj18ZrWYXudrs0mUx0dCO5vLx8FllalY1RWL43ZVnSaDTS0U/mueoFAAAXrEhfX1/rpMbwvbYcwGaz0QqL3G/s9XrkeZ7VujnseZ79T4K3lVjY5TaTXL7nsnmeUxRFlOc5+b5PRES+79u8et83y7K5pVfev02SZG5JdtV6eX9TlmU4r2ybV2t4fjqdDuV5bucBvBx878qytEv08t7yPXLdWymf0g5Ayr2uU4dJyIiUQVIyKdFyLFf/vNn3ifvWJPsE8Gf4OfDhwwedZNFyqZ8d8vmqVzqk/Nzd3VXSJJxPPt+kIlLXhyiKaDAY0Hg8tuW1zMr+8neiLEv7vah7NsrvK8s4j4+/LxyWeXX/ddiFHPfXr191cmU88rkgv7fy+9fpdCrPDHLMIX+X9TtF9lO//xg5x/p7r9+/3w3zQB5RZGWKojBEZIqiMGbWFl+TycSmTyYTY4wxYRiaMAwrdaRpatP4M5dL09SkaWriODbGGBMEgQmCwBhjzGQyqbQdhqEhIlu/7lsYhsb3fcPItKfUG8exHSPnlfmDIKh8LoqiMj6wHFpBhuM4rtxfSRzHFXnkqyiKyv3W9zYMQysXcRzbz8YY4/u+ba+uTh0uiqIiIyzXvu/Phfkzl2W4fFEUthwJWZKfwcsi71MdaZpW5IUvjXxumFnd/BzlOuSzU+dlWU3TtPK9kHIrkTIry8p2l/VBfz/kc5/bjOPYlvF9f+GzUX5fXd9Jro/L6vmUcy3DLvT3LAiCSlh+5mc+f5b94b5zeTnX/J1l5LwEQWDnRdaf1rz/0jSt3HM9l/r5weHnxDW38zFLcFWyLvQDnsMsqEYJ+WQyqdwwfolwPn2FMyXGNQb5EmDkl1wLoA5LpNAtq1c/HIxDWGS6zK/TwGrU3TfJKgqLcdxfKcNxHNfeHy3XXA/LsExfFtZysCgsHz4MiQcQKQXF9/1KGLwcq8ipViCMeEHJ+yxlQL8UOT0QL2r5vOJnZlEUJhAvQk7T7TOuZ60/U54X9cE4FAmJbLPue6q/A4z+vup2Fj27l4UlYRhW5l++L6TiI6/J7H0mnwsSnjuG77O+dH9cbWuCmUIkL9/3rTzovPoZ8hzodo0xZqO3hJbBxpC83Hd/f0/tdtumTyYTmillZIyh4XBI/X6fgiBwLsUtotvtku/7tq2vX786jY88z6PBYKCja5HL8cz+/r4zXjMcDmk0GjmX8MDT2N3d1VEVdnZ2dNQct7e3Ooqo5p6zLN/f3+uktTKdTnUUBUFQ21fQPE5OTigMw9rnkOtev3//nqbTKX379k0n0du3b4mI6Nu3bzQej+nNmzc6y8rwc2pRHxbR6XQqv0w6OTkhEtsr/N363s/Gq6urhc8QbShtZsb9/MOTVQmCYK4e+Q7s9XqVXygtev/FcVypZzqd0s3NjTVr2AQarbAQER0fH9PZ2ZnzJaAf/rxfd3l5SUZY07vKuvj06RMdHh5apUT+NJn3UY0xFMdxpdwi2u02XV1d6eiK0NXBP9EzxlBRFN9/f/GVUffwuL29Xen+tFotp2xxWde+9lNeBqvQ6XToy5cvOpparZaOAq8Al/y1Wi3nT1M7nY5VxG9ubnSyTdPP1Yeyu7u7sA8u2Ibi6upq7pdJ0+mUjDEUBIF9uW7Cs3GRfY9+tmRZRvnM5vEh86sVvCRJKvY5p6enc79Qqnv/aSWS35e6r9+TxissBwcHNB6P6ccff6R+v2/jwzCkw8NDezOyLKN3795RlmXWAGk4HFoBl/8xuwypyrKks7OzigbK5HlORVFU4mjW5rJ6P3z4QEVRVNJGoxF9/Pixks9Fr9ez49NCCZ4Gy5I0SnOFF8GyKQ0EuTz/ByzlMwiCZz8f4ujoqNKnsixpPB7b/1RB88myjEajEQVB4FSsDw4OiJQsf/78mU5PT6ndblMQBJVVjIuLCwrDkNrt9txz9ezsjIqiqFU0aPZ85L/j8Zj6/f7CPpBQoMuypJ9++onG4zEVRVEZT57n9Otf/9rKsvwHctVnY6vVqrz02dj3qQrO8fExDQYDO/bz83Oi2UoQP1tkG2dnZ9Ttdun4+HjubJu6Z87BwQEVRVFJ//LlC7XbbRqNRjSZTCrPk7Is6R//8R+d77+joyMajUaV5wKJ5yD3lZ8Xg8HA+T57dvQe0TIeUWQlQmE8SETmV7/6VSXM+3AyzNTtV8p9OU6XBkyk9nn9mdHhZDJxlpXt6/JclmZ7f7Lcsnr12HgPUueVc8Rh2a7euwRu6AEyLO+LvGfGcd90uFAGs6TsQ+T95H1z3jOW+ReF5cX78YvCxrGHzuh2pGzBjuXlkffGhbw/+pJ2GS4Z0HKm7SZcZerSXDYkRsiZzC+fUYv6wN8brlvWweNmWwqZxnLqejbq7yL3RcZxfTqv/s7osOvZq5/XJO7norHLclxGjsVlG6P7Ievgsv7MHq3u/SdtYuQ9lX31fd/OuxH3RcvPOuCxS+CteUXKsqSbm5vKKg7NVk3w32mz2FYZBs2i6XKazU7CbfIYwHLKsqSLi4u1vwdd8t/4LaGXIoqiuT1J1/4wAAAAsA1EUUT7+/trV1bqwArLipRlOWct7fv+nNET2Hy2VYZBs2iynPLqCtPUcYDvh0v+obCArQMyDJoA5BRsMy75x5YQAAAAADYeKCwAAAAA2HigsAAAwCvEczg1fA2UM4d//KMH6aTwNfBa79s6gMICAACvjEUHuTUZ148fut0uGXUkfVN5rfdtXUBhAQCAV8a6fr0YRdFGrVy02+2NOip+3azrvr1WoLAAAACYoyxLGo1GOhqA7wYUFgAAaDDezPOut8T7fJZlNp/eemDnrZ7nUZIk1hEfzc6biqLI2oqwYz32YSPr1bYkbG+i+8d1yTYZ2Qb3U9ZzcXFh85JoX8LOEj3Pm/MLxHXLi8fialvOjZy3KIqo1+tVxl+W5Vy4DtkP3UcSY5BtJklS6TfPJ89Pnue2nKxT3wfdP9kX6ZuI68rzvNan0Yuiz+pfxiOKALBRQIZBE1hFTmUe9gUj09i3TpqmFZ9Avu/bMPuY4XxcB/upKYqi4k/G5cuGYR82soz0b8M+joIgsG3Kfks/QYyrHg5LXzpMOPOzxsj62EcWo+dBt82+d4zoR5qmFb87XJ796siw7IdE9pHrZX88XK8My888D0EQ2L5xGc6r63TdYzmfnCbHyOPUbb0U5JD/+ZgluCoBoElAhkETWCan2gGffGEZpbBIh3d8+b5vJpNJ5QUukQqLK2xm9UoFxszajePYxHFc+8KWaKVH9tvMFBpZj1ZgpJKl02R6URTWuSGjw7ptjXzxSwVslbBE91Gi+yDblMi+awXFOBSdRWn6YiWG5/V74GobW0IAANBQfN+n2T+e9up2uzobERHFcVzJN51O6f7+Xmd7EC4j0SAI6Pb2lm5vb3XSHL1ej/b29nR0hS9fvlCr1dLRTr59+6aj6O3btzbt4OCAxuOx3Qr58uULvX//XpWYh7d51mHwu2ibaFU8z6PBYKCjawnDkM7Pz4lm23E0+3UVM5lMKrIxHA6p3+9TEARz20/fEygsAADQUPQLNMuy2heLViCiKKI3b97M1fEQOp0OffnyRUdTq9WiVqtV+3Jmm4nT01OaTCY6eQ7d9zp2dnaIiOjm5kYn0c7ODrXbbQrDkHzfJ29m97LIcR/b2lxfX5MxZu4n1Y+Bf37tUq6WwfY0xhiK41gn1/Lx40cajUbkeR7t7e3NzblWXNle5fLykowxFIYh7e3t1d7PlwIKCwAANJB+v080W6Vgzs7OnCssR0dHNBqN7IFk/OLpdrvWqJZhpYdf/jQz9nRxdHRE4/G4Uu94PKaTkxO7miEPQeN2RqMRTSaTSl/LsnQqW7rvbHTr+/7cC7TdblMQBBXHixcXFxSGIbXbbcqyjFqtll1JuLy8rJTXnJ+fUxiGNBwOK/FPPdgtDEM6Ojqy4bIsa+eYyfOciqKgP++W/IVV+rK/v1+7CheGIR0eHtq5zLKM3r17R1mW2T4Nh8O1KGtPRu8RLeMRRQDYKCDDoAmsIqdsu8CXyy6B7R+koai2W5H5pb0IG6LKslRjI8KXRBrFyr6EM8NZ7ov8q/Ma1XcuWxRFbdvSZkeOR/eHLx3Pbet4V1/ZuHZR2IXsI98P3QfZjg5LI2FZTvd5MpnM5eFyrr7wfKUzg2OOZ1slHpvLrmadkEP+4a0ZbB2QYdAEIKfrJ8syevv27dypuEmSLNwaajqu8dXNxapEUTS38rROXPKPLSEAAABbweHh4ZztSJZl9MMPP1TiXhNJkjjtjK6vrx+lrPBZMM+prNSBFRawdUCGQROAnK6fLMsq9i00s+H4Hi/fl6TT6cwZVxdF8SiF5aVwyT8UFrB1QIZBE4Ccgm3GJf/YEgIAAADAxgOFBQAAAAAbDxQWAADYcjzPW+k8Dw0frKbPQ3kMURRthoO9BXQ6naXnpYDnAwoLAABsMdpz86qUZbn0WP1ViaKIRqORjt4oer3enOEqeFmgsAAAwBbj8ge0Cu12e+6I98cyHA4pDEMdvTJ5nj965UOeFLyIy8vLzTjtdYuBwgIAAKDRfPr0SUetxGOVHPB9gMICAAANxpt505V2KGVZVuKlbUin07HOB72ZA0CG4/SqQ6/Xq01jZFu6fZ2HbV64H3pbim1jON1VJ4+p0+nQeDymwWDgbMur8TQcRRENBgMaj8eVPKuMleF+8sVEUUS9Xs86K+QVIFefpB0Q55f3S49bjkXWuayvrwJ9Vv8yHlEEgI0CMgyawCpyyr5izMzfDvukCcPQ+n5hfztFUVjfMHW+hGSYfcqEYVjxx0PCD430WyPDMi/3z8z6yH6IZL3sEykMw4p/JB4D53eNycx8Hsm8sg/sh8hFGIYVnzqLxmpUO+yjhwmCwARBUPF7JH0uyTDn1b6giqKwc1gUhU2Xc8ZtxnE8N2YZbjquezYfswRXJQA0CcgwaALL5JSd0y1Dv/T0y93M2pLO7NjRni7Laa6Xq3G0JZUoM3vhMrpeqSzoejW6HTkm7RCRL6k4MVIB0HWaJYpRKBwcykvX6yKO4zmlzzWHcRxX5kyinUXSAkeLTYTnUoItIQAAaCB3d3c6ao4oip5kKKr97hARvX37tjZNc3JyQkVRUJ7nlOc5vXv3jmi2DUIzw92HssqYfN+n2T/k9up2uzpbBdd4lo01DMO5dpbheR4NBgMd7eT29lZHVUjTtNL25eWlzvKqgMICAAANZHd3t/YXPmzb8O7du0f9FPfu7o46nQ7t7OwQEdHNzY3OYtOWEYYhffr0ic7Pz6nf71fSHnJ+y0PGpNOzLHPasUgeM1bd/0XnyLB9ijGG4jjWyU5ardZcGxKttC5q/zUAhQUAABpIv9+noigqv3RJkoTKsqTPnz9TmqZzCsKiw+Hky28wGNDp6Sm1220KgqDiMPDi4oLCMFx5deTjx480Ho8rcd1ul3zfp/39fRs3Go1oNBrVvnQXjYmNdrMss6si0gj17OzMucLSarWIZorHzc3Ng8b64cMHGo/HlfmvUy7yPKeiKOZWYBbdDyKig4MDGo/HlXw8P8fHxzQYDCrGuzyeV4veI1rGI4oAsFFAhkETWEVO2d6BL7avkIaf0tZBfnbZsfCl7T3YWJeEMa40uOUyMixtQYIgmKvTqDbZhqWunroxyTTum54XV9tGjEHa2bjGapTNSJ29jFG2Ldpgl+P5s7ZDcY1dx0lbo7q2XgPkkH94awZbB2QYNIHXJKdRFNFwONTRANTikn9sCQEAAHg2tmKrArwIWGEBWwdkGDSBpstpr9ej8XhMQRC8+l+vgPXjkn8oLGDrgAyDJgA5BduMS/6xJQQAAACAjQcKCwAAvBI6nc7Sn8o2AflT5afS6XQa5eRQ+hZ6KJ7wJ/UagcICAACvgE6nM3dgWhPJsqxyFspTmU6ndHJyoqM3krIsaW9vT0evxLoUvE0GCgsAALwCptPp0iPrm0C/36c0TXX02thkr8btdpsmk4mOXom6U49fE1BYAAAAbAV5ns+duguaAxQWAABoMOyjxnWkfRRF5HneXHpZljbe8zx7vHuSJNTpdKjX61XsITjseV7FHoTb9jyvsiWRZZltk90FMK52ZRnP8+Z85Cyi1+tRFEWV8rq9LMsoyzK73cLjYHsRnieeI/ZbxJeEy+iLkXPC8yftUhbdL8nNzY2tR865vKdcZx0yn1xZWjZncvx6q0nWucw/09rRR98u4xFFANgoIMOgCawip77v26Pa+Zh4DodhaD/zUfVpmtrPfOR9GIYmCILKMfPyKHt5rD4fEz+ZTEyapvY4eFm/mfXLiD5xW3JMfJw+55PH4/u+XwnXIY+m52P0gyCwn/noez1HRh3fL90U6L7wUf2MnB85BjNrj8fKbf3888+2HZ4LnkfpvoDhNJ5bDst7x/i+X3EfIMcax/GcG4XJZLJ0zuI4rhzzL+uUbeuxrxtX3fMxS3BVAkCTgAyDJrBMTieTydxLXSow/FKSVxiGlReZJo7jSp3aJw9f2g+RcbTNnxmpEMlrMplYhUnm1WOrQ75szUyJqXuJS4XFiBe5VBzkOMwSZU+Gtc8fvtI0nWtH1yPReY1jTHXxcqwanmuzZM5837f5JIvu33NADvnHlhAAADSQr1+/zi3XayaTCc3+MSVjDA2HQ7q9vdXZlsKehvmSv7rhbQX5C6U0Tenw8JA8tfXh+36lHmMMdbtdGo/H9ObNG5vve6J/adVut8n3fbq7u7Peqy8uLohm2za+71e8Oevxae/S64C39EajkU6ag7d3VkWPX1J3/14KKCwAANBQlv0y5P7+vhKOoohardZCuwcX3759s5/LsqzYf1xfX5MxpvILpX6/T8YYmkwmNBqNrA2GfhlmWWbtIHRfvxe+79P19bWOpt3dXSIiOj09pcFgQJ7n0eHhIV1dXVXyybnN83wt56KUZWn9MXmeR/v7+2SMoTAMdVYLK5I0U6JWxff92nux6P69BFBYAACggRwcHFBRFHYFI89zKoqCDg8PKcsyCsOQDg8P7Qs0yzJ69+4dHRwc0Hg8rrxI6wxAeUVBng1ycXFBP/zwA52fn1MYhnNemDNx6Fu326U4jolmSgypnxWfnZ1Rt9ud6+vZ2RkVRbF0BemhyFWcusPkjo+PaTQa2Rcx/+X+Hx0dVVYYeHWl2+2S7/u0v79v6zo/P6e3b9/a8ENgJZF/2XRyckJZlpHv+3OKqkspOjs7oziO586gceWVHB8fz52DE0XRwvv3Yug9omU8oggAGwVkGDSBVeRU2k0EQTBnf8EGoyQMLHU5mtk9sBElEc3Zj7DxKgn7FV0H52GbFFdd2iZG2j/ovnI57pfLbkaXCZVBqWxL2/ZomwxpM7LqXMi2GN2mnicdXmTHwpdExnNfZH+5XT0+ziv775ozo4yZSbS/6P6tG9kuA+eHYOuADIMmADmtEkXR3GrO9yBJkrlVC1cceBou+ceWEAAAgI2FbTE+fvyok16cKIqcRsuuOLB+sMICtg7IMGgCkNPNxPWLG9yn9eOSf6ywAAAAACti1M969UsVPB9QWAAAAACw8UBhAQAAAMDGA4UFAADAo4iiqHIux3MgD0BrIk3v/yYBo1uwdUCGQROAnDafPM/toXu4lw/DJf9YYQEAALASURQ9+Fj/l+a5V3weQrfbpTRNdTR4JFBYAAAALKUsy5Wc7X1PsiybO7YevB6gsAAAQEPpdDqUJIn1yKttJaIosvHSXxA7LtQXCe++fOV5TnmeW+eGvu/bunq9nv0sy/AqTKfTsXXIsOd5S33aMEmSVHwKcZtsG8LtJUlCh4eHVBSFrZ/z8DxIp418SZ9C7AW5ro+9Xs+m8WoTh3mMOqxxzS+Je8J9dfl3YpshWQeXd42Vy8g+MzyWPM8r8ZyX55Tb4nvA7XC4rt+yj2tb9dJn9S/jEUUA2Cggw6AJLJNT6UeH/ez4vm8/h2Fo/eewDxjpT4f9wLAfGoaEf5sgCEwQBMYI/zacxv5mpB8d7cuoKArbju/7tiz7uXH50ZFwPvbn4/J7EwSB/RzHsc0r/fFo/0ocdo2d+8ttc94gCOb8KBVFYedW+tVx1SPT9PxKHz0un0lG+TeS95jbco21TgbSme8oo+5xGIa237IdOa9mNia+n7pPnF+GdfoqyDmzcTpiGa5KAGgSkGHQBFaRU6mgGPVS5ReJvMIwtC8ZfmnqsCSO41qFxShlgfPLML8stTM/vuTLtQ79stRthjMHfq68WlnQcL+MGiujFQoXD1VYJMvmVxOGYaWPsm1XO3q+aSYDrrzGUT/jmletGMp+uxxEuupdhKt/2BICAIBXymQyodk/pmSMoeFwSO12m4IgoIuLCyIiurm5Id/3qd1uV8p6nkeDwaASt4yDgwMajUa1hrmyL8YY6vf7OsuL0ev17C94qMYf0Pv372k6ndK3b9900pN5zPxq9D1z4ZKBfr9PQRDYLRveVhoOhzQej238U0jTtNLu5eWlzvJgoLAAAMAr5f7+vhJm+4LT01MaDAbkeR4dHh7S1dWVzcN2JsYYiuNYlF6OVIayLKO3b99W0qUik+f5nI3IS8C2FqenpzSZTGx8q9Wi8XhcyUuz+djZ2SFS/X8sT5nfOrh/Lupk4PLykowxFIYh7e3t2bGxguH7fsV26KHc3d1Vwi6bnIcChQUAAF4hYRjS4eGhfRFlWUbv3r0jIqKjo6PKf7/8n3qe51QUBRljKnVlWVZ5KUpDVc3R0RF9/vyZ7u7ubL3dbpd836f9/X2b7/z8fE6heSq7u7v2c10fR6MRTSYT6na7Nq4sS2q1WkTqxfr582c6PT21iphMY4WLx8iKAbe7t7c3Z3i7aH5XRSpVSZJQEAS1Ky11MpBlme3ncDi0BtVRFNk+SyV2d3eXiqKw4dPTUyqKolahOT4+psFgUDEo5vl9EnqPaBmPKALARgEZBk1gmZxKOwG2hZBhowxztXGstC+Q6TKNP+u0yWRSW7eZ9d1lnyLb43Q2HHXlj4Whqe/7c21yWQ5LI1C20+CLkWV4PGyPIcuTsksxam6kTYbsJ3+WdiWyD6751fejzo6FbUxkeSPsZGQ7jJ4zzu+SF12/HL+WN9/352yTZL/lPD/UfsXUyD9OugVbB2QYNIHnlNMkSejk5GRp3EsSRRENh0MdDQTR7KfU67AH2XRc8o8tIQAA2CKiKHIamLriXgI+rwPKClgGVljA1gEZBk3gOeXU9QuQ52oLrIcoiuxJw0EQvPpVFpf8Q2EBWwdkGDQByCnYZlzyjy0hAAAAAGw8UFgAAAAAsPFAYQEAgIbCjuheC51OZ+UzSaTjxUVEM4eBoPlAYQEAgIbS7/fn9vmbSqfTqRxOtogoipyn0mqSJLGGqqD5QGEBAADw3ZlOp/bE1WUMh0MKgkBHz3FyckJhGOroZ+MlV3L4TJbHkmXZyqtZmwIUFgAAAOCJZFlG0+lURz8LZVk+eeXo9PRUR208UFgAAKChJElS8efCdh1s2+J5XuW/cHb853leZTXA8zybxvXleW7zSjsZWbfneZX/0nu9Hnkz77/SvoQPh9PtknAGuIo9yiK4HjkGiRy7nBM9HpnW6XQq5UiMUcYlSUKHh4dUFAV5Yk5kWdmnsiztmGVdnpgfnn89ljzP7UqU7/t23pbdryiKKEkS23ZRFHR4eDhX/0ajz+pfxiOKALBRQIZBE1gmp+w/hv3JaL86ZuZHhj+z7x0jfOZMJhPrI0b6e2FfQUwQBDbMPmTMrE7pz0b6MOL8cRzbeDMbF4d937c+hHg8Lp9CLuTY2DeOEWOr81XEYTMbp5xnTiuKwvrU4fFxfhmWY2H/Ogz7d2J837fp+j4ZR1/MrD8uOC/77ll2v4yYXy7zkLn+Hui5MObPnjofhKsSAJoEZBg0gVXkVL8k5UvcKCVFvqw0+uUllR95adI0nXshaqTTPL6CIJh7+XPeVV+ieqwSWU84c+gnIeHAUSpTnCYVKp0ukeX1veA2GFYyJpNJRWGUyDEVRVHbtlZYFt0vqlFM6uI3Be6/BFtCAADwynmMcWYYhjT7p9Zekk6nQ4eHhzbc7/cpCAK7JZHnuU1L07RSz+XlJX39+nXt2xG8/bHqr41cNidBECz1q8TbL3W/VHLNd7fbJSKi+/t7nWQ5PT21tikXFxd0cHCgs9RSd7/SNKXDw0O7LdRkoLAAAMArp91uExHRt2/fdFIt+qXLLzu24bi6uqI0TSt5Li8vyRhDYRjS3t6erePu7q6Sj+tyKQyPgRWI6+trMsYs/LUR92lnZ4c6nQ59+fJFZ6FWq6WjiITtyadPn8gYU/tLJZ7vr1+/6iR68+aNjrJ0u13yfZ+SJKHb21tbzyrU3S/+6ftkMqHRaERJklTyNQkoLAAAsAWEYUhHR0c2XJZl7cvrw4cPNB6PK+llWVJZljQej6koisrLNM9z+umnn2z+4XBolYbj42MaDAZ2xSXPc2q1WnRwcEBFUVSMRtkQ9KE/tz0/P6cwDOc8PnM9UjH68ccfKQxDarfbdHR0ROPx2Obj8Z2cnNj8kouLC6fjwSzLaHd314aTJKEwDGkwGFhFIssyCoLArrTU8enTJxoMBvTu3TudZNnZ2bGfkySpvV80WwmjmTIUx7FN5/tTJwMbid4jWsYjigCwUUCGQRNYJqdxHFtbBd/3rZEozYw5pV0D20XIPNoAVNs0sE0KX4yug2Y2KWz4ymnS/kL2RdqTsC0Gx0vbE67bZXejxyrrkf2SxsEyv6RunNL2hsfCtie6nTRNK2mMa9y6Dm3HYla490b0j8vXjUPfL4b7Vmcn871xzQG8NYOtAzIMmgDk9M+rLvf399Tv93XSqyaKornVom3DJf9QWMDWARkGTWDb5ZTPI9HbL6+dJEnohx9+WLp19NpxyT9sWAAAAGwcl5eXW6Ws8K+rSPyiCFTBCgvYOiDDoAlATsE245J/rLAAAAAAYOOBwgIAAACAjQcKCwAANBQ+2fUlYVuLl24XACgsAADQUPgU05ei0+lQURS2zUYdOgYaD4xuwdYBGQZN4DnktNfrPfqXN2VZku/7a+8TAC5c8o8VFgAA2AKyLHuS756H+CEC4DmAwgIAAA0lSZKKx+Ner0dRFFnbFs/zrM+gw8NDKoqCPM+zvnOSJLH5+KA2mm39RFFk06Ioor29PaLZf76cl50OapuWKIqo1+tRp9MhT3hu5rDsA9dRlqVN116FZRvSz1Bd/8ErRR3Vv5RHFAFgo4AMgyawTE7Zdwz7h3H5ywmCwH6O47jiSyaO44ofGfYrw75nZF4j/P7IsPQLFASBCYKg4uNI+gHyfd+Gue8///yzzcv5uR3OS8JfjhxDXf/B68Al//MxS3BVAkCTgAyDJrCKnGolRCooZqbE1Cks0rkfX6yA+L4/9/LXCotUkOTFaXVODuWVpumcgsLOAYuisA4VXSzqP2g+LEsSbAkBAMCWkqYpzf5xJWPMgw1ywzCslP/ze6YenXeZU8O7uzsdVeGp/QfNAgoLAABsKVoh0LYjyyjLshJeVl7mz/O8Yo/iYnd3d6Gh8FP7D5oFFBYAANgCdnd37eckSej4+JgGg4E1iM3znFqtliixmA8fPtB4PK6cxaIVGKbb7ZLv+7S/v2/jzs/P6e3bt5V8mn6/T0VRVNpIkoTKsnxy/0ED0XtEy3hEEQA2CsgwaALL5FQat/q+b41laWZ0q41w2TZE1ivzSPsVjmM7Fm2vwnYxbDwr63XVyci80n6FLx0uiqLSb1KGtYvaAs2GHPKPg+PA1gEZBk0Acgq2GZf8Y0sIAAAAABsPFBYAAAAAbDxQWAAAAACw8UBhAQAAAMDGA4UFAAAAABsPFBYAAAAAbDxQWAAAAACw8UBhAQAAAMDGA4UFAAAAABsPFBYAAAAAbDxQWAAAAACw8UBhAQAAAMDGA4UFAAAAABsPFBYAAAAAbDye0f6bl+B5no4CAAAAAFgrWj15lMLywCIAbBSQYdAEIKdgm3HJP7aEAAAAALDxQGEBAAAAwMbTaIUlz/NG2tREUUS9Xk9Hrw2el7IsdRIAAFg6nQ4lSaKjH0RZluR5HuV5rpO2gnXM4SI6nQ55nodn+iYpLFEU2ZvieR5FUaSzzNHtduf2uJrAcDiky8tLHb02eF7a7bZOAisgHxD6QSzTVpFRAJ4bKatlWT5ILqfTKZ2cnOjoB+H7vo7aKtYxh3X0ej06OzsjYwz5vk8//vijzrJVbJTRbVmW5Ps+FUWBly14NlaR4SRJ6PPnzzSdTnUSJUlCP/zwA3W7XZ0EwNpYRU57vR69f//evjA7nQ7R7CX6UvBzezKZ4DuxZjzPe5b3YROeYS7535gVFgAAAA9jPB7TDz/8YMPT6ZT29/creUAzec7tn8FgoKMawUYrLHJvtNfrked5FduPLMvIm9mwcDovh/IWE4c5r9568jzP7j8mSVIpswjet+R2uR+MbIf/62F6vV6lDd5m0Mu53B9X/Z7nUZZlth3ZhpwXEjYzbNviqW0O3Y6n5hnUI+2F+D7Ke8gy7Jr3OhmRcq/r1GES8iTvI6n7KmH54Es+GL0FcgU2D9/3aW9vr3IPh8Oh/cyyIWXNdb9pBVmWzzotU8uQW6nS3mORLPIzVsuiDtNM1judTqU+Hhd/n7gcP9tkXl0X99M1/jzPK/GyLVpxTHXfTSZJErvV5vu+7Z8cB8fJudXfV3nPoiiyc0FEtLe3V0nnMXB9HGYZ0uPhsPeS9kvmgTyiyMoURWGIyBRFYcysLb4mk4lNn0wmZjKZ2DQmCAIThqENh2FowjCs5E3T1KbHcWyCILBhLrOMIAgq/TLGGN/3bV26Xt/3je/7xszqJyLbThzHtk++79v4NE1tGSPa5Hx6PPxZz0scxzbMfQrD0H7m/LIdPSevDTneOuI4rsy/JI7jijzyVRSFnc+iKObkWc77Ihmpq1OHi6Kw8kREJo5jW5cO82d9v7l8URQL5Qq8PPI+1aFlUCJlg+9hEARWzvh+p2k6V4+Ws8lkUvk+kJAv+Vx24fu+bT9NU9vPRbIon7FSFnU4TVNbJ6nnKtel08ysHzLMz15uW9bB+Xm88hkp59A8YEyu76ZGPz+4LfncSNPUhjm/vNf6e1+I55K8X7KcEfdMypBEhuU8rRNXnfMxS3BVsi70DaqbWA5L4TcLFBZXXkbeqHT2wl8FLWiyft1nFhaOk/2sezHKL7lxCKP8rPPrscoXpVEvy1QpRjr8GnHJgabuvhihsBj1IDBKhuM4rsijZJGMaLlfFtZyvygsH2IMiQfoIrkCL8sqcsrIF0vdvTcOeZX3W6fp57FEypGWR8lEKTqSZbKon7GLwq7vK4/N1T+pPPDl+74zr3E8UyVyDh86Jld+xjX/si0X/H3lsi5cY9T1yu+9liGeC33pOXsqrv5v9JbQSxDHMZ2dnRER0fX19aONkN68eUNUs+/Idd7f3+skayynl9uKoqjka7fb5Ps+3d3dVeKfSr/fp6Io7JLe9fU19sCJaHd3V0dV2NnZ0VFz3N7e6iiiR8jIOnEZYwZBUNtX0AyGwyEZYygMQxqNRpUtCskqcrsI3jYaj8c6yckieX5uWVz266U4jsn8+Z92MsbQdDqldrtNcRzT3t4eeWL7qt/vUxAES7dAnntMdfA2FL83vn37prOsFd/3K3NnjHn0u/MhbL3CcnBwQOPxmLIso1arpZMfhO/71pr769evOtkqNZrpdErGGAqCoLJveX19rbMufZE+BvkFvbq6quyBbzNaaWRub29XstpvtVpO5eQxMrIuOp0OffnyRUc/WfbB90Hbmg2HQwqCYOk/NqvIr4RtHz59+mSfVavw5s2b2u/RS8jiou+TViLYLuXk5ISMMZSmKQ0GA6v8XV5eWqVQ2w0xLzEmCSuQ19fXZGY/fSahmLr6uA70Pc2yrFaJWyevSmFpt9v2BpVlSaPRiEajUcVAStNutykMQzo8PKSDgwOdvBApmJ8+faLj42MiIgrDkAaDge1LlmUUBIFTA02SpPKFYI6Pj2k0Glkh4L/9ft/mWQd5ntPt7W3lvwzwl3nWsqPDi5DKMMPlHyIj6+To6KjSp7IsaTweP9s5EuB5GY/HFSNWvp/yl0NXV1f2848//khhGNrwqlxcXFAQBHPnR9Wt5DDdbpd83698b/jltm5ZLIqi8n0isXKpOTo6qqxEyfcGK4H9ft/OVZZldp6Hw2Ht6s26x7SM8/NzCsNw7p/Mm5sbCoKgMu95nlOWZRVllcckV++zLKOiKOjw8NB5f/nZKJXls7Oz2rleK3qPaBmPKLIScg+WiMyvfvWruf0xHdb7irw3R7P9SLZh0XtumslkUrHxMMKQqG5/0Z8Z2XKd2lZBjkfWrcvEM3sSjpP7iNwHHg8jx8I2Jxz+u7/7u0q67oesMwiCypzpel8r5JCBOvS8uOwB+NLhQhnM6nnV98Y4jCi17OqwvMKZrdKisHHsQTO6HSlXr1keNhV5b+rgZ4i8d9pWQ8qAfBbJMv/wD/8wV4cM//zzz5Uwy8bvfve7uXIuZJ5F9hCMlD22T1kU5jgZbxzfJ9k/1/O1UMaxPF/pzLhVtmkc3xnOK+MZ3WdXfYy+pzKvbEvfJ26DxynbdL2HXH0Ow9DasLieH2bJvK4Lcsj/Rh0c91CyLKPT09MnrwrkeU739/fO1Ysoiua0V5ot/R0fHz+b5vxS8MqN1o6TJGn82OrYJBkGoI51yGmv16N2u+18hr0mkgUHPYJm4pL/xm8JrcNA9NOnT3PKSjYzYvr48WMl/rVxdHQ0ZxiX5/mz2MoAAAAAj0YvuSzjEUXWit72eSxyKe2hy1l6aa/J6CVFUkuHr5HvLcMArMJT5bRuOf+14draAc3HJf+N3hIC4DFAhkETgJyCbcYl/43fEgIAAADA6wcKCwAAAAA2HigsAAAAANh4oLAAAAAAYOOBwgIAAACAjQcKCwAAAAA2HigsAAAAANh4oLAAAAAAYOOBwgIAAACAjQcKCwAAAAA2nkcdzQ8AAAAA8Jxo9eTBCgsAAAAAwEuDLSEAAAAAbDxQWAAAAACw8fx/itUpEvmxcq0AAAAASUVORK5CYII=" alt="" width="556" height="772" vspace="0" hspace="0" border="0" style="width:556px;height:772px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>To reports any side effect(s):</p><p><strong><img src="data:image/png;base64,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" alt="" width="589" height="241" vspace="0" hspace="0" border="0" style="width:589px;height:241px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em><u>Chronic:</u></em> The symptoms of glucocorticoid overdose may include confusion, anxiety, depression, gastrointestinal cramping or bleeding, ecchymosis, Cushingoid facies and hypertension. Sudden discontinuation after long-term therapy may result in acute adrenal insufficiency. The latter may also occur in cases of stress. Cushingoid changes can result from continued use of high doses.</p><p style="text-align:justify"><em><u>Acute:</u></em> There is no specific treatment for acute corticosteroid overdose; therefore, supportive therapy should be instituted and, if gastrointestinal bleeding occurs, action should be taken as in the case of peptic ulcer.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: corticosteroids for systemic use, ATC code: H02AB08.</p><p style="text-align:justify">KENACORT-A is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in sterile aqueous suspension for intramuscular, intraarticular and intrabursal injection. Do not use this formulation for intravenous, intradermal, subtendinous, intranasal (turbinates), subconjunctival, retrobulbar or intravitreal (intraocular), epidural or intrathecal injection.</p><p style="text-align:justify">KENACORT-A has a long duration of action that can be permanent or extended over a period of several weeks.</p><p style="text-align:justify">Glucocorticoids of natural origin (hydrocortisone), which also cause sodium retention, are used as replacement therapy in states of adrenocortical insufficiency. Synthetic analogs, such as triamcinolone, are used primarily for their potent anti-inflammatory effects in a variety of diseases.</p><p style="text-align:justify">Clinical studies have shown that after a single dose of 60 to 100 mg of triamcinolone acetonide, suppression of adrenal activity occurs between 24 and 48 hours and then returns to normal values, generally in 30 to 40 days. These results are closely related to the prolonged therapeutic action achieved with this product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Triamcinolone acetonide is absorbed slowly but completely, following administration by deep intramuscular injection. Therapeutic levels of the product are ensured consistently over a long period (weeks to months). As with other corticosteroids, triamcinolone is largely metabolized by the liver as well as the kidneys, and is excreted in urine. The main metabolic pathway is hydroxylation.</p><p style="text-align:justify">Hepatic or renal dysfunction may affect the pharmacokinetics of the drug.</p><p style="text-align:justify">Clinically significant systemic levels of the product following intraarticular administration are unlikely to occur, except for large joints treated with high doses. Systemic effects are not usually observed with the use of appropriate doses and methods of intraarticular administration.</p><p style="text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The preclinical safety of the product as observed at the time of marketing authorization has been largely surpassed by more than 30 years of clinical use and postmarketing pharmacovigilance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Sodium</strong> carboxymethyl cellulose, <strong>sodium</strong> chloride, polysorbate 80, <strong>benzyl alcohol</strong>, water for injections, hydrochloric acid/<strong>sodium</strong> hydroxide (pH adjusters).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See section 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Store below 30<sup>o</sup>C. Do not freeze or refrigerate. Protect from light. Store vials upright.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">1 mL suspension for injection in a vial with a cap (chlorobutyl rubber) and a seal (aluminum) in packs containing 3 vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BRISTOL-MYERS SQUIBB S.r.l.,Via Virgilio Maroso, 50 - Rome (Italy)

MARKETING AUTHORIZATION NUMBER
0901233075

DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION
08/11/2002


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>